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A new family of methionine-sulfoxide reductase (Msr) was recently discovered, 
and was named free methionine sulfoxide reductase (fRMsr). This family includes 
enzymes with a reductase activity toward the free R isomer of a methionine 
sulfoxide substrate. The fRMsrs have a GAF domain topology, a domain, which 
was previously identified as having in some cases a cyclic nucleotide 
phosphodiesterase activity. The classification of fRMsrs as GAF domains revealed 
a new function can be added to the GAF domain family. Interestingly the four 
members identified in the fRMsr family share the GAF domain structure and the 
presence of three conserved cysteines in the active site with free R methionine 
sulfoxide substrate specificity. This thesis presents the crystal structures of 
reduced, free Met-SO substrate-bound and MES-bound forms of a new fRMsr from 
Burkholderia pseudomallei (BPSL2418). BPSL2418 was cloned, overexpressed 
and purified to enable protein crystallization. The crystallization trials for reduced, 
Met-SO-bound and MES-bound forms of BPSL2418 were prepared and reasonable 
crystals of each form were produced. The crystal structures of BPSL2418MES, 
BPSL2418Met-SO and BPSL2418Reduced were solved at 1.18, 1.4 and 2.0Å, 
respectively by molecular replacement. The BPSL2418MES crystal belongs to space 
group P 21 21 21 while BPSL2418Met-SO and BPSL2418Reduced crystals belong to 
space group P 1 21 1. All three forms share the GAF domain structure of six 
antiparallel β-strands and four α-helices with connecting loops. The antiparallel β-
strands (β1, β2, β5 and β6) are located in the center of the BPSL2418 structure 
flanked on one side by a three α-helices (α1, α2 and α4) and on the other side by a 
(loop1, β3, loop2, α3, β4 loop4) unit where loop4 forms a capping flap and covers 
the active site. The structural comparison of the three forms of BPSL2418 indicates 
that the catalytically important cysteine is CYS109, where the resolving cysteine is 
CYS75, which forms a disulfide bond with CYS109. They also suggest that the 
third conserved cysteine in the active site, CYS85, which is located in α3, is a non-
essential cysteine for the catalytic function but it may play a role in the binding of 
the substrate. The structural comparison of the three forms reveals that 
conformational changes appear in the active site particularly involving loop4 and 
CYS109 during catalysis. The 3D structure of BPSL2418 shows strong structure 
similarity to fRMsrs enzymes, which further suggests that BPSL2418 acts as a free 
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Chapter 1:  Introduction 
This thesis consists of two projects. The first and most important part in terms of 
achieved results is BPSL2418 the hypothetical protein from Burkholderia 
pseudomallei. The second project is the C-terminal domains of Polycystin 1 (CT1) 
and Polycystin 2 (CT2).  
 
First project: BPSL2418 from Burkholderia 
pseudomallei       
 
This chapter gives a general introduction of the hypothetical protein from 
Burkholderia pseudomallei (BPSL2418). It starts with a general view of the 
bacterial pathogen Burkholderia pseudomallei and its biological relevance as the 
causative agent of the human disease melioidosis. Then it focuses on the family of 
proteins to which BPSL2418 belongs. Finally it states the aims of this project.  
 
1.1  Burkholderia pseudomallei is the causative agent 
of melioidosis 
 
1.1.1  Background and history 
Melioidosis, is an infection caused by the Gram-negative bacterium Burkholderia 
pseudomallei, first identified by the British pathologist Captain Alfred Whitmore 
and his assistant C S Krishnaswami in Rangoon, Burma in 1911 (White, 2003b). 
They described melioidosis as a glanders-like disease among the ill residents of 
Rangoon. Glanders is an abscess-forming infection caused by Burkholderia mallei 
which affects horses, mules and donkeys although it can be contracted by other 
animals such as dogs, cats and goats and it occasionally affects humans (Bondi & 
Goldberg, 2008). Whitmore and Krishnaswami isolated the causative agent of 
 26 
melioidosis from autopsy specimens on peptone agar and potato slopes, they 
identified a new organism that corresponding to Koch’s postulates (Cheng & 
Currie, 2005b). This organism is distinguished from the organism causing glanders 
by its comparatively rapid growth, its motility and the lack of the Strauss reaction 
when it was injected into guinea pigs (Cheng & Currie, 2005b). In 1932 Stanton 
and Fletcher (from the Institute of Medical Research in Kuala Lumpur, Malaya) 
documented sufficient cases in man and animals of Whitmore’s disease to publish a 
definitive monograph on a disease they named as melioidosis (White, 2003b).  The 
name melioidosis was derived from two Greek words [melis]: which means a 
distemper of asses and  [eidos]: resemblance (Dance, 1991a). After the Second 
World War many more cases were reported in American and western soldiers 
fighting in Vietnam, who had been exposed to environmental Burkholderia 
pseudomallei through contaminated wounds and burns or by inhalation (Dance, 
1991a). The organism causing melioidosis has been known as Bacillus 
pseudomallei, Bacillus whitmorii (or Bacille de whitmore), Malleomyces 
pseudomallei and Pseudomonas pseudomallei but since 1992 it has been termed 
Burkholderia pseudomallei (Cheng & Currie, 2005b). However, melioidosis 
appeared as an infectious disease of major public health importance in Southeast 
Asia and northern Australia in the latter half of the 20th century (Chaowagul et al, 
1989).  
 
1.1.2  Epidemiology 
Melioidosis is considered as endemic to the tropical area of Southeast Asia and 
Northern Australia; multiple case series have been reported and described in 
Northern Australia, Thailand, Singapore, Malaysia, Burma and Vietnam (Dance, 
2000b) (Cheng & Currie, 2005b). Significant numbers of exported cases have 
occurred in countries classified as possibly endemic regions such as Southern 
China, Hong Kong, Brunei, Laos, Cambodia and Taiwan (Figure 1.1) (Cheng & 
Currie, 2005). Also a limited outbreak of the disease was reported in Europe. The 
most remarkable occurrence of melioidosis was in France in the mid-1970s: this 















Figure 1.1: Global distribution of the occurrence of melioidosis, linked to regions of 















from China, and subsequently the infection distributed to other zoos in and outside 
France, probably by transport of affected animals or contaminated muck. An 
unknown number of slaughtered animals and at least two fatal human cases 
resulted from this infection (Dance, 1991a). In Spain an isolation of Burkholderia 
pseudomallei from horses was reported. Also some human melioidosis cases have 
been announced in Berlin in 1947 (Dance, 1991a).        
Sporadic cases have appeared in Central and South America, the Middle East, the 
Pacific and several African countries, and at least five cases in the United Kingdom 
imported to the country from Bangladesh and two from India and Pakistan (Cheng 
& Currie, 2005).  However, the worldwide epidemiology of melioidosis shows 
that, Northeast Thailand has the highest incidence of melioidosis where the first 
case wasn’t reported until 1955, but since 1986 the MORU lab (Mahidol-Oxford 
Tropical Medicine Research Unit) in Bangkok has documented more than 3000 
cases (Stone, 2007) and Sappasitprasong Hospital in Ubon Ratchathani in north-
east Thailand admits around 200 patients annually that are positive for 
Burkholderia pseudomallei infection, of which nearly half die (Aldhous, 2005). 
Burkholderia pseudomallei is found in the environment of the endemic countries 
where the highest isolation rate was in wet rice fields in Malaysia and Thailand, but 
in Australia the highest rate was in dry soil. However, this bacterium exists in soil 
and water in all endemic countries (Dance, 2000a; Dance, 2000b). Although 
several studies have spotted melioidosis, it is thought that the extent of the disease 
in the endemic area as well as worldwide is misrepresented, with many unreported 
cases due to lack of awareness and diagnostic facilities in infected regions, 
especially in rural communities. Melioidosis is categorized as an emerging 
infection, because it has been recognized increasingly during the past two decades 
(Aldhous, 2005; Dance, 2000b).    
 
1.1.3  Burkholderia pseudomallei  
 
1.1.3.1  Bacterial strain and genomics  
The genus Burkholderia includes more than 30 species where the most pathogenic 
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types are B. pseudomallei, B. mallei and B. thailandensis, which exists with 
Burkholderia pseudomallei in the soil in Thailand but is less virulent (Cheng & 
Currie, 2005b). The Burkholderia pseudomallei strain K96243 was isolated in 1996 
from a 34-year-old female diabetic patient in Khon Kaen hospital in Thailand, and 
then the DNA was isolated from this strain (Holden et al, 2004). The B. 
pseudomallei genome possesses two chromosomes, of which BPSL (Burkholderia 
pseudomallei Large) is 4.07 megabase pairs and BPSS (Burkholderia pseudomallei 
Small) is 3.17 megabase pairs. The large chromosome regulates metabolism and 
growth, whereas the small chromosome has more accessory functions relating to 
adaptation and survival in various circumstances (Holden et al, 2004). A further 
astonishing aspect of the B. pseudomallei genomic structure is the presence of 16 
genomic islands that compose 6.1% of the genome, but are completely missing in 
the paraphyletic non-human pathogenic B. mallei and B. thailandensis, or in the 
plant pathogenic B. cenocepacia. This suggests a significant role for this genomic 
island in the pathogenicity of B. pseudomallei to humans and animals  ADDIN 
EN.CITE .  
 
1.1.3.2  Bacteriology 
Burkholderia pseudomallei is characterized as a Gram-negative aerobic bacillus 
with bipolar staining and has a slender, rounded end shape. It has been described as 
safety-pin like (Cheng & Currie, 2005b; White, 2003a). B. pseudomallei is a soil 
saprophyte, lives in water and wet soils in rice paddy fields in endemic regions, and 
it can be cultured from more than 50% of rice paddies (Cheng & Currie, 2005b; 
Dance, 2000a; White, 2003a). The bacterium is motile where Whitmore 
distinguished it from B. mallei by its ability to move on a hanging drop (Cheng & 
Currie, 2005b). The optimum growth condition of B. pseudomallei is in paddy soil, 
in crop-covered and dormant fields. It flourishes in neutral to acidic medium (pH 
6.5 or 7.5) but not in salty water or soil (Chen et al, 2003). 37 °C or 42 °C are the 
optimum temperatures for growth although this bacterium can still grow at 4 °C 
which explains the existence of melioidosis in some cold areas. Also the water 
content of the medium is a critical element influencing the degree of growth (Chen 
et al, 2003).  However the organism is highly resistant to difficult environmental 
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conditions and it is able to survive in a wide range of harsh circumstances in both 
soil or liquid media (Cheng & Currie, 2005b). The bacteria remain active and 
continue to grow under a diverse range of temperature, pH and dehydration 
conditions (Chen et al, 2003), they also conserve vitality after at least 16 years in 
distilled water (Pumpuang et al, 2011). Moreover they can survive even if exposed 
to disinfectant and antiseptic solutions (Gal et al, 2004) and they show a resistance 
to chlorinated water with levels used in water supplies proving only bacteriostatic, 
although use of high levels are sufficient for killing the bacteria (Howard & Inglis, 
2003). The organism is oxidase positive, where the enzyme is able to assimilate 
arabinose or glucose in the oxidative pathway, this also allows the distinction of B. 
pseudomallei from the closely related but less pathogenic B. thailandensis (Cheng 
& Currie, 2005b; White, 2003a). In the laboratory, B. pseudomallei can be cultured 
on most agar media, and colonies can be obviously seen within 24 h at 37 °C, 
although usually Ashdown’s selective medium is used for growing the organism 
where the B. pseudomallei colonies have a cornflower head appearance and they 
are stained with the crystal-violet dye from the Ashdown’s media (White, 2003b) 
(Figure 1.2). Isolates of the bacteria from environmental sources or from infected 
patients show various morphologies with seven colony types (Figure 1.3) where 
Type I is the most commonly isolated morphotype of the seven types (Chantratita 
et al, 2007). A wide range of morphologies further obscures identification of 
melioidosis upon culturing from infected patients (Stone, 2007).  
 
1.1.4  Melioidosis features  
 
1.1.4.1  Melioidosis acquisition  
B. pseudomallei is a soil saprophyte and can be cultured from soil and surface 
water in endemic regions, with postulated routes of infection being via 
contamination of broken skin and wounds, aspiration, inhalation of aerosolized 
bacteria, ingestion and possibly sexual transmission (Currie et al, 2001). Mother-
to-child transmission of B. pseudomallei may also possibly have occurred as a 












Figure 1.2: The B. pseudomallei colonies.  (A) B. pseudomallei growing on Ashdown’s 
selective medium.  













Figure 1.3: The seven morphotypes of B. pseudomallei. Colonies were morphotyped 
based on appearance, size and pigmentation. The percentages indicate the proportion of 
each form in a collection of 212 clinical isolates after growth for four days on Ashdown’s 
agar. Adapted from (Chantratita et al, 2007; Stone, 2007). 
 
 
A	   B	  
Type	  I	   75.1%	   Type	  II	   3.7%	   Type	  III	   5.4%	   Type	  IV	   5.0%	  
Type	  V	   3.3%	   Type	  VI	   5.8%	   Type	  VII	   1.7%	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1.1.4.2  Melioidosis symptoms 
Melioidosis is known as “the great mimicker” because of its similar symptoms to 
other infections and the difficulty with its diagnosis (Yee et al, 1988). This disease 
can be classified into two categories, an acute septicaemia infection and a chronic 
localized infection (Dance, 1991a). It can affect any organ or tissue but the 
common positions of infection include lungs, genito-urinary system, skin, liver, 
spleen, bones, soft tissues and skeletal muscle (Yee et al, 1988). Symptoms may 
include pain in chest, bones, joints, coughing, skin infections, lung nodules and 
pneumonia, the most common manifestation of melioidosis (Suputtamongkol et al, 
1999). Melioidosis occurs as an acute bloodstream infection, disseminated 
infection and most frequently as an acute pulmonary infection. Chronic melioidosis 
may present as a localized infection in the skin, liver, spleen, kidneys or prostate, 
but also it occurs as chronic pneumonia, visceral abscesses and osteomyelitis (Lim 
et al, 2001). The incubation period is generally 1-21 days, but may extend to 
months or years, symptoms appear 2-4 weeks after exposure. Without appropriate 
treatment, the case-fatality ratio may reach 90% within 48 hours of developing 
symptoms (Cheng & Currie, 2005a). 
 
1.1.4.3  Environmental exposure 
Melioidosis affects humans and animals that have been exposed to environments 
including B. pseudomallei. The mode of infection is considered to be either through 
cutaneous inoculation, inhalation, ingestion or aspiration (Pumpuang et al, 2011). 
The connection between the disease prevalence and the degree of environmental 
contamination with B. pseudomallei is a direct relation where the highest disease 
incidence is in the environments of the endemic regions that contain a very high 
level of the bacteria (Cheng & Currie, 2005b).  
 
1.1.4.4  Climate conditions  
The weather is another factor associated with the disease acquisition, where heavy 
rain, monsoon and winds trigger the highest number of cases (Dance, 2000a). This 
can be illustrated by rising opportunities for contamination with B. pseudomallei 
 33 
where the bacteria is widely spread in pooled surface water such as in rice paddies 
(Cheng & Currie, 2005b). The rice farmers in endemic areas plant at the start of the 
monsoon and work in flooded rice paddies until harvest in very low conditions of 
safety, they are always barefoot in rice fields, which explains the high risk of 
infection distribution in this kind of agricultural activity (Stone, 2007).            
 
1.1.4.5  The host immunity status 
One fifth of all melioidosis patients in northeast Thailand (80% of the population 
belong to rice-farming families) are children under 14 years of age, while the 
disease extent peak includes individuals between the fourth and sixth decade 
(Wiersinga et al, 2007). Most of them have other diseases, commonly diabetes 
mellitus, renal failure and thalassemia (Cheng & Currie, 2005b). There is a 
possibility that the development of these diseases causes immune dysfunction, 
which increases the chance of melioidosis infection to take place (Cheng & Currie, 
2005b; Wiersinga et al, 2007). Also it is uncertain whether the afflicted children 
with melioidosis have a major genetic tendency for disease. It also likely that 
melioidosis in childhood occurs due to the high bacterial distribution which 
increases the pathogenic capability (Wiersinga et al, 2007).  
  
1.1.4.6  Treatment of melioidosis 
The current therapy for melioidosis is similar to that of any Gram-negative 
septicaemia. The treatment consists of two stages, primary high intensity 
intravenous injections and oral treatment (White, 2003b). The primary treatment 
includes a high dose of ceftazidime for at least ten days or until progress appears, 
followed by oral treatment of a cocktail of four conventional antibiotics including 
chloramphenicol, doxycycline, trimethoprim and co-trimoxazole for 20 weeks. 
With the four-drug combination, chloramphenicol is given only for the first 8 
weeks (White et al, 1989). Without treatment the fatality rate of acute melioidosis 
is over 80%, the primary intravenous stage itself decreases overall mortality more 
than 50% (White et al, 1989). Reversion into melioidosis occurs in approximately 
10% of patients due to the reactivation of the original infection (White, 2003b). 
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1.1.4.7  New therapies and vaccines are needed 
Burkholderia infections are inherently difficult to treat due to their resistance to 
multiple antibiotics, biofilm formation, and the establishment of intracellular and 
chronic infection in the host (Wiersinga et al, 2006). Until recently, the four-drug 
combination of antibiotics has been the only available treatment for melioidosis but 
it is an imperfect remedy due to the extended time and cost of an antibiotics course 
with the fatality rate remaining high (Aldhous, 2005; Behera et al, 2012), and there 
is also the rise of a number of ceftazidime resistant strains (Behera et al, 2012). 
Preventive factors such as active immunization might significantly decrease the 
risk of disease incidence, but to date there is no commercially available effective 
vaccine that prevents B. pseudomallei infection, although several approaches have 
been taken to develop effective vaccines for use against melioidosis (Peacock et al, 
2012). Different live attenuated mutants have been used as vaccines in mouse 
models providing high levels of infection resistance (Nieves et al, 2011). The use 
of B. pseudomallei as a potential vaccine has been tested showing successful 
protection in mice but was found to be ineffective in human trials (AuCoin et al, 
2012). Also the use of monoclonal antibodies specific to the bacteria 
lipopolysaccharides and capsular polysaccharide for passive immunization has 
been shown to offer protection from infection in mice (AuCoin et al, 2012). But 
unfortunately these vaccines are unlikely to be developed for human use due to the 
high chance of reversion and the ability of the B. pseudomallei to start a persistent 
latent infection, which can remain dormant for extended periods of time (Nieves et 
al, 2011).     
 
1.1.4.8 Melioidosis as a potential bioweapon 
The United States Center for Disease Control considers B. pseudomallei as a class 
B potential biological threat which categorizes the organism in the second highest 
priority level among other potential bioweapons (Rotz et al, 2002). The disease is 
placed in this critical position due to the high mortality rate, the simplicity of 
disease acquisition and spreading, the ability of the bacteria to survive in a wide 
range of conditions, the lack of vaccine and the multi antibiotic resistance of B. 
pseudomallei (Cheng & Currie, 2005a).        
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1.1.5  Molecular pathogenicity factors 
 
1.1.5.1  Quorum sensing 
Quorum sensing is a cell-density-dependent communication system observed in 
Gram-negative bacteria that permits bacteria to regulate gene expression using the 
small signaling molecules N-acyl-homoserine lactones (AHLs) (Gamage et al, 
2011). The B. pseudomallei genome contains three LuxI and five LuxR genes 
responsible for producing eight quourum sensing homologous LuxI and LuxR 
proteins. The LuxI proteins play role in AHLs biosynthesis, and the LuxR proteins 
act as transcriptional regulators (Gamage et al, 2011). This system regulates the 
expression of a number of genes involving metalloproteases and phospholipase C, 
and also it is responsible for biofilm formation (Gamage et al, 2011; Wiersinga et 
al, 2007). Interruption of the LuxI or LuxR genes requires a significant increase in 
the LD50, increases the lifetime and decreases bacterial colonization and virulence 
in Syrian hamsters, which suggests that the synthesis of N-acyl-homoserine 
lactones (AHLs) is critical for full virulence in this rodent model (Ulrich et al, 
2004). Also there is proof for the requirement of the Bpe-OprB multidrug efflux 
pump for AHLs to be released from inside the cell (Chan & Chua, 2005a). The 
Bpe-OprB multidrug efflux pump in B. pseudomallei also is implicated in the 
antimicrobial resistance to aminoglycosides and macrolides (Wiersinga et al, 
2007). 
 
1.1.5.2  Capsular polysaccharides 
 Pathogenic bacteria commonly produce a thick and mucous-like layer of 
polysaccharide that forms a capsule outside the cell wall. The capsule covers 
antigenic proteins on the bacterial surface that stimulate an immune response. It 
protects the cell from phagocytosis where a capsule-specific antibody may be 
required for phagocytosis to take place. However it is known that bacterial capsules 
are available in several different types and immunity to one type does not result in 
immunity to the other types. Also this layer assists the cell to adhere to surfaces. 
The bacterial capsule regularly consists of polysaccharides although it can be 
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composed of polypeptides (O'Riordan & Lee, 2004). Burkholderia pseudomallei is 
morphologically distinguished into three types based on its polysaccharide capsule 
(Puthucheary et al, 1996). One type has no capsule while the other two types have 
various capsule thicknesses. The B. pseudomallei possesses a capsule with a 
homopolymer of structure -3)-2-O-acetyl-6-deoxy-β-D-manno-heptopyranose-(1- 
(Reckseidler et al, 2001). The presence of polysaccharide capsule is significant for 
B. pseudomallei virulence in experimental animal models. The addition of purified 
B. pseudomallei capsule to a serum bactericidal test boosts the survival of B. 
pseudomallei SLR5 (Reckseidler et al, 2001). Also an increase in the numbers of 
wild-type B. pseudomallei cells in the blood was shown after 48 h while the 
number of capsule-deficient mutant cells in the blood decreased after 48 h 
(Reckseidler-Zenteno et al, 2005). 
 
1.1.5.3  Lipopolysaccharide 
Lipopolysaccharides (LPS) are macromolecules composed of lipid and 
polysaccharide bound by a covalent bond. It is a major component of the outer 
membrane of Gram-negative bacteria, functions as an endotoxin and plays a role in 
immune responses in animals (Nikaido & Vaara, 1985). Burkholderia 
pseudomallei owns an individual LPS structure with an unbranched repeating unit 
of alternating glucose and talose residues in the form -3)-β-D-glucopyranose-(1–3)-
6-deoxy-α-L-talopyranose-(1- with the talose subunits acetylated on the 2’ and 3’ 
positions (Perry et al, 1995). B. pseudomallei is highly resistant to the bacterial 
activity of normal human serum (NHS) where the bacteria multiplies in 10-30% 
NHS. But it was found that B. pseudomallei mutants in the LPS synthetic pathway 
are debilitated in rodent models with the bacteria becoming susceptible to be killed 
by the alternative complement pathway and to be less virulent (Deshazer et al, 
1998).  
 
1.1.5.4  Flagella 
 B. pseudomallei has a polar tuft of two to four flagellae that supply motility but the 
flagella’s role in virulence is still obscure due to conflicting data. Flagella-deficient 
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B. pseudomallei mutants are show a reduction in numbers in lung and spleen of 
mice as compared with the wild type (Wiersinga et al, 2007). But in another study 
there was no difference between the wild type and the mutant when invading and 
replicating in human lung cell in vitro (Chua et al, 2003). 
 
1.1.5.5  Pili 
Adherence is a critical virulence factor in many Gram-negative bacteria, mediated 
by carbohydrate molecules, pilus and non-pilus adhesion. The Burkholderia 
pseudomallei K96243 genome includes multiple type IV pilin-associated loci, 
including the pilA gene, which is responsible for producing a putative pilus 
structural protein (Essex-Lopresti et al, 2005). Mutations (deletion) in the pilA 
gene reduce the bacterial adherence to human epithelial cells in vitro and they also 
decrease bacterial virulence in nematode models, indicating a role for type IV pili 
in Burkholderia pseudomallei virulence (Essex-Lopresti et al, 2005; Wiersinga et 
al, 2007).        
 
1.1.5.6  Biofilm formation 
A biofilm is a group of microorganism in which cells adhere to each other on a 
surface. These sticking cells are encased in an extracellular polymeric substance 
(EPS) of microbial origin. Biofilm (EPS) is described as slime consisting of 
extracellular DNA, proteins and polysaccharides (Costerton et al, 1999). 
Burkholderia pseudomallei is capable of forming biofilms (Vorachit et al, 1995). 
Biofilm formation increases the cells’ antibiotic resistance (Sawasdidoln et al, 
2010), but mutants lacking biofilms are not attenuated in mouse models, suggesting 
it is not essential for virulence (Taweechaisupapong et al, 2005). However the 
embedding of bacteria in biofilms in infected lung tissue indicates a function in 
bacteria survival, vitality and antibiotic resistance inside the host (Sawasdidoln et 
al, 2010).  
 
1.1.5.7  Antibiotic resistance 
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Burkholderia pseudomallei is resistant to a wide range of antibiotics such as β-
lactams, aminoglycosides, macrolides and polymyxins (White, 2003b). The 
genome contains genes encoding seven β-lactamases providing resistance against a 
series of β-lactam based antibiotics which includes penicillin derivatives (penams), 
cephalosporins (cephems), monobactams, and carbapenems. Most β-lactam 
antibiotics work by inhibiting cell wall biosynthesis in the bacterial organism. 
Bacteria usually develop resistance to β-lactam antibiotics by producing β-
lactamases (White, 2003b). Also the B. pseudomallei genome encodes a putative 
aminoglycoside acetyltransferase, which is responsible for some of the bacteria’s 
resistance to aminoglycosides alongside other systems (White, 2003b).  
In addition to the antibiotic resistance enzymes, B. pseudomallei produces a 
number of multi-drug efflux pumps, seven putative systems of unknown function 
and three that are fully characterized, AmrAB-OprA (BPSL1802 – BPSL1805), 
BpeAB-OprB (BPSL0813 – BPSL0816) and BpeEF-OprC (BPSS0290 – 
BPSS0294) (Kumar et al, 2008). The AmrAB-OprA efflux pump is a 
distinguishing system for the extraction of aminoglycosides and macrolides (Moore 
et al, 1999). The BpeAB-OprB multi-drug efflux pump also provides antimicrobial 
resistance by the extrusion of aminoglycosides and macrolides (Chan & Chua, 
2005b). Most Burkholderia pseudomallei strains are intrinsically aminoglycoside 
resistant, mainly due to AmrABOprA and BpeAB-OprB multi-drug efflux pumps, 
but in a single separate study the data show that BpeAB-OprB from 1026b strain 
does not mediate efflux of aminoglycosides, but is a multidrug efflux system which 
extrudes macrolides, fluoroquinolones, tetracyclines, acriflavine, and, to a lesser 
extent, chloramphenicol (Mima & Schweizer, 2010). The BpeEF-OprC efflux 
pump is responsible for the extrusion of chloramphenicol and trimethoprim (Kumar 
et al, 2008). 
 
1.1.5.8  Secretion systems   
Clinical isolates of Burkholderia pseudomallei from humans were tested for their 
ability to produce extracellular, biologically active substances, which are thought to 
contribute to the virulence of bacteria. B. pseudomallei is able to produce lipases, 
proteases, haemolysins and siderophores (Ashdown & Koehler, 1990). Different 
 39 
strains of B. pseudomallei show various levels of proteolytic activity in cell free 
supernatants, but nevertheless there is no correlation between protease activity and 
virulence in mouse models of infection (Gauthier et al, 2000). The protease 
enzymes are capable of huge damage to cell lines, localized tissue harm and 
necrosis if injected into guinea pig or rabbit models (Ling et al, 2001). Also B. 
pseudomallei produces phospholipase C enzymes, which are found to contribute to 
cytotoxicity of HeLa cells (Korbsrisate et al, 2007). It is also able to produce 
siderophores high-affinity iron chelating compounds, which increase iron uptake 
into the cell (Yang et al, 1991).   
 
1.1.5.8.1  Type II secretion system 
It has been demonstrated in several studies that B. pseudomallei secretes protease, 
lipase and phospholipase C into the extracellular environment. The bacteria possess 
a type II general secretory system (T2SS) that is able to secrete the above-
mentioned proteins (DeShazer et al, 1999). However T2SS mutants are not 
significantly debilitated in hamster models, indicating a minor role for these 
proteins in pathogenicity (Gauthier et al, 2000).      
 
1.1.5.8.2  Type III secretion system 
The B. pseudomallei contains three type III secretion system T3SS (T3SS1, T3SS2 
and T3SS3). T3SS1 and T3SS2 are homologous to the T3SS of the plant pathogen 
Ralstonia solanacearum, while T3SS3 shows homology to the T3SS of pathogenic 
Salmonella species. The T3SS secretion apparatus functions like a molecular 
syringe. A subset of type III proteins (translocators) interact with the eukaryotic 
cell membrane and inject other type III proteins (effectors) into the target-cell 
cytosol, where they destroy host-cell processes (Wiersinga et al, 2006). T3SS3 has 
been shown to have a role in survival and persistence inside macrophages, escape 
from endocytic vesicles, multinucleated giant cell formation and induction of host 
cell apoptosis (Stevens et al, 2002) (Suparak et al, 2005). An initial study using 
deletion mutants of the SctU subunit, a major component of the inner membrane 
assembly for the three systems found only T3SS3 to be an important pathogenicity 
determinant in mouse and hamster models (Warawa & Woods, 2005).        
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1.1.5.8.3  Type VI secretion system   
One of the factors that offer B. pseudomallei the ability to survive and multiply 
 within a variety of eukaryotic cells, including macrophages, is the presence of six 
type VI secretion systems (T6SS I, T6SS II, T6SS III, T6SS IV, T6SS V, T6SS VI) 
(Shalom et al, 2007). Mutations in T6SS I destroy the ability of the bacteria to 
form multinucleated giant cells, to escape from phagosomes, to survive and 
multiply inside macrophage cell lines and to remove the cytotoxicity of 
macrophages. The T6SS I mutants are attenuated in hamster models, which 
indicates that the T6SS I is essential for virulence and plays an important role in 
the intracellular lifestyle of B. pseudomallei (Burtnick et al, 2011).  
 
1.1.5.9 The intracellular lifestyle of B. pseudomallei  
B. pseudomallei has several mechanisms to escape macrophage killing and evade 
host immunity. It is able to survive and multiply within neutrophils and monocytes 
in vitro (Jones et al, 1996). These mechanisms include resistance to human 
defensin proteins (small cysteine-rich cationic proteins found in immune system 
cells to assist in killing phagocytosed bacteria) when exposed in vitro and the 
abolition of DNA and protein synthesis in host cells by secreting at least one 
uncategorized exotoxin (Jones et al, 1996). Moreover, B. pseudomallei is able to 
generate intracellular motility where the bacteria spread from one eukaryotic cell 
(host cell) to another by inducing continuous actin polymerization at one pole of 
the bacterial cell. Actin polymerization mobility allows cell to cell bacterial spread 
(Wiersinga et al, 2006). Also it is essential in the formation of multinucleated giant 
cells, although the mechanism by which this is produced is still obscure. However 
it has been observed in infected tissues from melioidosis patients, that B. 
pseudomallei is able to form multinucleated giant cells in both phagocytic and no-





1.2 Methionine sulfoxide reductases, members of 
GAF domain family 
 
1.2.1 The GAF family   
The GAF domain family is one of the largest families of small-molecule binding 
domains that exists in nature and is widespread in all kingdoms of life (Martinez et 
al, 2002b). In mammals GAF domains are mostly present in cyclic nucleotide 
phosphodiesterases (PDEs), which are critical cellular enzymes controlling cGMP 
and cAMP second-messenger levels (Martinez et al, 2005). There are about 2000 
GAF domain-containing proteins in which GAF domains have been shown to play 
several roles including the binding of small-molecules, protein-protein interactions 
(including dimerization) (Heikaus et al, 2009). The name GAF was given after the 
first three GAF domain-containing protein families were identified: the mammalian 
cyclic GMP-dependent phosphodiesterases (PDEs), Anabaena Adenylyl cyclase 
and E.coli transcription factor FhIA (Aravind & Ponting, 1997). However, the vast 
majority of GAF domains have not been studied, so their functions and ligand 
binding properties remain unclear (Heikaus et al, 2009). 
 
1.2.1.1 GAF family history 
The GAF domain was initially described by Aravind and Ponting in 1997 using the 
position-specific iterative BLAST method (Aravind & Ponting, 1997). The GAF 
domain has been described as one of the largest and most widely distributed 
families of small-ligand binding regulatory domains, although confirmed proofs of 
ligand binding remain insufficient, as few examples of GAF binding ligand are 
available (Zoraghi et al, 2004). The first demonstration GAF binding ligand was 
the binding of cGMP to mammalian PDE5 (Francis et al, 1980). Progressively 
more evidence has emerged. About 2000 proteins have been predicted to contain 
GAF domains but in humans they are found only in cyclic nucleotide 
phosphodiesterases (PDEs). Eleven different PDEs have been determined in 
mammalia. The PDEs are distinguished by a C-terminal conserved catalytic 
domain and one or more N-terminal regulatory domains, some of which bind 
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cGMP (Martinez et al, 2002b). Five PDE families have two regulatory domains in 
the N-terminus. Later on, by using bioinformatics techniques, it was shown that 
this regulatory domain exists in many other proteins, many of which do not bind 
cGMP; this regulatory domain was then renamed as a GAF domain (Aravind & 
Ponting, 1997). The first crystal structure of a GAF domain was identified by Ho 
and his colleagues in 2000. This GAF domain was seen in the structure of yeast 
YKG9 but no ligand for YKG9 has been reported (Ho et al, 2000). Then the first 
X-ray crystal structure of PDE GAF domains, with bound cGMP was determined 
in 2002; this structure revealed the dimerization role of the GAF domain where two 
GAF domains were found in PDE structure, and both have very similar folds to 
those seen in the single GAF domain of YKG9 (Martinez et al, 2002b).  
 
1.2.1.2 GAF domain structure  
All recorded structures of cyclic nucleotide-binding GAF domains indicate that the 
GAF domain consists of a core of a six-stranded antiparallel β sheets with the 
strand order 3-2-1-6-5-4. The N-and C-terminal portions of the sequence form one 
outer layer of the structure, composing of three helices: α1, α2 and α4 where the 
opposite outer layer of the structure is a mixture of loops and a short α-helix, α3, 
which is often packed against the domain and may take part in domain 
dimerization  (Figure 1.4) (Heikaus et al, 2009; Ho et al, 2000). The first reported 
atomic resolution structure of the GAF domain was the crystal structure of the 
dimeric YKG9 (PDB code), a yeast protein of unknown function. Although no 
bound ligand was found in this structure, the overall topology of the domain 
suggests a cGMP binding role (Ho et al, 2000). In YKG9 the N-terminus extends 
41 residues before the N-terminal end of the GAF domain as described by Aravind 
and Ponting (Aravind & Ponting, 1997). These 41 residues involve the first two 
helices, α1 (residues 8-14) and α2 (residues 20-38) where these helices form an 
integral portion of the α-helical layer, indicating that the stable folding unit for 
GAF domain corresponds to residues 8-179 of YKG9 (Ho et al, 2000). YKG9 
dimerizes and most of the dimer interface is made up of residues of the N-terminal 
tail, α3, β2, β3 and the β2- β3 loop (Figure 1.4). CYS91 and CYS125 form a 
disulfide bond in YKG9, this disulfide bond reduces the conformational freedom of 















Figure 1.4: The structure of the GAF domain of yeast protein PDB code YKG9. (A) 
Overall structure of YKG9 dimer. (B) YKG9 monomer in two different views related by a 














loop and β3- β4 loop containing CYS91 and CYS125. It has been suggested that 
the disulfide linkage provides stability to the YKG9 crystal, since crystals grown in 
high concentration of reducing agent (dithiothreitol DTT) are small and diffract 
poorly (Ho et al, 2000). The first structure of any PDE GAF domain was the 2.9 Å 
resolution crystal structure of PDE2A tandem GAF domain. The structure shows a 
parallel homodimer in which GAF A contains no ligand but forms a dimerization 
link with a second GAF A, while GAF B does not contribute to the dimerization 
interface but binds cGMP in a deeply buried pocket (Figure 1.5) (Martinez et al, 
2002a). 
 
1.2.1.3 GAF domain functions  
A subfamily of GAF domains has emerged as cyclic nucleotide (cNMP)-binding 
domains that allosterically control the catalytic activity of cyclic nucleotide 
phosphodiesterases (PDEs). Five PDEs (PDE2, 5, 6, 10 and 11) contain two N-
terminal GAF domains, the first N-terminal domain is labeled as GAF A and the 
second C-terminal as GAF B (Heikaus et al, 2009). So far, only one GAF domain 
in each PDE monomer has been shown to bind cyclic nucleotide. It has been found 
that the GAF A domain of PDE5, 6, and 11 and the GAF B domain of PDE2 bind 
cGMP, while cAMP binds to the GAF B of PDE10 (Heikaus et al, 2009). PDEs 
regulate the cellular concentration level of the cyclic nucleotides cGMP and cAMP, 
both of which are essential second messengers in many signal transduction 
pathways (Martinez et al, 2002b). Cyclic GMP binds immediately to ion channels, 
activates protein kinase G (PKG), and controls the activity of phosphodiesterases. 
Cyclic AMP activates protein kinase A (PKA), which like PKG, phosphorylates a 
number of protein substrates. Adenylyl and guanylyl cyclases catalyze the 
synthesis of cyclic nucleotides, where 3,5-cyclic nucleotide phosphodiesterases 
(PDEs) hydrolyze these second messengers to the inactive 5-monophosphates 
(Martinez et al, 2002b). Because of their critical role in many disease-related 
pathways, PDEs are valuable drug targets. For example Vigra, Cialis and Levitra 
target PDE5 as it plays role in the male erectile pathway (Heikaus et al, 2009). 
However, in 2007 a new GAF domain function appeared when Lin and colleagues 
found that the E. coli free methionine-(R)-sulfoxide reductase (fRMsr) was the first 















Figure 1.5: The structure of PDE2A the regulatory segment of mouse (PDB code 
1MCO). Each PDE2A subunit contains a GAF A and a GAF B domain. The GAF A domain 
and seven turns of the connecting helices form a dimer interface. The two GAF B domains 














domains bind cyclic nucleotides, chromophores and many other ligands for signal 
potentiation (Lin et al, 2007). 
 
1.2.2 Methionine sulfoxide reductases  
 
1.2.2.1 Reactive oxygen species (ROS) and oxidative stress 
Reactive oxygen species (ROS) or free radicals are chemically reactive molecules 
containing oxygen, such as the superoxide anion and hydrogen peroxide. ROS are 
generated as part of the normal aerobic cellular existence and have essential roles 
in cell signaling and homeostasis but during times of environmental stress, ROS 
levels can increase dramatically, and this stimulates the formation of many other 
molecules able to cause oxidative stress in cells (Hoshi & Heinemann, 2001). 
Several non-enzymatic and enzymatic procedures are used to maintain the overall 
balance between ROS production and elimination (Finkel, 2000). ROS, specifically 
in the presence of cofactors such as certain metal ions (Fe2+, Cu2+, Co2+ and  Mn2+), 
are able to oxidatively damage and modify many cellular components such as 
DNA, proteins and lipids. This damage is likely to contribute to ageing, age-
associated changes and age-related degenerative diseases like Alzheimer’s and 
Parkinson’s diseases (Hoshi & Heinemann, 2001; Stadtman, 1992). The oxidative 
stress induced by these reactive oxygen agents might cause DNA damage which 
may lead to cell death, abnormal cell growth and mutations, which in turn may 
result in cancer (Lee et al, 2009). It can lead also to lipid peroxidation which 
results from oxidation of cholesterol and fatty acids and may change membrane 
rigidity, and permeability, and may disrupt membrane networks and generate toxic 
products such as malondialdehyde (Nair et al, 2007). Oxidized proteins may 
become dysfunctional due to structural modification and catalytic failure (Lee et al, 
2009). Amino acids in proteins have a high tendency to be oxidized by the ROS 
and this oxidative change affects the backbone as well as the amino acid side 
chains. Side chain oxidation can modify the overall chemistry of the amino acids 
which spontaneously changes protein function (Stadtman & Berlett, 1998). The 
sulfur-containing amino acids, cysteine and methionine, are the most sensitive 
residues to ROS-mediated oxidation, but also the side chains of lysine, histidine, 
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arginine, proline, tryptophan and tyrosine are prone to be oxidized (Stadtman & 
Berlett, 1998). Moreover the thiol-containing cysteine oxidation is regularly 
stimulated by the presence of small amounts of metal ions such as Fe2+, Cu2+, Co2+ 
and  Mn2+ producing several products like sulfenic ions, disulfides and sulfonic 
ions. Disulfide formation is the most common result of cysteine oxidation, but this 
reaction can be easily reversed to thiol by using reducing agents such as 
glutathione in vivo or dithiothreitol (DTT) in vitro (Finkel, 2000).  
 
1.2.2.2 Oxidation of methionine 
Methionine is a sulfur-containing amino acid susceptible to oxidization by a range 
of different ROS, such as O2-., H2O2, peroxynitrite (ONOO-) or .OH to methionine 
sulfoxide (Met-SO). The formation of methionine sulfoxide has been recorded in 
native proteins and reveals that methionine side chain oxidation is a 
physiologically consistent phenomenon. Methionine oxidation to methionine 
sulfoxide (Met-SO) or even further oxidation to methionine sulfone (Met-SO2) is 
expected to induce significant changes in the methionine side chains physical 
properties, leading to protein function alteration (Hoshi & Heinemann, 2001). A 
change in hydrophobicity is one aspect of these changes where the side chain of the 
normal methionine is long, flexible, and non-polar but the side chain of methionine 
sulfoxide with the additional oxygen atom is stiffer and more polar than the 
methionine side chain. The specific oxidation and reduction of methionine residues 
in proteins may cause serious effects in protein function and cell physiology. 
Methionine oxidation is considered as one of the essential factors that contribute in 
physiological dysfunctions to the long-term age-associated changes and 
degenerative diseases. Moreover methionine oxidation is expected to play a role in 
physiological dysfunctions if there is acute local generation of excess ROS (Hoshi 
& Heinemann, 2001). Several examples of protein damage by methionine 
oxidation leading to critical clinical issues have been described, like reperfusion 
injury resulting from ischaemic episodes, which can take place in almost all organs 
but notably in brain and cardiac tissues. Reperfusion occurs in the condition of 
amble production of ROS and cell damage (Chan, 1996). The proteins damaged by 
oxidation play a significant role in inflammatory processes (Winrow et al, 1993). 
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The level of methionine oxidized protein increases with age (Stadtman, 1992) in 
different systems especially the human brain, human eye lens and human 
erythrocytes. Various degenerative diseases have been linked to methionine 
oxidation proteins such as Parkinson’s disease, Alzheimer’s disease and eye lens 
cataracts (Hoshi & Heinemann, 2001). Also animal models show that old animals 
are more sensitive to oxidative stress and the life period of animals corresponds to 
the amount of oxidized protein (Yu et al, 1998). However, there are many proteins 
that have methionine side chains and oxidation of these residues does not seem to 
damage function. Accordingly, it has been suggested that the cyclic 
oxidation/reduction of these methionine residues is regulated by an anti oxidative 
system (Lee et al, 2009). 
 
1.2.2.3 Methionine sulfoxide reductase (Msr) family 
Oxidation of methionine produces a diastereomeric mixture of methionine S-





Methionine sulfoxide (Met-SO) has been involved in a variety of diseases and in 
the aging process. Several types of methionine sulfoxide reductase (Msr) mediate 
the reduction of Met-SO. The first Msr enzyme called MsrA was identified in 
1978, and it was found that this enzyme is able to rescue the function of oxidized 
ribosomal protein L21 in E. coli by reducing the oxidized state of the protein 
(Caldwell et al, 1978). After the discovery of the first Msr enzyme, many Msrs 
have been found in a wide range of organisms, and currently these enzymes can be 
classified into three types (Lee et al, 2009): 
1. MsrA: 
MsrA catalyzes the reduction of free and protein-based methionine-S-sulfoxide 
Met-S-SO Met-R-SO 
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 (Met-S-SO) (Lee et al, 2009). It is a small cytosolic enzyme that exists in a wide 
range of organisms from bacteria to plants and mammals, including humans. The 
amino acid sequence is well conserved among various species (Hoshi & 
Heinemann, 2001). In mammals MsrA is the only recognized enzyme able to 
reduce methionine-S-sulfoxide (Moskovitz et al, 2000). It has been found that 
MsrA is expressed in different tissues in rat such as liver, kidney, heart and brain 
(Moskovitz et al, 1996). In adult humans it is highly expressed in liver and kidney 
and this corresponds with the theory that MsrA plays a role as an anti-oxidant 
enzyme. In addition MsrA has been found in human heart and brain, and the brain 
also has a high level of overall MsrA expression (Kuschel et al, 1999) but it is 
highest in the cerebellum which suggests that methionine oxidation may play a role 
in neural function (Hoshi & Heinemann, 2001). At the subcellular level MsrA is 
found in the cytosol, mitochondria and nucleus, however the molecular mechanism 
and regulation remains unclear (Kim & Gladyshev, 2005b).      
 
2. MsrB: 
The second Msr named MsrB is responsible for the reduction of protein-based 
methionine-R-sulfoxide (Met-R-SO) and also it may catalyze the reduction of free 
methionine-R-sulfoxide, but with low efficiency (Lee et al, 2009). For example, the 
reduction capability of E.coli MsrB on the free methionine-R-sulfoxide is 1000 fold 
lower then the catalytic ability of E.coli MsrA for the reduction of free methionine-
S-sulfoxide (Grimaud et al, 2001). Moreover in humans MsrB is not efficient at 
reversing the free methionine-R-sulfoxide to free methionine (Lee et al, 2009). In 
mammals, MsrBs have been classified into three types: MsrB1, MsrB2 and MsrB3   
according to their catalytic mechanism. All three types have Zinc (Zn), coordinated 
by two CxxC motifs (two cysteines separated by two residues) which stabilizes the 
MsrB structure (Kryukov et al, 2002). Among three mammalian methionine-R-
sulfoxide reductases (MsrBs), MsrB1 is a Selenocysteine-containing protein, 
whereas MsrB2 and MsrB3 contain CYS in the active site (Kim & Gladyshev, 
2005a). Mammalian MsrB1 occurs in the cytosol and nucleus, MsrB2 in the 
mitochondria and MsrB3 in endoplasmic reticulum and mitochondria (Lee et al, 
2009).      
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3. fRMsr: 
The third type of Msr is the free methionine-R-sulfoxide reductase (fRMsr). This 
type was discovered in 2007 when Lin and his colleagues purified the enzyme from 
the MsrA and MsrB strain and determined the identity of (fRMsr) through 
proteomic analysis. The fRMsr domain was identified as a member of the large 
GAF domain family, which were initially known as cGMP-binding 
phosphodiesterases. Sequence analysis of fRMsr shows that the domain is 
conserved among unicellular organisms, like bacteria and yeast, but it is absent in 
multicellular organisms including mammals (Lin et al, 2007).     
The three Msr types maintain proteins function by catalyzing the reduction of free 
methionine sulfoxide and methionine sulfoxide-containing proteins. Methionine 
sulfoxides and Msrs may also contribute in sensing changed redox (reduction-
oxidation reactions) status and regulating certain proteins (Lee et al, 2009). 
However, the three types of Msr have different catalytic features: The mammalian 
MsrA and fRMsr have three conserved cysteines involved in the reaction as 
catalytic and resolving cysteines. The catalytic cysteine attacks the sulfur of 
methionine sulfoxide generating a cysteine sulfenic acid intermediate (CYS-SOH) 
with release of methionine. The generated thiol (catalytic cysteine bonded sulfenic 
acid) forms a disulfide bond with the resolving cysteine, which is finally reduced 
by thioredoxin (Figure 1.7). The difference between MsrA and fRMsr includes the 
binding site volume, where the fRMsr has a narrow binding pocket, which restricts 
access to bulky substrates. This difference corresponds to the substrate specificity 
of both types (Boschi-Muller et al, 2008; Lin et al, 2007; Lowther et al, 2000). 
MsrB enzymes have various mechanisms. MsrB1 possesses one conserved cysteine 
in the N-terminal part and the catalytic selenocysteine in the C-terminal part. A 
selenic acid intermediate at the catalytic selenocysteine is produced when this 
catalytic residue attacks the sulfur of methionine-S-sulfoxide and then this 
intermediate rearranges into selenenylsulfide with the assistance of the resolving 
cysteine and it is finally reduced by thioredoxin (Kim & Gladyshev, 2005a). In 
comparison MsrB2 and MsrB3 have only one conserved cysteine, which suggests a 
different catalytic mechanism where the sulfur of methionine-S-sulfoxide is 
attacked, by the catalytic cysteine and the sulfenic acid intermediate produced and 
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directly reduced by thioredoxin without disulfide formation between catalytic and 
resolving cysteines (Kim & Gladyshev, 2005a). 
 
1.2.2.4 Role of methionine sulfoxide reductases in bacterial 
pathogenicity 
The methionine sulfoxide reductases (Msr) may be a determinant agent for 
bacterial pathogenicity. Several recorded studies show that these enzymes may play 
significant roles in bacterial virulence and they assume that these roles are related 
to the function of the methionine sulfoxide reductases as antioxidant systems 
(Ezraty et al, 2005). In one of these studies for example, they found that Erwinia 
chrysanthemi, which is a plant pathogen, attacks plants by producing a massive 
amount of plant cell degradation, can prevent the infection of the whole plant by 
destroying the MsrA in this bacterium. They found a significant difference in 
virulence of the wild type Erwinia chrysanthemi and the MsrA mutant Erwinia 
chrysanthemi (El Hassouni et al, 1999). Another example of restricting bacterial 
virulence by generating Msr mutants is in Staphylococcos aureus, a leading cause 
of hospital and community-acquired infection (Singh & Moskovitz, 2003). Also it 
has been shown that MsrA and MsrB mutants in Neisseria gonorrhoeae and 
Neisseria meningitidis are not able to cause the sexually transmitted infection 
Gonorrhoea and the meningitis respectively, while wild types of both pathogens are 
capable of producing the diseases (Shafer & Rest, 1989). 
 
1.2.3 Examples of methionine sulfoxide reductases 
containing GAF domain 
All the known methionine sulfoxide reductases containing GAF domains are of the 
free methionine-R-sulfoxide reductase fRMsr type (Lee et al, 2009). The genomic 
analysis of fRMsr showed that its existence is restricted to unicellular organisms, 
where multicellular organisms, including mammals lack this enzyme (Lee et al, 
2009). So far, four crystal structures of fRMsr are available and they are deposited 
in the Protein Data Bank with the following codes: 1VHM, 3KSF, 3MMH and 
3RFB (3RFB has been identified as an fRMsr in PDB but is still not published). 
 52 
These enzymes are from Escherichia coli, Staphyloccus aureus, Neisseria 
meningitidis and Streptococcus pneumonia, respectively.   
 
1. Free methionine-R-sulfoxide reductase from Escherichia coli  (1VHM):    
The crystal structure of E. coli fRMsr in complex with a MES buffer molecule has 
been solved by Badger and his colleagues (Badger et al, 2005) but no known 
function was recorded, this structure has the code 1VHM in Protein Data Bank 
(PDB). Two years later, the type three Msr, fRMsr was first named and identified 
by Lin and his colleagues (Lin et al, 2007). In this study they determined and 
characterized the Escherichia coli fRMsr by its extraction and purification from the 
MsrA-B- strain and proteomic analysis. The fRMsr sequence is highly conserved 
across bacteria and yeast but is absent in multicellular organism including humans. 
The sequence database shows many homologous sequences including many 
hypothetical proteins of unknown function (Lin et al, 2007). The recombinant 
fRMsr DNA was created and the histidine tagged fRMsr protein was expressed 
with a molecular weight of ~24 kDa. The reducing system and substrate specificity 
of E. coli fRMsr were examined by evaluating the reductase activity using different 
test conditions, containing substrates of different sizes and isomers of Met-SO, and 
the reductase activity was estimated by monitoring the decrease in NADPH 
absorbance at 340 nm. fRMsr exhibited the highest Met-SO reductase activity 
when all components of the NADPH-TrxR-Trx system were present in the 
reaction. The enzyme shows precise substrate specificity to free Met-R-SO, and it 
was not able to catalyze the reduction of Met-S-SO, Met sulfone, dimethyl 
sulfoxide or the Met-SO when binding the synthetic peptide NH2-Pro-Thr-Ser-Met-
(RS)-O-Glu-His-Val-NH2. In contrast they found that the control proteins, bovine 
MsrA and Neisseria gonorrhoeae MsrB are able to reduce both free and peptide 
bound forms of Met-S-SO and Met-R-SO, respectively (Lin et al, 2007). The 2.1 Å 
resolution crystal structure of E. coli fRMsr in complex with a MES buffer 
molecule consists of six antiparallel β-strands, four α-helices and two loops. The 
structure shows that the MES sulfonic acid group is close to CYS94 and the 
disulfide bond between CYS84 and CYS118 and this is similar to the arrangement 











Figure 1.6: E. coli fRMsr structure (PDB code 1VHM). (A) Overall structure shows the 
MES molecule in stick rendering and located in the active site. (B) Close up in cartoon 
represention view of the active site shows the MES molecule close to the three conserved 
CYS residues: CYS 84, CYS 94 and CYS118. The disulfide bond is shown between CYS 















of the DALI database with the E. coli fRMsr structure showed a high homology to 
the GAF domain family suggesting that the fRMsrs use three cysteine residues for 
catalysis and formation of a disulfide bond to enclose a small active site cavity. 
The E. coli fRMsr has been considered as the first a GAF domain family member 
to exhibit enzymatic activity, as the previous only known function of GAF domain 
was binding cyclic nucleotides for signal potentiation. This suggests that the free 
Met-R-SO may act as signaling molecule in response to oxidative stress (Lin et al, 
2007).  
 
2. Free methionine-R-sulfoxide reductase from Staphylococcus aureus (3KSF)   
Crystal structures of the reduced, substrate-bound and oxidized forms of fRMsr 
from Staphylococcus aureus have been obtained by Bong and his colleagues (Bong 
et al, 2010). Staphylococcus aureus is a leading cause of hospital-and community-
acquired infections (Singh & Moskovitz, 2003). The S. aureus fRMsr sequence 
reveals that the enzyme like the E. coli fRMsr, contains three conserved cysteine 
residues (CYS68, CYS78 and CYS102) for catalyzing the free methionine-R- 
sulfoxide reduction. Also the S. aureus fRMsr has a narrow and small active site 
and these enclosed cavities in all fRMsr enzymes confirm the obvious substrate 
specificity for free methionine-R- sulfoxide in comparison with the peptide based 
methionine sulfoxide which requires a wider active site. It had been suggested in 
previous studies that the catalytic cysteine in Staphylococcus aureus fRMsr is CYS 
78 and the disulfide bond between CYS68 and CYS102 (Lin et al, 2007). But in 
the Bong study the biochemical analysis suggests CYS102 as a catalytic cysteine 
but also it forms a disulfide bond with CYS68 while, the CYS78 that was 
previously thought to be a catalytic cysteine, is not essential for catalytic function 
(Bong et al, 2010). In this study the biochemical analysis was achieved by using 
the wild type Staphylococcus aureus fRMsr and single and double mutants where 
the three conserved cysteines were replaced with serine residues. To decide what 
the function of each cysteine residues  (CYS68, CYS78 and CYS102) was, the 
following single and double mutants were created: (C68S, C78S, C102S, 
C68S/C78S and C68S/C102S) and they compared the Trx-dependent activities of 
these mutants with the wild type. Interestingly, they found that the C78S mutant 
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retains 75% of enzyme activity in comparison with the wild type, although the 
CYS78 is thought to be the catalytic residue in Escherichia coli fRMsr. The mutant 
C68S/C78S kept 22% of enzyme activity but in contrast, C102S had no catalytic 
activity and C68S/C102S had no activity either. The catalytic activity of C68S was 
32% of the wild type. Accordingly, Bong et al suggested CYS102 is the catalytic 
cysteine, CYS68 may act as the resolving cysteine that forms a disulfide bond with 
CYS102, and CYS78 is not critical for catalytic activity. So the suggested catalytic 
mechanism of Staphylococcus aureus fRMsr is: CYS102 attacks free methionine-
R-sulfoxide leading to the formation of the thiol (Cys-sulfonic acid intermediate) 
and releasing of methionine. CYS68 interacts with the Cys-sulfonic acid to form a 
disulfide bond. Finally the disulfide bond is reduced by a reductant (Trx in vivo or 
DTT in vitro) (Figure 1.7) (Bong et al, 2010). Structural comparisons between the 
reduced substrate-bound and oxidized forms of Staphylococcus aureus fRMsr 
suggests that conformational changes appear in the active site during catalysis 
(Figure 1.8) (Bong et al, 2010). 
 
3. Free methionine-R-sulfoxide reductase from Neisseria meningitides 
(3MMH) 
Interestingly, another fRMsr structure from Neisseria meningitides presents 
conflicting results. The crystal structure of oxidized Neisseria meningitides fRMsr 
was solved at 1.25 Å resolution in complex with free methionine-R-sulfoxide 
(Gruez et al, 2010). Like all the fRMsrs, Neisseria meningitidis fRMsr contains 
three conserved cysteines (CYS118, CYS94 and CYS84) but also had an additional 
cysteine residue in position 136. Biochemical and kinetic data from the wild type 
and mutants in which the cysteines were replaced by alanine was performed to 
determine the catalytic mechanism. Single, double and triple mutants were made 
and the Trx-dependent activities of these mutants were compared with the wild 
type. They found that all mutants remained active except the mutant C118A which 
indicates that the catalytic cysteine is CYS118. This result is consistent with 
Staphylococcus aureus fRMsr where the CYS118 corresponds to CYS102 in 
Staphylococcus aureus (Gruez et al, 2010). But a significant difference was noticed 
between the crystal structure of the substrate-bound form of Staphylococcus aureus 
fRMsr and the structure of oxidized Neisseria meningitidis fRMsr when binding  
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Figure 1.7: Staphylococcus aureus fRMsr (PDB code 3KSF) reduction activity. (A) 
Suggested catalytic mechanism of Staphylococcus aureus fRMsr. (B) Structural 
comparison shows conformational changes in the active site. Reduced fRMsr exhibits an 
open conformation in the active site and after binding of substrate the enzyme changes to 
closed conformation. Oxidized fRMsr displays a more closed conformation by the 


















Figure 1.8: Conformational changes of fRMsrred, fRMsrsub, and fRMsrox forms of 
Staphylococcus aureus fRMsr (PDB code 3KSF). The active site is shown with 


















substrate. The difference is in the orientation of the position of substrate binding 
where the sulfoxide moiety in the Staphylococcus aureus fRMsr replaces the 
position of the carboxylate group in Neisseria meningitides fRMsr and vice versa 
(Bong et al, 2010; Gruez et al, 2010). However the Staphylococcus aureus fRMsr 
substrate bound structure was obtained using a mutant of CYS68 (corresponding to 
CYS84 in Neisseria meningitides fRMsr), which is the resolving cysteine that 
forms the disulfide bond with the catalytic cysteine CYS102 (CYS118 in Neisseria 
meningitidis fRMsr) (Bong et al, 2010). While the oxidized- substrate bound 
complex of Neisseria meningitidis fRMsr form a disulfide bond between CYS118 
and CYS84 (Gruez et al, 2010). The structure of Neisseria meningitides fRMsr 
(Figure 1.9) shares the overall topology of GAF domains. The structure of a 
subunit is arranged around a central twisted antiparallel β-sheet composed of six 
strands (β3-β2-β1-β6-β5-β4) bounded on one side by a three-α-helix bundle 
comprising the helices α1, α2 and α4, and on the opposite side by a unit consists of 
loop- β3- α3-loop (Gruez et al, 2010). Loop- β3- α3-loop motif links the overall β-
sheet and the loop between β4 and β5 strands functions as a capping flap that shield 
the active site.    
 
1.2.4 A new free methionine-(R)-sulfoxide reductase from 
Burkholderia pseudomallei (BPSL2418) belongs to the 
GAF domain family 
The rise of drug resistance in pathogenic microorganisms represents a major 
challenge to human health and life. Burkholderia pseudomallei is one of the high 
resistance organism to antibiotics including the currently used drug, ceftazidime 
(Thibault et al, 2004). The growing number of microbial genome sequencing 
projects and the improvement of bioinformatics tools faciliate in silico analysis of 
gene sequence information (Kaminski, 2000). This computer-aided facility is 
useful in the identification, validation, and selection of the potential genes leading 
to further experimental analysis and characterization, which could also be potential 
drug candidates. Recently in silico analysis of the Burkholderia pseudomallei 
genome sequence has identified 312 essential genes, which might be drug targets 















Figure 1.9: Cartoon ribbon of oxidized- binding substrate complex of Neisseria 
meningitides fRMsr (PDB code 3MMH). The two subunits are in white and yellow. The 
flap of the gray subunit is in red. The Met-R-SO is represented in a stick representation 
with the carbon atoms in purple, the oxygen atoms in red, the nitrogen in blue and sulfur 










survival of B. pseudomallei including outer and inner membrane proteins, 
regulators, proteins involved in pathogenenicity, adaptation, chaperones as well  as 
proteins involved in degradation of small molecules and macromolecules, energy 
metabolism, information transfer, central/ intermediate/ miscellaneous metabolism 
pathways and some conserved hypothetical proteins of unknown function (Chong 
et al, 2006). Also a proteomic analysis between pathogenic strains of Burkholderia 
determined a list of possible candidates that might play roles in B. pseudomallei 
pathogency. BPSL2418 is one of these putative targets in B. pseudomallei and it 
has been identified as a conserved hypothetical protein of unknown function 
(Chong et al, 2006; Wongtrakoongate et al, 2007). Sequence analysis shows that 
BPSL2418 gene encodes a protein containing a GAF conserved domain (Figure 
1.10). A blast search was conducted to find potential homologs in other organisms 
of known function or structure, and shows that BPSL2418 shares high homology 
with the GAF domain fRMsr enzymes. High sequence identity has been found 
between BPSL2418 and the fRMsrs of known structure, 1VHM, 3KSF, 3MMH 
and 3RFB, which suggest that BPSL2418 might act as methionine sulfoxide 
reductase (Figure 1.11). Amino acid sequence alignment between the fRMsrs 
including BPSL2418 shows that the three cysteines that are thought to catalyze the 
reduction are fully conserved. BPSL 2418 contains the three conserved cysteines 
(CYS75, CYS85 and CYS109) in the active site and an additional cysteine residue 
in position 154 (Figure 1.12).  
In the Protein Data Bank a crystal structure of peptide methionine-R-sulfoxide 
reductase in Burkholderia pseudomallei (PDB code 3CEZ) is available, but up to 
date this work is not published. This protein was represented as an MsrB family 
member and it has similar structure features of the MsrBs, which are composed of 
8 β strands and two N-terminal α helices (Figure 1.13). The 3CEZ protein structure 










Figure 1.10: BPSL2418 is a GAF domain-containing protein. Available from the 






Figure 1.11: The percentages of sequence identity and similarity between the 
hypothetical protein from Burkholderia pseudomallei BPSL2418 and the GAF 
domain fRMsrs enzymes: Escherichia coli fRMsr, Staphyloccus aureus fRMsr, Neisseria 
meningitidis fRMsr and Streptococcus pneumonia fRMsr which have the Protein Data 






3MMH          MH-ALHFSASDKAALYREVLPQIESVVADETDWVANLANTAAVLKEAF-GWFWVGFYLVD 
BPSL2418      MFALSEALPSSKPALYETLAAQARALVETETDIVANAANFASLVYHSLDGLNWAGFYFFD 
1VHM          ---------MNKTEFYADLNRDFNALMAGETSFLATLANTSALLYERLTDINWAGFYLLE 
3KSF          -------MTTINPTNYTLLKKQAASLIEDEHHMIAILSNMSALLNDNLDQINWVGFYLLE 
                         :   *  :  :  :::  *   :*  :* :::: . :    *.***:.: 
 
3MMH          TRSDELVLAPFQGPLACTRIPFGRGVCGQAWAKGGTVVVGDVDAHPDHIACSSLSRSEIV 
BPSL2418      G--RELVVGPFQGKPACVRIPLGKGVCGTAAQTRGTQVVHDVHAFAGHIACDSASQSEIV 
1VHM          D--DTLVLGPFQGKIACVRIPVGRGVCGTAVARNQVQRIEDVHVFDGHIACDAASNSEIV 
3KSF          Q--NELILGPFQGHPACVHIPIGKGVCGTAVSERRTQVVADVHQFKGHIACDANSKSEIV 
                   *::.****  **.:**.*:**** *     .  : **. .  ****.: *.**** 
 
3MMH          VPLFSD-GRCIGVLDADSEHLAQFDETDALYLGELAKILEKRFEASRQAV------- 
BPSL2418      VPLVARDGALIGVWDVDSPLVGRFDAEDAIGMEALCRVFVEVAWENATRRGE----- 
1VHM          LPLVVK-NQIIGVLDIDSTVFGRFTDEDEQGLRQLVAQLEKVLATTDYKKFFASVAG 
3KSF          VPIFKD-DKIIGVLDIDAPITDRFDDNDKEHLEAIVKIIEKQLA------------- 
              :*:.      *** * *:    :*   *   :  :   : :                 
 
Figure 1.12: Amino acid Alignment of BPSL2418, E. coli fRMsr (1VHM), 
Staphyloccus aureus fRMsr (3KSF) and Neisseria meningitidis fRMsr (3MMH) 
proteins. (*) indicates a fully conserved residue. (:) indicates conservation between 
groups of strongly similar properties. (.) indicates conservation between groups of weakly 
similar properties. The three fully conserved cysteines are in red. Cysteines in green are 
non-conserved residue. The amino acid alignment was achieved using Clustal omega 




















Figure 1.13:  Cartoon representation of peptide methionine-R-sulfoxide reductase in 
Burkholderia pseudomallei (3CEZ) protein. The structure is composed of 8 β strands 
and two N-terminal α helices with an acetic acid binding ligand. Adapted from the Protein 

























1.3 Aims of the projects 
Melioidosis has emerged as a lethal disease threat in the endemic areas and 
potentially all over the world. Unfortunately, the molecular mechanisms of 
virulence and pathogenicity of Burkholderia pseudomallei remain unknown. But 
genomics and proteomics research have selected putative targets in Burkholderia 
pseudomallei that might play roles in the virulence and pathogenicity of the 
organism. This project aims to determine the structure of one of the hypothetical 
unknown function target proteins in Burkholderia pseudomallei, BPSL2418. It has 
been predicted from the sequence analysis that BPSL2418 might function as a free 
methionine sulfoxide reductase and interestingly there is a link between the level of 
the methionine sulfoxide in pathogen tissues and its virulence (Ezraty et al, 2005). 
Currently few structures of free methionine sulfoxide reductase are known, and the 
more structures of this domain to be solved will help in understanding their role 
and the mechanism of these enzymes.  
Therefore in this thesis I describe the cloning expression, purification and 
crystallization of BPSL2418 and the solution of its 3D structure using X-ray 
crystallography. Also we aimed to identify the substrate bound, MES bound, 
unbound and reduced forms of the enzyme in order to increase the understanding 











Second project: The C-terminal domains of 
Polycystin 1 (CT1) and Polycystin 2 (CT2) 
 
1.4 Polycystin 1 and Polycystin 2  
Polycystin 1 and polycystin 2 are human members of a conserved family of 
proteins that includes homologues in the mouse, the Fugu fish, the sea urchin and 
the worm Caenorhabditis elegans (Wilson, 2001). They are highly expressed on 
renal tubular epithelia (Wilson, 2004). Mutations in genes encoding polycystin 1 
and polycystin 2 are associated with autosomal dominant polycystic kidney 
disease, the most common human genetic disease, with a prevalence of 1 in 800 of 
the world’s population (Wilson, 2001). Although the function of these proteins is 
still unknown, many studies suggest that polycystin 1 is involved in cell-cell or 
cell-matrix interactions whereas polycystin 2 is thought to be a channel protein 
(Wilson, 2001). Polycystin 1 is a large membrane protein with a long extracellular 
N-terminal portion, 11 transmembrane domains and a 200 amino acid intracellular 
C-terminal portion, whereas polycystin 2 is predicted to be a membrane protein 
with six transmembrane-spanning domains and both the N- and the C-terminis are 
predicted to be intracellular. A cytoplasmic interaction has been suggested between 
PC1 and PC2, but no structural study has proved the PC1-PC2 interaction (Wilson, 
2001). 
 
1.4.1 Autosomal Dominant Polycystic Kidney Disease 
(ADPKD): 
Autosomal Dominant Polycystic Kidney Disease is the most common lethal 
inherited disorder that affects the kidneys. It occurs in 1 in 800 live births (Fogazzi, 
1998). Two types of ADPKD are classified: 
Type I is caused by mutations in the Polycystic Kidney Disease1 (PKD1) gene, 
which encodes the polycystin 1 protein. ADPKD type I accounts for 85 to 90 
percent of patients. 
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Type II is caused by mutations in the Polycystic Kidney Disease 2 (PKD2) gene, 
which encodes Polycystin 2 protein, and accounts for 10-15% of all ADPKD cases 
(Reeders et al, 1988). ADPKD is a very widespread genetic disease, and parents 
with ADPKD have a 50 percent chance of passing the disease on to each of their 
children (Wilson, 2001). In addition to the autosomal dominant inherited disorder, 
there is also a recessive form called Autosomal Recessive Polycystic Kidney 
Disease (ARPKD). However ARPKD is much less frequent than ADPKD 
(Stawicki & Lombardo, 2008). One of the significant reasons of renal failure is the 
formation of fluid-filled cysts due to ADPKD. The fluid-filled cysts are formed by 
dysfunction in renal epithelial cells, and they cause a massive enlargement of both 
kidneys (Figure 1.14) (Chapin & Caplan, 2010). Polycystic kidney disease may be 
acquired in adult life as a consequence of aging, drugs and hormones, but most 
forms of PKD are hereditary (Wilson, 2004). 
 
1.4.2 Polycystin 1  
Polycystin 1 is a large membrane protein, which is subdivided into three parts or 
domains (extracellular, transmembrane and intracellular domains) (Figure 1.15). 
 
1.4.2.1 Domain structure of Polycystin 1 
Analysis of the amino acid sequence produced from the cloned full-length PKD1 
gene using UniProt (Universal Protein Resource) predicted that polycystin 1 is a 
massive membrane protein of 4303 amino acids and molecular weight ≥ 462 kDa 
with a long extracellular N-terminal portion, 11 transmembrane helices and short 
intracellular C-terminal portion of ≥ 200 amino acids (Hughes et al, 1995) (Figure 
1.15). 
Extracellular Domain: The first > 3000 amino acids form the long extracellular 
portion that consists of multiple domains of various types such as: Leucine-rich, C-
type lectin motif, Low-density lipoprotein A (LDL-A) domain, Immunoglobulin 
like Polycystic Kidney Disease (Ig-like PKD) domains and Receptor for Egg Jelly 
(REJ) domain (Wilson, 2001). 












Figure 1.14: Kidneys affected by Polycystic Kidney Disease. 
Adapted from http://pathologyproject.files.wordpress.com  



























Figure 1.15: Domain structure of polycystin1. The Extracellular domain: cysteine- 
rich       leucin-rich repeats     C-type lectin motif       LDL-A               Ig-like PKD  
 















The Polycystin 1 transmembrane domain consists of 11 transmembrane regions 
with intervening intracellular and extracellular loops (Hughes et al, 1995). 
Intracellular Domain: The C-terminal of polycystin 1, (CT1) consists of 
approximately 200 amino acids. The sequence alignment of CT1 suggests 
homologs domains from different species that involve in protein-protein interaction 
and phosphorylation signaling (Wilson, 2004). The structure prediction of CT1 was 
obtained using Phyre2 (www.sbg.bio.ic.ac.uk/phyre2/), the predicted structure 
consists of three α helices with connecting loops (Figure 1.16).  
 
1.4.2.2 Cellular and subcellular localization of Polycystin 1  
Several studies have used anti-polycystin 1 antibodies and cDNA to investigate the 
tissue, cellular and subcellular distribution of polycystin 1. Polycystin 1 is highly 
expressed in various tissues including brain, liver, pancreas, heart and intestine, 
and it is also highly produced in the renal tubular epithelial cell of the kidneys 
(Adelsberg et al, 1997; Geng et al, 1996; Ward C et al, 1996). The cellular and 
subcellular patterns of polycystin 1 expression in the human and mouse kidney 
suggest that polycystin 1 is fairly concentrated in the epithelia of the ureteric bud 
(develops to adult kidney) during embryogenesis (Wilson, 2001).  
 
1.4.2.3 Function of Polycystin 1 
Although the polycystin 1 function in the kidney is not fully understood, there is 
strong evidence of a developmental regulation role for it in the kidney. This has 
been shown by mutations of the PKD1 gene in mice leading to cystic kidneys and 
embryonic or perinatal death (Lu et al, 1997) It has been deduced from a wide 
range of studies that polycystin 1 functions as a membrane receptor, capable of 
binding and acting with proteins by forming multiprotein complexes at focal 
adhesion, cell-cell junctions and cilia. Also it is able to bind and interact with 
carbohydrates and lipids. These interactions with the extracellular matrix or with 
other cell lead to intracellular signaling via a phosphorylation cascade and 
transcriptional regulation of proteins that regulate renal morphogenesis and 









 Figure 1.16: The structure prediction of the C-terminal domain of Polycystin1 (26 
kDa). The structure consists of three α helices with connecting loops. The structure 























1.4.3 Polycystin 2  
 
1.4.3.1 Domain structure of Polycystin 2 
The PKD2-encoded protein polycystin 2 is a 110 KD membrane protein. 
Sequential analysis using UniProt Predict shows that polycystin 2 consists of six 
transmembrane domains and that both N-terminal and C-terminal of polycystin 2 
are intracellular domains (Figure 1.17). Polycystin 2 belongs to the Transient 
Receptor Potential (TRP) channel superfamily which is distinguished by six 
transmembrane domains and an ion pore between the fifth and sixth 
transmembrane domains (Luo et al, 2003). 
Transmembrane Domain: 
The Polycystin 2 transmembrane domain (Figure 1.17) contains six helices with 
connecting loops homologous to the last six transmembrane helices of polycystin1 
(Mochizuki et al, 1996) As it shares homology with the Transient receptor 
potential TRP superfamily the cation channel is located between the fifth and sixth 
transmembrane helices. 
The C-terminal domain of polycystin 2 CT2: 
The C-terminal portion of polycystin 2, CT2, consists of approximately 289 amino 
acids. Sequence analysis suggests three interesting regions in CT2: an EF-hand 
domain in the N-terminal of CT2 (residues 720 to 796), a linker region (797-825) 
and an oligomeric coiled coil region (833-893) (Mochizuki et al, 1996). Structures 
of two domains from CT2 have been solved recently: the CT2EF-hand by NMR 
(Petri et al, 2010), and the CT2 coiled coil by X-ray crystallography (Yu et al, 
2009). The study by Petri et al has described the NMR structure and the dynamics 
of Ca2+ -bound CT2-EF. They found that human CT2-EF contains a divergent non-
Ca2+ -binding helix-loop-helix (α1-loop- α2) motif packed against a canonical Ca2+ 
-binding helix-loop-helix (α 3-Ca2+ -binding loop- α4) motif (Figure 1.18) (Petri et 
al, 2010). The X-ray study of Yua et al (2009) on the C-terminal region of 
polycystin 2 solved the structure of a fragment from amino acids G833 to G895 at 
1.9 Å resolution. It shows that this fragment forms a continuous α helix and 












Figure 1.17: Domain structure of Polycystin 2. Six transmembrane helices and an ion 
pore between the fifth and sixth transmembrane domains. The intracellular domain 
contains the N-and the C- terminus. CT2EF-hand domain      ,Linker domain      


























Figure 1.18: Human CT2-EF domain: This domain consists of two HLH (alpha helix-loop-
alpha helix) motifs. The (α 1-loop- α 2) on the N-terminal is a non-Ca2+ -binding loop, and 










Figure 1.19: Human CT2 coiled coil domain: The CT2 coiled coil domain forms a trimer 
and also the C-terminal portion of α helices (A873 to G895) splays open to form an 







portion of the α helices from A873 to G895, splays open and in the crystal lattice 
this region interacts with the same region of another trimer, forming a hexameric 
assembly (Yu et al, 2009). The structure prediction of CT2 was obtained using 
Phyre2 (www.sbg.bio.ic.ac.uk/phyre2/), the predicted structure consists of the EF-
hand domain and two helices may be representing the coiled coil domain, and they 
connected by link loop  (Figure 1.20).  
 
1.4.3.2 Cellular and subcellular localization of Polycystin 2 
Polycystin 2 is widespread in many tissues and it regulates the development and 
differentiation of the kidneys with the highest level in the renal tubular epithelium 
(Ong et al, 1999). Although there are some overlapping expression areas of 
polycystin 1 and polycystin 2, which suggests the possibility of interaction between 
them, there are some tissues in which polycystin 2 is expressed but polycystin 1 is 
not, indicating independent functions (Foggensteiner et al, 2000). Also at the 
subcellular level some similar tubular cell types are able to produce both proteins 
but their locations do not overlap with each other (Foggensteiner et al, 2000). 
 
1.4.3.3 Function of Polycystin 2 
In comparison with polycystin 1, polycystin 2 function is less well defined and 
studied. However some current results suggest that polycystin 2 can form 
heterodimers with polycystin 1 (Qian et al, 1997). The sequence homology 
between polycystin 2 and the transient receptor potential (TRP) has led to the 
prediction that polycystin 2 functions as a Ca2+ permeable nonselective cation 
channel (Luo et al, 2003). 
 
1.4.4 Polycystin 1 and polycystin 2 interaction 
Many studies have suggested that the presence of coiled coil motifs in the C-
terminal tails of both polycystin 1 and polycystin 2 may allow protein-protein 
















Figure 1.20: The structure prediction of the C-terminal domain of Polycystin 2 (35 
kDa). CT2 is composed of the EF-hand domain on the right side and the coil-coiled 
domain on the left. The 3D structure was predicted from the protein amino acid sequence 















Coil coiled domain 
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has been shown to bind polycystin 2 in vitro in experimental analyses using yeast 
two-hybrid and overexpression techniques (TSIOKAS et al, 1997). 
Immunolocalization studies have been used to investigate the polycystin 1- 
polycystin 2 interaction in vivo, suggesting that polycystin 1 and polycystin 2 
























1.5 Aims of the project 
Given that the autosomal dominant polycystic kidney disease is the most common 
human genetic disease, with a prevalence of 1 in 800 of the world’s population, the 
Polycystin 1 and Polycystin 2 proteins became important targets for many 
laboratories. The determination of the 3D structures of these proteins may be a 
significant target for researchers to increase the understanding of their functions. 
However, from the point of view of the E. coli protein overexpression system, 
which is the easiest, quickest, and most commonly used procedure, the 
overexpression of a large transmembrane protein such as Polycystin 1 or 
Polycystin 2 would be impractical. Thus many structural studies focus on the 
domains that made up the full protein, and together these studies can create an 
image of the whole protein. It has been thought that the C-terminal domains of 
Polycystin 1 and Polycystin 2 play a role in protein-protein interactions but the 3D 
structures of these domains remain undefined. In order to investigate the roles of 
the C-terminal domains of Polycystin 1 (CT1) and Polycystin 2 (CT2), this project 
aims to obtain the 3D crystal structure of each C-terminal domain. The primary aim 
of this project was to overexpress, purify, crystallize and determine the 3D 
structures of CT1 and CT2. The interaction between CT1 and CT2 has shown in 
vitro, several studies suggest that the interaction between Polycystin 1 and 
Polycystin 2 may be regulated through the coiled-coil domains (Wilson, 2001). 
Therefore a secondary goal of this project was to achieve the 3D crystal structure 










Chapter 2:  Materials and Methods 
 
This chapter includes a general description of the methods and techniques used 
during the work in these two projects. Also this chapter describes the reagents and 
equipments used in this thesis. The work in all two projects in general is aimed at 
the crystallization of these proteins and obtaining the 3D structures using X-ray 
crystallography. X-ray structural studies demand large quantities of soluble, 
properly folded pure protein. But it has become clear that obtaining these proteins 
from their natural sources is often impractical, due to low of expression yields. 
Therefore use of recombinant DNA technologies is an alternative feasible 
application that is able to produce large amounts of a desired protein. The 
technique involves extraction of the DNA from the organism being studied, 
followed by amplification of the gene of interest by use of PCR. The gene is then 
inserted into an expression plasmid and transformed into a host that can be 
manipulated into producing large amounts of the protein of interest. 
 
2.1 Bacterial strains, DNA, plasmids and 
oligonucleotides 
- Bacterial strains: The following E. coli strains were all purchased from 
Novagen; E. coli BL21(DE3), E. coli BL21(DE3)-RIPL,  E. coli Novablue and E. 
coli Tuner DE3 pLacl.  
- Genomic DNA: Burkholderia pseudomallei strain D286 genomic DNA, 
taken from a melioidosis patient at Kuala Lumpur Hospital. 
- Plasmids: The following plasmids were used in this thesis: 
1. The recombinant C-terminal polycystin2 plasmid His-CT2 pET-28a(+)        
Dr Yaoxian Xu from Prof Albert Ong’s team (Academic Unit of Nephrology, 
Department of Infection and Immunity The University of Sheffield Medical 
School) has supplied this plasmid.  
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4. The recombinant C-terminal polycystin1 plasmid GB1-CT1 GEV-S2  
Also provided by prof Albert Ong team.  
5. pETBlue-1 vector 
The vector was purchased from Novagen  
- Oligonucleotides: The oligonucleotides used during the course of this thesis were 
synthesized by Eurofins MWG Opera. 
1. BPSL2418 forward primer  
BPSL2418-F: 5’ ATGTTCGCGCTTTCCGAAGC 3’ 
2. BPSL2418 reverse primer  
BPSLl2418-R: 5’ GATGCCGATTTACTCGCCGC 3’ 
3. pETBlue-1 up: 5’ TCACGACGTTGTAAAACGAC 3’   
4. pETBlue-1 down: 5’ GTTAAATTGCTAACGCAGTCA 3’ 
 
2.2 Materials 
Most of the chemicals, reagents and apparatus used in this thesis were common 
materials and are extensively offered by a wide range of producers. Chemicals 
were purchased from BDH Laboratory Supplies, Poole, England; Fisher Scientific 
UK Ltd., Leicestershire, UK; Bio-Rad Laboratories, Inc., CA, USA; Sigma-
Aldrich, St. Louis, MO, USA; Invitrogen Corporation, CA, USA; Qiagen, Hilden, 
Germany; and GE Healthcare, Freiburg, Germany.  
Substrates:  Free Met-SO (L-Met-R-sulfoxide) from Sigma-Aldrich, St. Louis, 
MO, USA  
 
2.3 Microbiological Methods 
2.3.1 Growth media 
1. Luria-Bertani (LB)  
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Bacterial strains were grown in sterilized Luria-Bertani (LB) medium (Sambrook 
& Russell, 2006). 
The table below describes the composition of media used for E. coli culture. 
                                               LB medium LB-agar 
Tryptone 10 g/l 10 g/l 
Yeast extract 5 g/l 5 g/l 
NaCl 10 g/l 10 g/l 
Bacteriological agar - 15 g/l 
 
2. The SOC medium    
This growth medium was used in the transformation of competent cells with 
recombinant plasmid in the BPSL2418 project (Sambrook & Russell, 2006).   
The table below describes the composition of media used for E. coli culture. 
                                               Amount for 1L 
Tryptone 20 g 
Yeast extract 5 g 
NaCl 0.5 g 
1M KCl 2.5 ml 
1M MgCl2 10 ml 
1 M MgSO4 10 ml 
ddH2O  To 1000 
 
All media were sterilized by autoclaving, and desired antibiotics were added. 
The table below describes the antibiotics used and their working concentrations 
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Antibiotic Final antibiotic concentration 
Ampicillin (Amp) 100 µg/ml 
Chloramphenicol (Cam) 75 µg/ml 
Kanamycin (Kan) 50 µg/ml 
Carbenicillin (Car) 50 µg/ml 
Tetracycline (Tet) 15 µg/ml 
 
 
2.4 Polymerase chain reaction (PCR) 
PCR (Bartlett & Stirling, 2003) was used for two different applications during this 
work: (1) amplification of inserts for cloning and (2) colony PCR to confirm the 
insert’s presence in the purified plasmid post-cloning. In both applications the 
following reaction mixture was used. Occasionally the PCR mixture was varied by 
the addition of 10% DMSO to reduce primer secondary structure formation: 
Genomic template (~ 2 µM) 1 µl 
Sense primer (10 pM) 1 µl 
Antisense primer (10 pM) 1 µl 
BioMix 25 µl 
Sterile, deionized water 22 µl 
Total volume                                                                            50 µl 
BioMix is a premixed PCR cocktail containing Taq DNA polymerase, reaction 
buffer and free dNTPs available from Bioline.  
The PCR reaction mixture was set in thermal cycling using the protocol below: 
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Initial denaturation 94 ºC 4 mins 
Denaturation 













In order to carry out colony PCR the genomic template was changed by boiled cell-
lysate from colonies picked from an agar plate resuspended in 30 µl sterile water.   
 
2.5 Agarose gel electrophoresis 
Agarose gel electrophoresis was used for the separation of DNA fragments to 
either analyze the PCR products or to confirm the presence of inserted genes in 
recombinant constructs. This procedure was accomplished by running samples on 
1% agarose gels and visualizing their migration through the gel matrix. Gel 
formation was carried out by melting 0.5 g agarose into 50 ml of TAE buffer (40 
mM Tris pH 8.0, 20 mM glacial acetic acid, 1 mM EDTA) into a 200 ml Duran 
using a microwave. When the melted agarose cooled down enough to be easily 
touched by hand, a 5 µl of x10,000 GelRed or ethidium bromide was added to 
permit fluorescent visualization of DNA migration under UV light. The gel was 
poured into BioRad Mini-Sub Cell gel-bed (gel rack) with a comb stuck in to form 
the wells. The gel was allowed to set for approximately 20 minutes. Once it had 
solidified the gel was submerged in TAE buffer and the samples, combined with 
loading buffer (0.25% bromophenol blue, 30% glycerol) were loaded into the 
formed well. In order to determine the molecular weight of DNA fragments, a 
molecular weight marker (Hyperladder I from Bioline) was loaded. Electrophoretic 
fractionation was carried out by connecting the gel-tank to its correctly oriented 
electrodes and was run at 100 V. Times ranged between 40-70 minutes depending 
on DNA size, where smaller PCR products were run for 40 minutes and larger 
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fragments such as digested plasmids were run for 60-70 minutes. The gel was 
visualized using a UV lamp and photographs were taken using a digital camera.    
 
2.6 Purification of PCR products by gel extraction:    
 The following protocol was used to extract and purify the DNA of PCR products 
from an agarose gel using a QIAquick Gel Extraction kit and a microcentrifuge: 
The DNA fragments were cut from the agarose gel with a clean sharp scalpel and 
placed in 1.5 ml tubes. Gel slices were weighed, and for gel solubilisation and 
DNA binding to the column’s membrane, 3 volumes of buffer QG (from Qiagen 
Gel Extraction Kit which contains Guanidium Thiochloride), were added to 1 
volume of gel. Gel tubes were incubated at 50 ºC for 10 minutes or until the gel 
slices had totally dissolved. The mixture was placed in a QIAquick spin column. 
To bind DNA, 1 gel volume of isopropanol was added and centrifuged for 1 minute 
at 13000 rpm. 0.5 ml of QG buffer was added and centrifuged for 1 minute. 0.75 
ml of ethanol-containing PE washing buffer was added and centrifuged for 1 
minute. The flow-through was discarded and an additional 1 minute of 
centrifugation was run to remove the remaining buffer. The QIAquick spin column 
was replaced into a clean 1.5 ml tube. To elute the DNA, 30 µl of EB buffer (10 
mM Tris-Hcl, pH 8.5) was added to the center of QIAquick membrane, the column 
was allowed to stand for 2-5 minutes, and then centrifuged for 1 minute.   
 
2.7 Plasmid purification  
All plasmids used in this thesis were extracted from their E. coli hosts by applying 
the standard protocol of Plasmid DNA Purification using the QIAprep Spin 
Miniprep Kit from (QIAGEN) and a microcentrifuge. A colony of E. coli cells, 
containing a particular plasmid vector growing on LB agar containing 100 µg/ml 
carbenicillin, was picked into 3 ml of LB media containing the appropriate 
antibiotics and grown overnight at 37 ºC at 200 rpm. Cells were then harvested by 
centrifugation at 5,000 g for 20 minutes before the plasmids were extracted. Cell 
pellets were resuspended in 250 µl buffer P1, this buffer contains RNase to degrade 
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any RNA, preventing it contaminating the purified plasmid. The cells were then 
subjected to alkaline lysis by the addition of 250 µl buffer P2 and mixing by gentle 
inversion. The solution was neutralised and the salt concentration adjusted to allow 
binding to a QIAprep spin column by the addition of 350 µl buffer N3. DNA 
adsorbs to the silica membrane of the spin column in the presence of high 
concentrations of chaotropic salts at a pH below 7.5. The lysate is then cleared of 
cell debris by centrifugation at 17,000 g for 10 minutes in a benchtop centrifuge. 
All subsequent centrifugation was done at 17,000 g for 60 seconds. The 
supernatant was applied to a QIAprep spin column, centrifuged and the flow-
through discarded. A wash was carried out using 750 µl buffer PE, which contains 
ethanol to precipitate the DNA on the column while removing the salts. The 
column was centrifuged, the flow-through discarded and the column was again 
centrifuged to ensure all ethanol had been removed from the column. The column 
was then transferred to a clean microcentrifuge tube and the DNA was eluted by 
adding 65 µl of water, incubating at room temperature for 2 minutes and finally 
centrifuging to collect the pure plasmid DNA. Yields from minipreps typically vary 
between 10 and 100 ng/µl.         
 
2.8 Cloning of expression construct  
The BPSL2418 expression construct (bpsl2418 pETBlue-1) was cloned during this 
thesis. The general methods and materials used in cloning this construct will be 
described below, but more details are given in chapter 4. 
 
2.8.1 Cloning with pETBlue-1 vector  
The plasmid pETBlue-1 vector (Figure 2.1) facilitates the expression of native 
unfused proteins and allows convenient subcloning of target genes already fused to 
existing detection and purification tags. The EcoRV cloning site is appropriately 
spaced down stream of an E. coli ribosome-binding site. The insert must encode an 
ATG start codon at its 5’ end if expression is desired. The pETBlue-1 vector    
allows insertion of the target gene through blunt ended cloning into an EcoRV 


















Figure 2.1: pETBlue1plasmid map.  










produced plasmid can then be transformed into a bacterial strain deficient in the T7 
polymerase gene to restrict any background expression and with a copy of the ω-
peptide gene of LacZ in its genome. Blue/white screening on agar containing IPTG 
and X-gal can be used to select colonies containing a plasmid with an insertion. 
The lacZ gene fragments are responsible for β-galactosidase expression, which 
allows the break down of X-gal, generating a blue pigment. If the LacZ α-peptide 
gene does not contain an insertion, it is expressed and can combine with the ω-
peptide of LacZ, produced by expression from the genome, giving a functional 
copy of β-galactosidase and a blue colony. Plasmids with an insertion give white 
colonies because they are able to prevent the expression of the α-peptide and 
therefore β-galactosidase activity. In protein expression, expression strains that 
contain a copy of lacI gene such as the pLacI strains should be used in combination 
with the plasmid (pETBlue-1), because it is lacking a copy of this gene. The pLacI 
strains can be selected by a chloramphenicol resistance marker.  
 
2.8.2 Ligation and transformation for pETBlue-1 cloning 
Ligation reactions were set up containing 2 µl purified PCR product 
(approximately 50 ng) and 50 ng AccepTor vector in ClonablesTM ligation premix 
buffer (Novagen) and were incubated at 16 ºC for 30 minutes. Ligation reactions 
were then used to transform Novablue E. coli cells. Eppendorf tubes containing 50 
µl aliquots of cells were removed from the -80 ºC freezer and incubated on ice for 5 
minutes. Once defrosted 1 µl of the ligation reaction was added before being left to 
incubate on ice for 5 minutes. The cells were subjected to a heat shock at 42 ºC for 
30 seconds before being returned to ice for 2 minutes. 250 µl of SOC media was 
then added and the cells were then incubated at 37 ºC at 200 rpm for 60 minutes 
before plating on LB agar containing 100 µg/ml carbenicillin, 15 µg/ml 
tetracycline, 70 µg/ml X-gal and 80 µM IPTG for selection and blue-white 
screening of colonies to select for transformants, that had white colonies containing 
an insert in the vector.  
  
2.8.3 Confirmation of cloning results 
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White colonies were selected and transferred into 100 µl water and boiled at 100 ºC 
for 10 minutes. The mixture was centrifuged at 17,000 g for 5 minutes to remove 
cell debris. PCR conditions were set up as mentioned earlier in (2.4). Results from 
pETBlue-1 cloning were confirmed using two reactions for each colony using 
pETBlueDOWN or pETBlueUP. PCR products were analyzed by electrophoresis 
on a 1% TAE agarose. Desired colonies with correctly sized band(s) were selected 
and transferred into 3 ml LB including 100 µg/ml ampicillin and grown overnight 
at 37 ºC at 200 rpm. The cells were harvested and plasmids were purified using a 
QIAprep Spin MiniPrep Kit (QIAGEN) and the same protocol as before in (2.7). 
Purified plasmids were sent for sequencing using T7F and T7R primers 
(SourceBioscience or Geneservice).    
 
2.9 Transformation   
Recombinant plasmids were transformed into overexpression hosts such as E. coli 
BL21(DE3), E. coli BL21(DE3)-RIPL and E. coli Tuner DE3 pLacl (Tu et al, 
2005). Eppendorf tubes containing 20 µl aliquots of cells at -80 ºC were defrosted 
by incubating the tubes on ice for 5 minutes. 1 µl of plasmid DNA (approximately 
10 ng/µl) was added to the defrosted cell and the reaction was incubated on ice for 
5-30 minutes. The cells were exposed to a heat shock at 42 ºC for 30-60 seconds 
before incubating again on ice for 2 minutes. 250 µl of SOC media was then added 
in case of transformed plasmid into Tuner DE3 pLacl while LB media was added 
in case of E. coli BL21(DE3) and E. coli BL21(DE3)-RIPL. The cells were 
incubated at 37 ºC at 200 rpm for 30 minutes but the Tuner DE3 pLacl was 
incubated at 37 ºC at 250 rpm for 60 minutes before plating on LB agar containing 
the desired antibiotics to select for successful transformants. 
 
2.10 Protein expression  
The E. coli expression system was used to express BPSL2418, CT1 and CT2. 
Optimization work was performed to produce soluble protein. Most of the proteins 
in this thesis were successfully produced as a large amount of soluble proteins but 
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in a single case the protein expressed as inclusion bodies. Several attempts at 
protein refolding were made in order to achieving soluble proteins.  
 
2.10.1 Regulation of protein expression in the pET 
expression system  
The expression hosts used in this thesis are all DE3 lysogen strains containing a 
copy of T7 prophage DNA that includes the T7 polymerase gene downstream to a 
lac promoter site and lac operator-binding site. These strains also have a copy of 
the lacI gene that produces lac repressor protein. The lack of lactose (under normal 
conditions) permits the binding of the lac repressor to the lac operator sequence 
restricting the T7 polymerase expression. Inducing the culture by IPTG (a non-
hydrolysable lactose analog), the IPTG binds to the lac repressor preventing it from 
binding to the operator sequence and permitting the T7 polymerase gene 
transcription. Desired genes are cloned into pET vectors downstream of a T7 
promoter and lac operator site. When T7 polymerase is produced, it transcribes a 
gene within a pET vector resulting in expression of the target gene. The plasmids 
pET-28a(+) and GEV-S2 (vector backbone pET21a) have an extra copy of the lac 
repressor gene to prevent basal expression without the induction of IPTG. The 
absence of the lac repressor gene in pETBlue-1 imposes the use of strains, which 
possess an additional copy of the gene encoded on a plasmid, such as the pLacI 
strains. 
 
2.10.2 Protein overexpression protocol 
In general a similar procedure has been used to express all proteins involved in this 
thesis, where changes have been done to optimize expression yield, there will be 
mentioned in the following chapters.   
 
2.10.2.1 Small-scale overexpression trials 
An initial overnight 5 ml culture grown in LB containing suitable selectable 
antibiotics was used to inoculate 500 ml LB (1% culture dilution) containing the 
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same antibiotics in primary culture. In some cases 1% glucose was added to LB 
culture to increase growth. The culture was grown at 37 °C and 200-250 rpm until 
the optical density at 600 nm reached 0.5-0.8 at which point the culture was 
divided into 50 ml aliquots in 250 ml flasks. Each individual culture was induced 
by the addition of IPTG and treated with various post-induction conditions. 
Different conditions were prepared by changing in temperature, induction time and 
IPTG concentration in order to produce a soluble overexpressed protein, e.g. 
temperature (18 – 37 ºC), time (3 – 20 hours) and IPTG concentration (0.3 – 1 
mM). Samples were taken before and after 1, 2, 3, 4, 18 and 20 hours of induction 
to determine the optimum condition for each protein. Samples where centrifuged at 
17,000 g for 5 minutes in a bench top centrifuge. Samples then stored at -20 ºC 
before cell lysis using bugbuster (Novagen) and PAGE analysis. A mixture of 100 
µl bugbuster A with 1 µl bugbuster B (Novagen) was used to resuspend the cell 
pellets and then the resuspended cell were incubated at room temperature for 15 
minutes. Cell debris and insoluble protein were discarded by centrifugation at 
17,000 g for 10 minutes and the supernatant (the soluble fraction) was collected. 
The pellet, which includes the inclusion bodies, was resuspended in 100 µl 4% 
SDS and incubated at room temperature for 15 minutes. The resuspended pellet 
was centrifuged at 17,000 g for 10 minutes and the supernatant was collected as the 
insoluble fraction. The different overexpression conditions were then judged by 
running fractions of each condition on polyacrylamide gels to identify the optimum 
conditions.     
 
2.10.2.2 Large-scale overexpression trials 
Once optimum conditions were determined for each protein the overexpression 
culture was scaled up to between 2 and 4 l of media in 500 ml aliquots in 2 l 
conical flasks. Cells resulting from overexpression were harvested by 
centrifugation at 5,000 g for 45 minutes and then resuspended in approximately 70 
ml LB. The cells were aliquoted in 50 ml falcon tubes and centrifuged again at 
5,000 g for 30 minutes to remove any excess media. The supernatant was removed 
and the cell pellets were stored at -20 ºC until required. 
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2.11 Sodium dodecyl sulfate Polyacrylamide gel 
electrophoresis (SDS-PAGE) 
SDS-PAGE was used routinely throughout this thesis for analysis of proteins and 
to evaluate the quality of protein expression and purity. SDS-PAGE was carried 
out according to the protocol mentioned in Laemmli’s study (Laemmli, 1970). All 
PAGE equipment was purchased from BioRed and all gels were stained with 
coomassie Brilliant Blue. Gel and buffers ingredients used in this thesis were taken 
from ‘Manual of Molecular Cloning’ (Sambrook & Russell, 2006). All SDS-PAGE 
gels reported in this thesis were 12% (acrylamide concentration). 
 
12% SDS-PAGE separating gel: 
Acrylamide/ Bis solution 5 ml 30% (w/v) 
1 M Tris-HCl, pH 8.8 4.69 ml 
10% SDS (w/v) 125 µl 
Milli-Q water 2.56 ml 





6% SDS-PAGE stacking gel: 
Acrylamide/ Bis solution 1.5 ml 30% (w/v) 
1 M Tris-HCl, pH 6.8 0.94 ml 
10% SDS (w/v) 75 µl 
Milli-Q water 2.6 ml 





1x SDS-running buffer: 
Glycine 14.4g /l 
Tris-HCl 3g /l 
SDS 1g /l 
*Adjust to pH 8.8 2.56 ml 
 
2x SDS-loading buffer: 
Glycerol 20% (v/v) 
Tris-HCl 100 mM 
SDS 4% (v/v) 
Bromophenol blue 0.02% (v/v) 
β-mercaptoethanol 200 mM 
 
1x Coomassie blue stain: 
Methanol 20% (v/v) 
Acetic acid 7.5% (v/v) 
Coomassie Blue 4% (v/v) 
Bromophenol blue 0.1% (w/v) 
 
Destain: 
Methanol 20% (v/v) 
Acetic acid 7.5% (v/v) 
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2.12 Solubilisation and refolding of proteins 
As mentioned above, CT1 was overexpressed as insoluble inclusion bodies in E. 
coli. The inclusion bodies were isolated and attempts at protein solubilisation and 
refolding were performed. 
 
2.12.1 Inclusion bodies preparation   
The following method illustrates the treatment of CT1 inclusion bodies from 5 l of 
E. coli culture. The pelleted cultures were dissolved on ice and resuspended in lysis 
buffer (10 mM Tris, 1 mM EDTA, 10 mM DTT, pH 8.0 + protease inhibitor 
cocktail tablet in a 1:5 w/v ratio). In order to inhibit proteolysis a 1 mM PMSF 
protease inhibitor was added, and to break the bacterial cell walls 500 µg/ml 
lysozyme was added. This suspension then was kept on ice for 30 minutes, with 
shaking by inversion every few minutes. The suspension was divided into 3-4 
Sorval centrifuge tubes (each tube contained ~10 ml). Cell disruption was carried 
out using the sonication method, where each tube of all suspension was sonnicated 
on ice for 60 seconds, five times, with 4 minutes rest on ice between each 60 
seconds sonication. Sonication was run at the maximum attainable amplitude. The 
suspension was centrifuged at 40,000 g for 30 minutes and the supernatant was 
removed. Each pellet was resuspended in 25 ml of ice-cold wash buffer (50 mM 
Tris, 1 mM EDTA, 10 mM DTT, 2% w/v sodium deoxcholate, pH 8.0). To enhance 
the pellet homogeneity, an additional 2 x 60 seconds of sonication was applied to 
the resuspended pellet (as mentioned above). The suspension was centrifuged at 
40,000 g for 30 minutes and the supernatant was removed. The last step (washing 
and centrifugation) was rerun for four times, saving the pellet each time. To discard 
residual detergent, an additional washing was done using distilled water instead of 
wash buffer, a centrifugation step (40,000 g) for 60 minutes was needed to 
completely extract the inclusion bodies from buffer and detergent. A final wash 
step using distilled water and sonication step (30 sec) were accomplished to 
sufficiently disperse the pellet. Inclusion bodies were saved at 4 ºC for 
solubilisation the next day or at -80 ºC for long-term storage.   
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2.12.2 Solubilisation and refolding of inclusion bodies 
CT1 was refolded using a general protocol mentioned in the literature (Sandowski 
et al, 2002).  
 
2.12.2.1 Refolding CT1 
This protocol explains the refolding of CT1 inclusion bodies produced from 2.5 l of 
E. coli culture. The CT1 inclusion bodies were denatured using a solubilisation 
buffer (100 mM Tris, 8 M urea, 500 mM L-arginine, 10 mM cysteine, pH 8.0), 
which was prepared on the day of use. 2 g of TMB mixed bed resin 
(Sigma-Aldrich) was added to deionise the solubilisation buffer, this step was 
performed at 4 ºC in the dark for 2 hours. The buffer was filtered before the 
solubilisation step. CT1 inclusion bodies were added to 500 ml of ice-cold 
solubilisation buffer, and the pH adjusted to 11.3, the mixture was stirred at 4 ºC in 
the dark for 2 hour. The mixture was transferred to dialysis tubing and dialysed 
against 10 l of ice-coled refolding buffer (10 mM Tris, pH 8.0 at 4 ºC). CT1 
refolding was accomplished for a course of 48 hours with 6 external buffer changes 
(4 hours between each change). After 48 hours the solution was centrifuged (13000 
rpm for 10 mins) to pellet the refolded protein and to discard the buffers. The 
protein pellet was diluted with 50 mM Tris pH 8.8. The refolded protein was 
immediately used for purification.  
 
2.13 Protein purification 
Protein crystallization procedures demand pure, homogeneous and concentrated 
(regularly between 5 and 30 mg/ml) protein. In order to achieve pure concentrated 
proteins, several types of column chromatography were used throughout this thesis. 
The first step in the purification of all desired proteins was the lysising of the cells 
that contain the target protein. This was achieved by the procedure of sonication, 
which utilizes high frequency of sonic pulses to destroy the membranes and cell 
walls of bacteria. Cell pellets frozen at -20 ºC were defrosted and resuspended in a 
suitable buffer before homogenization by sonication. Sonication was run on ice for 
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20 seconds 3 times with 20 seconds rest on ice between each sonication, using the 
maximum attainable amplitude. Insoluble proteins and cell debris was separated by 
centrifuging the crude cell extract at 70,000 g for 15 minutes or 60,000 g for 20 
minutes before purification. The following purification methods were used in this 
thesis:  
 
2.13.1 Ion exchange chromatography 
Proteins are separated using ion exchange chromatography on the basis of their 
overall net surface charge. The net surface charge of a protein is determined by the 
amino acids located on its surface and it also dependent on its pH (Hames & 
Hooper, 2005). If the isoelectric point (pI) of a protein is equal to the pH of its 
environment there is no overall charge on its surface. The protein has positive net 
surface charge if the pH is below the pI and it has negative charge if the pH above. 
According to this, ion exchange chromatography can be divided into two types: in 
cation exchange chromatography, the column includes negatively charged beads to 
bind a protein that has a positive charge. The second type is anion exchange 
chromatography, where the column contains positively charged beads to bind a 
negatively charged protein. Protein with a net surface charge opposite to the 
charged column bind, and then these proteins can be eluted by washing the column 
with increasing concentrations of a solution of sodium chloride. Na+ and Cl- ions 
compete for the charged groups on the column leading proteins to elute from the 
column. In this thesis, columns including positively charged diethylaminoethyl 
(DEAE) were used such as DEAE Hi Trap 108 (anion exchange column DEAE-
sepharose Fast Flow weak anion exchanger) from GE Helthcare and Resource Q 
(HPLC) (strong anion exchanger) from GE Healthcare.       
 
2.13.2 Hydrophobic interaction chromatography 
Proteins separate in this type of purification according to diversity in their 
hydrophobic groups on their surface such as phenyl, hexyl, butyl or ethyl groups. 
The existence of an anti-chaotropic salt such as ammonium sulphate increases the 
interaction between the hydrophobic groups on the protein surface and the 
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hydrophobic groups linked to the matrix by competing for dissolution. Protein 
solutions are loaded onto a hydrophobic column in a high concentration buffer, 
permitting hydrophobic patches on the surface of a protein to interact with 
hydrophobic groups of the beads leading to the binding of the protein to the 
column. To elute proteins from the column, the concentration of the buffer is 
reduced, the protein with highest hydrophobicity eluting last. In this work, the 
hydrophobic column used was a 5 ml Hi Trap Phenyl HP cartridge from GE 
Healthcare. A reverse gradient of ammonium sulphate concentration was used to 
elute proteins.   
 
2.13.3 Gel filtration  
Gel filtration is a technique that separates a mixture of proteins based on their size 
and shapeby passing them through a column filled with porous beads. The volume 
inside the column isin two parts, the excluded volume outside the beads, and 
included volume inside the beads. Molecules larger than the pores are unable to 
enter the beads and can therefore only occupy the excluded volume whereas 
molecules that are small enough to enter the beads are able to occupy both the 
included and excluded volumes. Therefore larger molecules will elute first from the 
column, and as the size of a molecule decreases it can enter a larger proportion of 
the beads, retarding its progress down the column and causing it to elute later, until 
finally proteins that can enter all beads elute last. Assuming a protein is globular 
there is a linear relationship between the elution volume of a particular molecule 
from a given column and the logarithmic value of its molecular weight based on its 
partition coefficient: 
Kav = Eluted volume – Void volume 
        Total Volume _ Void volume 
 
Therefore gel filtration can also be used to estimate the molecular weight of a 
protein by comparing its partition coefficient, Kav, to a calibration curve of partition 
coefficient plotted against the log of molecular weight for a particular gel filtration 
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purification step for all proteins, it was also used to determine the oligomiric state 
of CT2 (details given in chapter 7).  A Hi-Load Superdex 200 1.6x60 cm column 
from GE Healthcare, was the gel filtration column in this work. 
 
2.13.4 Nickel Nitrilotriacetic acid (Ni-NTA) Sepharose  
The Ni-NTA is an affinity chromatography method for purifying recombinant, 
histidine tagged proteins. In this type of column, histidine residues in a tagged 
protein bind to the immobilized nickel ions in sepharose porous bead of the 
column. The histidine tag binds to the column with high specificity and affinity, 
and the non his-tagged proteins pass through the sepharose matrix. The bound 
protein is eluted from the column by adding increasing gradient of imidazole, 
which has a higher affinity for the metal more than the histidine affinity to the 
metal.           
 
2.14 Protein concentration    
Protein concentration is a critical factor for crystallization. Concentration was 
achieved using centrifugal ultrafiltration concentrators (Vivascience). This device 
contains two chambers and a polyethersulfone membrane between them. The 
membrane has pores of controlled size; proteins smaller than the pore size will pass 
from the first chamber to the second one. This device was available in different 
sizes such as 10, 30 or 100 kDa. Protein concentration was determined using a Bio-
Rad protein assay protocol of the Bradford method (Bradford, 1976). Reagents 
used in this protocol were purchased from BioRad. In this protocol, protein 
molecules bind Coomassie Brilliant Blue G-250 dye causing a change in the 
solution colour. The changing in colour was measured by using a 
spectrophotometer. The absorbance maximum for the dye changes from 465 nm to 
595 nm when binding to a protein. Protein concentration was determined from the 
absorbance at 595 nm. 
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2.15 Protein crystallization to structure 
identification  
The procedures for producing crystals, crystal mounting, data collection and 
solving a protein structure will be explained in chapter 3. This section describes the 
laboratory techniques employed to produce crystals and solve the structures for the 
target proteins.  
 
2.15.1 Producing crystals  
Initial crystallization screening trials for proteins were set up using a Matrix Hydra 
II Plus One crystallization robot (Figure 2.3). In event of the robot not functionary, 
the initial crystallization screens were set manually. Screens were performed in 96-
well plates where each plate consumes a total of 20 µl of protein, with 200 nl for 
each condition well. Different crystallization screens were used (JCSG suite, PACT 
suite, Classics suite, PEG suite, (NH3)SO4 suite and pH clear suite) from QIAGEN 
and (Crystal screen 1, crystal screen 2) from Jena Bioscience. Conditions produce 
promising crystals were optimized to generate desired size and quality of crystals. 
Optimization of conditions was determined manually in 24-well Linbro plates 
(Hampton Research) using the hanging drop vapour diffusion method. 1-2 µl of 
protein were used in each of the 24-wells, where 500-1000 µl of crystallization 
buffer used in each well. Conditions for optimization were obtained by varying the 
proteins concentration, the precipitant concentration, the pH and the temperature.     
 
2.15.2 Cryoprotection of crystals  
Good-looking crystals were picked and soaked in a cryoprotectant buffer, which 
was used to protect crystals from freezing and from X-ray radiation damage. The 
cyprotectant solution was composed of a cryprotactant agent such as ethelenglycol, 
glycerol, sugar or low molecular weight PEG, mixied with precipitant. In this 
thesis cryoprotected crystals were frozen in a nitrogen stream at 100k. Different 
concentration of ethylene glycol were used as the cryoprotectant agent. The quality 




























an in-house X-ray source at 100 K using the Rigaku Micromax 007 copper rotating 
anode generator that produces X-rays at a wavelength of 1.542 Å to chose the 
optimum cryoprotactant condition. The best cryoprotectant solution is the one that 
offer a clear appearance and maximizes protein diffraction. 
 
2.15.3 Data collection and processing  
The collection of X-ray diffraction data was achieved by mounting crystals 
between an X-ray source and an X-ray detector. Diffraction images were collected 
by rotating the crystals in the X-ray path. Initial crystal testing was done using a 
Rigaku MM007 copper rotating anode generator and a Mar Research image plate 
detector at the Molecular Biology and Biotechnology department, the University of 
Sheffield. For generating high quality diffraction data, synchrotron X-ray beams at 
the Diamond Light Source in Oxford, United Kingdom were used. The collected 
data were integrated using IMosflm program (Leslie, 1994) at home (Sheffield X-
ray generator) or XDS and xia2 (Kabsch, 2010b) at the Diamond Light Source. The 
XSCALE program (Kabsch, 2010a) was used to scale the integrated data. Data 
collection for this thesis was carried out at the Diamond light source in Oxford on 
the I02 and I04 beamlines.    
 
2.15.4 Structure determination  
Molecular replacement (with a known structure of high identity) using the program 
PHASER (McCoy et al, 2007) from the CCP4 suite was run to solve the structure. 
Water and un-modeled molecules of electron density were defined using the 
program COOT (Emsley & Cowtan, 2004). Refinement of the model against the 
electron density map was accomplished using the program REFMAC (Murshudov 
et al, 1997). The electron density map was improved and the model was rebuilt 
between the rounds of refinement using the program COOT. In this work we were 
able to determine three forms of the BPSL2418 protein structure (BPSL2418-
bound MES, BPSL2418-bound Met-SO and reduced BPSL2418), more details on 
solving these structures are in chapter 5.    
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2.16 Electron Microscopy    
Electron Microscopy was used to investigate the CT2 oligomeric state. Diluted 
samples of His-CT2 (0.1 mg/ml) were negatively stained using 2% Ammonium 
Molybdate Stain, pH 7.  Negatively stained electron images were record on a 
Philips CM100 transmission electron microscope, by a Gatan MultiScan 794 















Chapter 3: Theory of X-Ray Crystallography 
 
Several molecules, including proteins are able to solidify, forming crystals under 
certain conditions (Rhodes, 2006). X-ray crystallography is an approach that is 
used to identify the three dimensional structures of biological molecules. In 
additional to the X-ray technique, the three-dimensional structures can be 
determined using nuclear magnetic resonance (NMR) and cryo-electron 
microscopy (Brändén & Tooze, 2009). It is clear that X-ray crystallography is most 
used procedure as thousands of X-ray structures are saved in the Protein Data Bank 
(Barman et al, 2013).  
This chapter gives a brief demonstration of the methods and theory of X-ray 
crystallography, as it is the main used technique in this thesis. The information in 
this chapter was manly provided from these bibliographic sources: 
‘Crystallography Made Crystal Clear’ (Rhodes, 2006), ‘Biomolecular 
Crystallography: Principles, Practice, and Application to Structural Biology’ 
(Rupp, 2010) and ‘Protein Crystallography’ (Blundell & Johnson, 1976).   
 
3.1  The use of X-rays to produce images of protein 
molecules 
In order for a specimen to diffract light and be observed under magnification, the 
shortest distance between two separate points must be larger a half of the light 
wavelength. However, the wavelength of visible light is limited between 400-700 
nm, therefore light microscopes cannot obtain an image of molecules smaller a 200 
nm. To obtain an image of individual atoms in macromolecules, for example 
proteins, in which distance between atoms are only about 0.15 nm, electromagnetic 
waves with shorter wavelength (about 0.1 nm) such as X-rays must be used. X-rays 
waves are diffracted by individual atoms but cannot be focused by lenses (as 
visible light waves are in light microscopes) thus an image cannot be viewed 
directly. Alternatively the X-ray diffraction of the object can be recorded by 
measuring the directions and strengths (intensities) of the diffracted X-ray beams 
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using a detector. The measurements are transferred to a computer, takes the place 
of the action of a lens, to obtain a graphics image of the object. To associate the 
diffraction pattern to the structure of the object, a mathematical construct called 
Fourier Transform can be used. However X-ray diffraction from a single molecule 
is too weak to be detected, but the ability of many molecules including proteins to 
form crystals can solve this problem, where a crystal is composed of individual 
molecules arranged in an ordered lattice so that the contribution from individual 
molecules are added together to give detectable X-ray diffraction.   
 
3.2  The features of crystals 
Under certain conditions many macromolecules including proteins are able to 
solidify forming crystals. In state of protein crystallization, each molecule of the 
protein appropriate one or a few identical orientations, is produces a crystal in an 
orderly three-dimensional array of molecules. The molecules in protein crystals are 
packed together, forming a repeating lattice, by non-covalent interactions and a 
mixture of protein-protein and water-mediated hydrogen bonds. A crystalline 
lattice consists of an identical repeating unit, which can include multiple copies of 
the protein and is called a unit cell; this is the smallest component that is totally 
representative of the whole crystal (Figure 3.1). The unit cell has three dimensions 
defined by three lengths a, b and c and three angles α, β and γ. There are seven 
various crystal systems, which are determined by dimensions and angles of the unit 
cell: triclinic (a≠b≠c, α≠β≠γ≠90°) the simple crystal system, monoclinic (a≠b≠c, 
α=γ=90° β≠90°), hexagonal (a=b=c, α=β=90° γ=120°), cubic (a=b=c, α=β=γ=90°), 
tetragonal (a=b≠c, α=β=γ=90°), orthorhombic (a≠b≠c, α=β=γ=90°) and 
rhombohedral (a=b=c, α=β=γ≠90°). The lattice types can be sub-divided into five 
types depending on the position of the molecules inside the unit cell: primitive, 
body-centered, face centered and base centered. Within the unit cell the biggest 
aggregate of molecules, which has no internal crystallography symmetry, but can 
be superimposed on other exact adjacent aggregates of molecules by applying 
crystal symmetry operations is defined as the asymmetric unit. The symmetry 
operations that used to represent unit cell symmetry are rotation, translation, 
inversion and reflection. According on the crystal system, lattice type and the 
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asymmetric unit the crystal can be assigned to a space-group. The space-group 
provides a description of the symmetry of the crystal, where a total of 230 space-
groups, can be formed for the non-chiral molecules by applying combinations of 
symmetry operations, but only 65 space-groups are possible for chiral protein 
molecules because mirror symmetry cannot be applied. The unit cell dimensions 
and symmetry of the space-group can be derived from the diffraction image.          
 
3.3  Producing protein crystals        
 Producing crystals can be a complicated and time consuming step in the X-ray 
structural analysis of a protein (Drenth, 1999). Crystal formation demands 
dissolving purified protein in an aqueous buffer including a precipitant. These 
chemical precipitants are sufficient to control the precipitation of proteins without 
causing protein denaturation. Several chemical precipitants are able to drive this 
process, including salts such as ammonium sulfate, high molecular weight straight 
chain polymers, such as PEGs and organic solvents (Rhodes, 2006). The procedure 
of protein crystallization driven by a precipitant is a phase development 
phenomenon (Figure 3.1). Protein crystallization is basically set up with a protein 
in an aqueous buffer containing precipitant molecules at concentrations that allow 
protein precipitation. As the procedure progresses, the water in the solution 
evaporates leading to an increase in the protein and precipitant concentrations. This 
moves the protein molecules from the bulk of the solution, and the molecules start 
either to integrate in ordered layers forming crystals, or form amorphous 
precipitant (Rhodes, 2006). There are three stages of protein crystallization (Figure 
3.1), the first stage is the unsaturated phase at which the solution is not saturated 
with protein. Crystal production appears in the other two stages the nucleation and 
growth and the growth phases, where the solution is supersaturated with protein. 
The nucleation is the primary production of molecular clusters from where crystals 
grow, this phase occurs once the concentration of the protein and/or precipitant is 
higher then the optimal condition for slow precipitation. When the concentration of 
protein and precipitant is reduced permitting slow precipitation the crystal growth 
phase occurs.  
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Figure 3.1: Protein crystallization phases. (a) A diagram showing the crystallization 
phases. The red area represents the unsaturated stage when the solution is not saturated 
with protein. The blue area represents the conditions that allow both nucleation and 
growth. The green area represents the conditions that support growth only. (b) An ideal 
approach for achieving large crystals is the crystallization process moves from the 
unsaturated phase to the nucleation and growth phase, then move quickly to the growth 












The decreased supersaturated level allows individual protein molecules to 
incorporate in an orderly manner. The rapid precipitation in nucleation stage is 
more likely to generate a large number of small crystals or amorphous solid but the 
slow precipitation is more likely to produce a small number of large crystals. Thus 
in the ideal approach the nucleation phase occur first, then quickly the growth stage 
start preventing more nucleation and supporting a few larger crystals to be 
produced.   
 
3.3.1  Crystallization techniques 
The initial crystallization hit was obtained using a Matrix Hydra II PlusOne robot 
as mentioned before in section 2.15.1. In order to produce larger and higher quality 
crystals the initial conditions can be optimized by changing protein concentration, 
precipitant concentration, ratio of protein to precipitant in drops, volume of drops, 
pH and temperature etc. The vapour diffusion method is a manual technique 
commonly used to optimize the initial screens and to produce desirable crystals. 
The method requires blending the protein and crystallization solution in a suitable 
ratio. Then the mixture and a reservoir of a precipitant are placed separately and 
close to each other in a sealed container and diffusion of volatile solvents occurs 
between them through the vapour phase. The concentration of the crystallization 
mixture is less than the concentration of the reservoir that induces the solvent/water 
to transport from the crystallization mixture to the reservoir. Consequently the 
concentration of protein and precipitant increase and this pushes the protein out of 
the solution. There are two types of vapour diffusion method: The hanging drop 
vapour diffusion and the sitting drop vapour diffusion.   
 
3.3.1.1  Hanging drop technique        
In hanging drop technique (Figure 3.2), usually 1 to 2 µl of purified protein at high 
concentration are combined with crystallization solution (precipitant), often in a 
1:1 ratio. The protein/precipitant drop is pipetted onto a clean pre-siliconised glass 
coverslip, which is inverted and suspended over a well of 500-1000 µl precipitant 
solution. The coverslip is sealed to the well using immersion oil to ensure an 
































3.3.1.2  Sitting drop technique 
 In a sitting drop method the protein/precipitant drop pipetted in a well of a micro-
bridge, which placed above a reservoir of precipitant solution (Figure 3.3). As in 
the hanging drop the well is sealed using a coverslip and sticky oil. In hanging drop 
and sitting drop vapour diffusion, usually a 1:1 ratio of protein to precipitant is 
applied, but changing this ratio can improve crystal size.  
 
3.4  Crystal mounting 
In order to collect diffraction data, the protein crystal should be mounted onto a 
goniometer head, which is a device to control the orientation of the crystal while it 
is exposed to an X-ray beam. The protein crystal is typically mounted in a loop 
composed of a twist of nylon or plastic material connected to metal pin ending with 
magnetic base. The magnetic base facilitates the binding of the loop onto the 
goniometer head (Figure 3.4). Crystals were mounted with a droplet of the mother 
liquor plus cryoprotectant agent, to keeps the crystal hydrated and to prevent 
crystals damage. The crystals are held in the loop by surface tension in a droplet of 
liquid and permits for crystal transferring without drying them. The good quality 
crystals produce sharp diffraction patterns at large angles emerging from the X-ray 
beam.     
 
3.4.1  Cryo-cooling protein crystals   
In the early stage of protein crystallography, crystals were mounted at room 
temperature, but this was associated with crystal radiation damage, which 
consequently affects the diffracting quality of the crystal. Exposure of protein 
crystal to X-rays produces free radicals by ionizing X-ray photons, which cause 
either a localized damage, such as destruction of disulfide bonds or a general 
damage to the whole crystal. However, the less quality of crystal diffraction means 
that several crystals will used to collect sufficient data for structure identification. 














Figure 3.4: This photo shows the loop that holds the crystal. The loop consists of a 




















cryoprotectants and X-ray data have to be collected at very low temperature. By 
cooling the crystal to liquid nitrogen temperature, molecular order in the crystal 
will raise and automatically develop crystal diffraction. Using this advantage 
enables the collection of complete data sets from single crystals. 
 
3.4.2  The requirement for a cryo-protectant  
The technique of mounting crystals in a cryoprotected mother liquor is necessary to 
maintain the crystal hydrated and to reduce radiation damage to the crystals. This 
method includes transferring crystal from the drop of mother liquor from where it 
has grown to a solution that contains mother liquor and convenient cryo-
protecctant like ethylene glycol, glycerol or low molecular weight polyethylene 
(PEGs). The presence of cryo-protectant prevents the water inside and surrounding 
crystal from freezing and forming ice crystals that will also diffract. It is important 
to optimize the length of soak in cryoprotectant, type of cryprotectant and 
cryoprotrctant concentration depending on the size of the crystal and a number of 
experiments that need to be applied.    
 
3.5  Collecting X-ray data 
The cryoloop including a crystal is mounted onto a goniometer head between an X-
ray source and X-ray detector. The mounted crystal is kept cold by a cold nitrogen 
gas stream generated from a liquid nitrogen source. The goniometer rotates the 
crystal in the X-ray beam while a series of diffraction images are collected, from 
the different degrees of rotation. Usually each image is collected by rotating the 
crystal through a small angle of about 0.1-1.0°, and this will produce a dataset 
which can be used to determine the protein structure. The spacegroup of the crystal 
and the degree of mosaicity can determine the whole dataset size and the number of 
degrees of rotation for each diffraction image. For example a smaller dataset is 
required when the crystal belongs to a higher symmetry space group, as the 
equivalent reflections will appear more often. Also a small degree of rotation per 
diffraction image is recommended to use with crystal having a large cell  
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dimension or a crystal with a high mosaicity to separate the reflections while 
diffraction images are collected.                 
 
3.6  X-ray sources 
In X-ray crystallography three sources are used to generate X-rays: Rotating anode 
tubes (Figure 3.5) and synchrotron radiation source (Figure 3.6), which produce 
more intense X-rays.  
 
3.6.1  Rotating copper anode tubes    
The rotating anode X-ray source is an evacuated tube with a rotating copper anode 
at one end and a cathode (usually a tungsten filament) on the other end. The X-rays 
are produced by bombarding a metal target (the rotating anode) with electrons that 
have been generated from the heated filament. The cathode is heated, which allows 
the electrons to be released and accelerated towards the rotating copper anode 
through an electronic field. These high-energy electrons collide with, and displace, 
low-energy electrons in the target metal. When a high-energy electron hits an 
electron from a low energy orbital, the electron from higher energy orbital will 
drop down, emitting an X-ray photon. The wavelength of the produced X-ray 
radiation is determined by the metal that X-rays emits from. For protein 
crystallography, the anode is usually made of copper due to its high heat 
conductivity. The cooper anode is able to emit two high-energy X-rays: Kα has a 
wavelength of 1.54 Å while Kβ has a wavelength of 1.39 Å. The produced X-ray 
radiation emerges from the rotating copper anode tube through windows of 
beryllium. Initial crystal data collection for this thesis, was performed at the 
crystallography lab, in the University Of Sheffield, using a Rigaku Micromax 007 















Figure 3.5: A Rigaku Micromax 007 copper rotating anode generator. 
used in X-ray crystallography lab in MBB/ The University of Sheffield. X-rays are generated 
from a rotating copper anode source (not shown), and come through a metal collimator (1). 
A cryoloop containing the crystal is mounted on the goniometer to be struck by the X-ray 
beam (2). An image plate detector captures the X-ray reflections (3). A nitrogen gas source 
















3.6.2  Synchrotron   
A synchotron X-ray source (Figure 3.6) is a big particle accelerator that is able to 
generate electrons and accelerate them nearly to the speed of light to produce 
higher intensity X-rays with wavelengths in the range from 0.5 Å to 1.8 Å. A 
synchrotron contains a particle accelerator and a circular path around a central 
storage ring and a series of bending magnets. Electrons are injected by a particle 
accelerator inside the ring and accelerated close to the speed of light controlled by 
radio transmitters and kept in a circular motion due to the powerful magnets 
(Figure 3.7). The obligatory curved path leads the electrons to lose energy and to 
change velocity, which cause the emission of X-ray radiation at tangents to the 
circle (beamlines) (Figure 3.7). The synchrotron has also two accessory devices; 
wigglers and undulators, which can increase the intensity of the radiation by 
changing the direction of the electrons several times during a short distance. A 
series of beamlines are located tangentially around the storage ring supplying X-
ray beams to where crystals are mounted for data collection. The synchrotron has 
many distinct features, such as the high intensity of radiation that permits 
collecting X-ray data in shorter exposure times before the protein crystals are 
damaged, and also allows data collection from very small crystals. Further, the 
capability of selecting the wavelength of the X-ray beam is a very useful feature of 
the synchrotron for phase determination using Single Wavelength Anomalous 
Dispersion (SAD) or Multi Wavelength Anomalous Dispersion (MAD).     
 
3.7  X-ray Detectors         
X-ray detectors are able to record the intensity and direction of the crystal 
diffracted X-rays. A pattern of crystal X-ray diffraction is obtained through the use 
of detectors.  
 
3.7.1  Image plate detectors 



















Figure 3.6: An aerial view of Diamond Light Source, the UK’s national synchrotron 
science facility, at the Harwell Science and Innovation Campus near Didcot, Oxfordshire. 
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phosphorescent material, usually crystalline BaFEu. Once X-ray photons hit the 
plate they interact with the Eu2+ leading to excitation of the phosphorescent 
material. In order to record the X-ray, a He-Ne laser scans the plate leading to 
emission of a blue light at a wavelength of 390 nm that is captured by a 
photomultiplier and transformed to a digital signal. A high intensity tungsten light 
is used to erase the detector and return the phosphorescent material into a ground 
state. The image plate detector takes a long time to collect a data set, which can be 
a disadvantage of using this type of detector. Initial crystal testing for this thesis 
was run at Sheffield in the crystallography lab using MarResearch MAR345 image 
plate detector.         
 
3.7.2  Charged-coupled device (CCD) detectors  
In a charged-coupled device detector the image is immediately appeared to the user 
in a fluorescent screen linked to a charged-coupled device by fiber optical strands. 
Crystal diffracted X-rays hit the phosphor screen and are transformed into photons 
of visible light, which are conducted towards the CCD chips over the fiber optical 
strands. The total of signal that knock the CCD chips corresponds to the total X-ray 
photons hitting the detector. The detector systems on the diamond synchrotron 
lightsource are the charged-coupled device detector. The advantage of the CCD 
detectors is the reduction of data collection time, which consequently reduces the 
amount of radiation damage, can affect the crystal.    
 
3.7.3  Pilatus Detectors  
The Pilatus system is a single photon counting pixel array where the incoming 
photons are directly measured allowing data to be collected continuously. The 
principle advantage of the Pilatus system over CCD detectors, and CCD detectors 
over image plate detectors, is the reduced read-out time, reducing the data 
collection experiment time and therefore the amount of radiation damage sustained 
by the sample. The Pilatus detector can also produce a greater signal to noise ratio 
by applying an energy threshold to the photons that are counted. 
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3.8 The principles of X-ray diffraction 
 
3.8.1 Diffraction from crystals 
During the procedure of shooting X-rays through crystals to generate diffraction, 
most of the X-rays do not clash with the crystal and directly pass through, colliding 
with the backstop. Occasionally an X-ray hits an electron surrounding an atom 
inside the crystal, leading to electron oscillation. The electron oscillates at the same 
frequency as the incident X-ray generating a secondary wave, which is recognized 
by the detector as a reflection. These reflections are representative of the crystal on 
a particular set of lattice planes, which slice into the crystal, determined by Miller 
Indices, but only if Bragg’s law is satisfied. 
 
3.8.2 Bragg’s Law       
A crystalline state is composed of atoms arranged in repeated ordered arrays 
forming a lattice. The crystal unit cell contains planes that divide up and cut across 
the axes of the unit cell, which determined by Miller index h k l. Bragg’s law 
revealed that a set of parallel planes with Miller index h k l and different interplanar 
spacing dh k l generates a reflected beam when X-rays of wavelength λ strike upon 
the planes at an angle θ and reflected at the same angle, when θ reaches the 
condition. Bragg’s law describes the conditions necessary for a set of lattice planes 
to generate a reflection. 
If n is an integer and λ is the wavelength of the X-ray that hit the planes (incoming 
X-rays); d is the distance between planes with indices h k l; θ is the angle of the 
incidence of the incoming X-rays, which strike the planes. The diffracted waves are 
in phase and will contribute to a reflection spot if the difference in X-rays path 
length (the distance 2dsin θ) is equal to an integral number of the wavelength of the 
incoming X-rays (Figure 3.8) and so:             
n λ = 2dsin θ 
If Bragg’s law is not satisfied, the X-ray diffraction will not be observed and not 













Figure 3.8: Bragg’s law describes the needed condition for a set of lattice planes to 
generate a reflection. X0 is the incoming X-ray beam and X1 is the diffracted beam 
(outgoing beam) which hits the detector. d is the distance in angstroms (Å) between the 
lattice planes.  The diffracted waves X1 will be observed only if the distance 2dsin θ is 























3.9 From diffraction to electron density 
The collected data is made up of a list of intensities of reflections each with an 
index h k l representing a position in reciprocal space and that refer to atoms on a 
set of lattice planes in real space. Each reflection in a diffraction image includes 






The structure factor (Fhkl) is a Fourier sum of the contributions of each atom (j) 
within the unit cell containing (n) atoms, to the reflection with indices h,k,l in the 
reciprocal lattice. ( fj ) is the scattering factor of each atom (j) and it provides the 
amplitude of the wave contribution of atom (j) to the Fourier sum. The contribution 
of each atom to the Fourier sum is treated as a sphere of electron density dependent 
on the number of electrons present in the atom. The exponential term represents a 
simple three-dimensional periodic function with both sine and cosine components. 
It represents the position of the atom (j) within the unit cell as (xj, yj, zj) and h,k,l 
are the indices of the specific reflection in reciprocal space. Alternatively (Fhkl) can 
be defined by the electron density volume element (ρ) of each atom:     
 
 
 ρ(x,y,z) is the electron density at position (x,y,z) and (V) is the volume of the unit 






3.10 Processing data from diffraction images 
 
3.10.1 Data indexing and integration  
When a dataset is collected, the measurement of the intensity of each reflection will 
be needed. A dataset was automatically indexed and integrated using programs 
such as MOSFLM and XDS. For data indexing these programs are able to measure 
the distance between reflections to determine the dimension of the unit cell and the 
space group that the crystal belongs to. They can measure the intensity of each 
reflection (spot) in pixels in contrast to the background level of the detector and 
combine this value with the information of the spot position (hkl). The data are 
then integrated where all collected images containing all reflections are converted 
into a single file (the mtz file).  
 
3.10.2 Data merging and scaling      
The program SCALA was used to merge and scale symmetry related reflections 
across all images so that they have a consistent intensity scale. Scaling images must 
be from the start to the end of the dataset and from low to high resolution on each 
image. The quality of the dataset can be gauged by the R-factor and Rmerge, which 
estimate the agreement of related reflections and the correlation within the dataset. 
The repetition of the same reflection or the degree of multiplicity can be measured 
through the series of dataset by the Rpim and CC1/2, which also can be used with 
Rmerge to evaluate the quality of dataset. Rpim is an alternative measure that also 
takes account of multiplicity. CC1/2 has superior properties compared with Rmerge.        
Its properties in the presence of systematic error are documented.  
 
3.11 structural determination 
 
3.11.1 initial phasing  
During the diffraction experiment the intensity of each reflection is only measured 
while the phase cannot be directly recorded, this known as the phase problem. 
Therefore the initial phase needs to be obtained by other methods such as the 
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multiple-wavelength anomalous diffraction (MAD), single-wavelength anomalous 
diffraction (SAD) and molecular replacement (MR) experiments. In the BPSL2418 
project the method used to estimate the phases is the molecular replacement (MR).     
 
3.11.1.1 Molecular replacement (MR) 
In this method protein homolog with high sequence identity to the target protein 
can be used as a search model to determine the orientation and position of the 
molecules inside the unit cell. The obtained phases can be used to produce electron 
density maps. The existence of high sequence identity homologs to BPSL2418 
allows the use of molecular replacement method in this project. MR can be run 
using a program called PHASER (McCoy et al, 2007). The presence of a 
homologue protein permits for applying a calculated set of phases to the 
experimental intensities to find a solution for the phase problem. In order to do this 
we must know the rotational and translational position of the protein molecules 
within the unit cell, which can be obtained by comparing the Patterson Function of 
the search model and the trial model.  
A Patterson Function is a vector map that shows the atomic distances, which are 
correlated with the crystallized molecule. Molecular replacement demands first that 
the search model to be rotated in all possible orientation as the unknown protein in 
the unit cell. This can be done by comparing Patterson map of the search model 
and the unknown protein. The next step is the translation function, which is 
required to determine the correct position within the unit cell.  
The rotation function includes comparisons between the search model (Known 
protein) Patterson map and the unknown protein Patterson map in different 
orientations. The Patterson maps are aligned and oriented in steps through three 
dimensions. In each orientation step the structure factor amplitudes of the trial 
model were calculated and compared with the known model structure factor 
amplitudes. The rotation function solution is obtained when the maximum overlap 
or similar orientation is found. Then this solution is applied to the search model’s 
coordinates and new rotated model is put out and used in the translation function 
step. The translation function is a positioning process of the protein to be placed in 
the correct orientation and position in the asymmetric unit. The rotated model 
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demands be translated into the correct coordinates, x,y,z axis in order to be placed 
correctly within the unit cell. A similar comparison is made between the rotated 
model Patterson map and the unknown model Patterson map to find the best 
solution. The electron density map can be produced by calculating the phases from 
the search model by Fourier Transform and are combined with the experimentally 
derived intensities.       
                 
3.12 Structure re-building and refinement  
 Once the molecular replacement obtains the suitable model, this model needs to be 
refined and improved. The program COOT was used to visualize the electron 
density map to re-build the model. The REFMAC5 program in the CCP4 suite was 
used to refine the model by running several cycles of refinement and re-building to 
boost the agreement between the model and the electron density.  The refinement 
includes repositioning side-chains, mutating residues, defines density aspect and 
modeling ligand, adding water molecules. The refinement progressing can be 
evaluated by comparing the value of the R-factor and the free R-factor. The R-
factor (reliability factor) is a measure of the agreement between the obtained model 
and the collected data.   
 
3.13 Structure validation  
During the refinement cycles it is important to monitor the difference between the 
structure factors amplitudes of the observed data (the experimental data) Fobs and 
the calculated search model Fcalc.  The quality of the refined model is associated 
with the lower value of R-factor. The R-factor measures the different between Fobs 
and Fcalc and it is described as:       




During scaling a test set of the observed data usually 5% is excluded from the 
refinement process (R-free), which described as: 
  
        
 
If R-factor and R-free reduce during the refinement and rebuilding of the model 
this indicates correct changes have been made to the model.  
After refinement the final atomic coordinates should be validated by checking that 
the model represents the targeted protein very well. This includes the analysis of a 
Ramachandran plot, the geometry of main and side chains, clashes between atoms. 
This can be made by using the PROCHECK (Laskowski, 1993) and the Molprobity 
(Chen et al, 2010) server.  
  
  














Chapter 4:  BPSL2418 Cloning, Expression, 
Purification and Crystallization 
 
This chapter represents the cloning, overexpression, purification and crystallization 
for Burkholderia pseudomallei BPSL2418 the MES-bound, substrate-bound, 
unbound and reduced forms.       
 
4.1  Cloning of BPSL2418  
 
4.1.1  Amplification of the bpsl2418 gene  
The bpsl2418 gene was amplified from Burkholderia pseudomallei strain D286 
genomic DNA by PCR as described in section 2.4., using the BPSL2418 forward 
and reverse primers and BioMix Red reaction mixture. To analyze the PCR 
products, they were run on a 1% agarose gel (see section 2.5). The agarose gel 
shows a band of the expected size of approximately 513 bp (Figure 4.1), and the 
Gel Extraction Kit was used to purify the PCR products (see section 2.6).  
 
4.1.2  Ligation of bpsl2418 gene into pETBlue-1 vector and 
transformation into Novablue competent E. coli cells    
The insert was ligated into the E. coli linearized expression vector pETBlue-1 and 
then the recombinant plasmid was transformed into Novablue cells (see section 
2.8.2), which have blue/white screening capability. The ligation with the insert 
should produce white colonies while the ligation without the insert should produce 
blue colonies. 4:1 was the ratio of the white colonies to the blue colonies (Figure 
4.2). A number of the desired white colonies were picked to inoculate 5 ml LB 
media each, and grown overnight. Plasmids were extracted from each cell pellet as 












Figure 4.1: 1% DNA agarose gel of bpsl2418 gene amplification: Lane M is DNA hyper 











Figure 4.2: Blue/white screening of Transformation of ligation products into 
competent E.coli cells: Black arrow indicates white colonies (ligation with insert). Red 
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4.1.3  Confirmation of the presence and orientation of the 
insert gene in the pETBlue-1 plasmid  
The presence and orientation of the bpsl2418 insert gene in the pETBlue-1 plasmid 
was confirmed by DNA sequence analysis (Figure 4.3) and by using PCR to 
amplify bpsl2418 DNA sequence (513 bp) from the recombinant pETBlue-1 (see 
section 2.8.3). The PCR reaction produced a band of approximately 523 bp, where 
the additional 20 bp is the size of pETBlue up primer. The PCR product was 
visualised on a DNA agarose gel (Figure 4.4). 
 
4.2 Transformation of Tuner (DE3)pLacl competent 
cells with pETBlue-1 bpsl2418 recombinants   
Cloning in pETBlue vectors regularly requires the use of NovaBlue and Tuner 
(DE3)pLacl competent cells. NovaBlue allows the blue/white-screening technique 
that detects the recombinant colonies but contains no source of T7 RNA 
polymerase. The Tuner (DE3)pLacI is an expression host that provides inducible 
expression of T7 RNA polymerase. Eppendorf tubes containing 20 µl aliquots of 
Tuner (DE3)pLacI cells were removed from the -80 ºC freezer and incubated on ice 
for 5 minutes. Once defrosted 1 µl of plasmid DNA (approximately 10 ng/µl) was 
added and the reaction was left to incubate on ice for 5 minutes. The cells were 
subjected to a heat shock at 42 ºC for 30 seconds before being returned to ice for 2 
minutes, and then an 80 µl of SOC media was added to the mixture. The cells were 
incubated at 37 ºC at 250 rpm for 60 minutes before plating 50 µl on LB agar 
containing 1% glucose, 50 µg/ml carbenicillin and 34 µg/ml chloramphenicol.  
 
4.3  BPSL2418 overxpression 
Different small-scale overexpression trials were accomplished for BPSL2418 to 
obtain the best overexpression condition, and finally the following protocol was 
used: One colony from transformation plate of Tuner (DE3)pLacI with pETBlue-1 














Figure 4.3: The bpsl2418 insert gene was sequenced and then analyzed by BLAST, 
http://blast.ncbi.nlm.nih.gov/Blast.cgi. BLAST shows that the bpsl2418 insert gene 
sequence is 99% identical to hypothetical protein BPSL2418 [Burkholderia pseudomallei 
























Figure 4.4: Confirmation of the presence and orientation of the insert gene in the 
pETBlue-1 plasmid: Lane M: hyper ladder 1 molecular weight marker; Lane 1: the PCR 


















50 µg/ml carbenicillin and 34 µg/ml chloramphenicol. The 3 ml primary culture 
was incubated at 37 ºC with shaking at 250 rmp until the OD600 reached 
approximately 0.6-1, then it was stored overnight at 4 ºC. The cells were collected 
the following morning by centrifiugation and resuspended in 3 ml fresh media 
containing the desired antibiotics and 1% glucose. A 100 ml (x10) culture of LB 
containing all required antibiotics and 1% glucose was inoculated with the 3 ml 
(x10) starter culture and incubated at 37 ºC with shaking at 250 rmp until the OD600 
reached 0.5-1. Expression was induced by addition of 300 µM IPTG for 4 hours at 
37 ºC, 250 rpm. BPSL2418 was overexpressed and an SDS-PAGE gel (Figure 4.5) 
reveals a strong expression band in the soluble fraction. The molecular weight of 
expressed protein is the same as expected, about 18 kDa.     
 
4.4 Purification of BPSL2418 
About 4 g cells were defrosted and suspended in about 35 ml of (50 mM tris-HCl 
pH 8.0) buffer. Cells were disrupted by sonication and cell debris was removed by 
centrifugation at 70000 g for 10 min. The protein concentration was estimated in 
the supernatant fraction (Cell Free Extract) CFE  as 7.5 mg/ml. Total protein in the 
cell free extract was 260 mg. This sample was applied on a 10 ml column with 
DEAE fast flow Sepharose (2 x 5 ml Hi Trap DEAE Fast Flow cartridges, GE 
Healthcare) which is a weak anion exchanger. Proteins were eluted with 100 ml 
gradient of NaCl concentration from 0 to 0.5 M in 50 mM tris-HCl pH 8.0 buffer at 
flow rate 5 ml/min (Figure 4.6). Four ml fractions were collected and analysed  on 
12% SDS-PAGE (Figure 4.7). The most pure fractions, 17 and 18, were combined, 
V=8 ml, C=6 mg/ml, total 48 mg (Peak). Fractions 16, 19 and 20 were also 
combined, V=12 ml, C=4 mg/ml, total 48 mg (sides).  
The peak fractions were diluted 3 fold with ultra pure water and applied to a 6 ml 
Resource Q column (GE Healthcare), a strong anion exchanger. Proteins were 
eluted from the column by 90 ml gradient of NaCl from 50 mM to 150 mM in 50 
mM MES-NaOH buffer pH 6.3 at flow rate of 4 ml/min (Figure 4.8). 2.5 ml 
fractions were collected and fractions across the peak were analyzed on a 12% 













Figure 4.5: 12% SDS-PAGE gel showing the overxpression of BPSL2418. Lane M: 
molecular weight marker; Lane 1: pre-induction fraction; Lane 2: insoluble fraction; Lane 3: 



































Figure 4.6: A DEAE purification step showing column loading and elution of 
BPSL2418. This Figure represents the elution of protein with 100ml gradient of NaCl 













Figure 4.7: 12% SDS-PAGE analysis of DEAE fast flow Sepharose of BPSL2418. 
Visualised by staining with coomassie blue stain. Lane M: molecular weight marker; Lane 
1: CFE; Lane 2: unbound proteins; Lanes 3,4,5,6,7,8,9,10,11,12,13 and 14 are fractions 
12,14,15,16,17,18,19,20,21,22,23 and 25 respectively. Fractions 16,17,18,19 and 20 were 
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Figure 4.8: A Resource Q column purification step showing column loading and 
elution of BPSL2418. Proteins were eluted from the column by 90 ml gradient of NaCl 











Figure 4.9: 12% SDS-PAGE analysis of Resource Q column purification of 
BPSL2418. Visualised by staining with coomassie blue stain. Lane M: molecular weight 
marker; Lane 1: peak fraction DEAE FF; lanes 2,3,4,5,6,7,8,9 and 10 are fractions 
18,19,20,21,22,23,24,25 and 35 respectively. Fractions 21,22,23,24 and 25 were 









































The most pure fractions, 21-25, were combined, V=12.5 ml, C=0.95 mg/ml, total 
12 mg. To prepare a sample for gel filtration, the volume was reduced to 1 ml using 
a VivaSpin 20 MWCO 10000 concentrator (Sartorius). Fractions 18-20 with less 
pure protein were also combined, V=7.5 ml, C=1.4 mg/ml, total 8.2 mg. 7.5 ml of  
4 M ammonium sulphate was added to this sample to precipitate it for storage.  
The concentrated sample of the most pure BPSL2418 was applied to a 16x60 
HiLoad Superdex200 gel filtration column (GE Healthcare). Gel filtration was 
performed in a buffer containing 0.5 M NaCl 50 mM tris-HCl pH 8.0 at flow rate 
of 1.5 ml/min. 2 ml fractions were collected starting from 0.5 column volume 
(Figure 4.10). BPSL2418 was eluted from the column at 84 ml, corresponding to 
an apparent MW of 38 kDa, indicating its dimeric state in solution. Peak fractions 
11 and 12 were combined, V=4 ml, C=1.1 mg/ml, total 4.4 mg. This sample was 
concentrated as above and the buffer was changed to 10 mM tris-HCl pH 8.0 using 
a diafiltration cup. V=0.2 ml, C=20 mg/ml, total 4 mg. The purification progress of 
BPSL2418 preparation 1 was analyzed by using SDS-PAGE (Figure 4.11). This 
preparation 1 was used to screen for crystallisation conditions. 
In preparation 2 of BPSL2418 the suspension of precipitated protein from fractions 
16,19 and 20 from the DEAE column and fractions 18-20 from the Resource Q 
column were combined and the pellete collected by centrifugation at 70000 g for 5 
min. These stored fractions from preparation 1 are less pure, which suggests the 
need for an additional purification step to be applied. A hydrophobic 
chromatography column was also used in preparation 2 of BPSL2418. The pellet 
was dissolved in 10 ml of 50 mM tris-HCl buffer pH 8.0. V=10 ml, C=2 mg/ml, 20 
mg. The ammonium sulphate concentration in the solution was checked by 
refraction and was about 0.8 M. The sample was applied to a 5 ml Hi Trap Phenyl-
HP cartridge and eluted with an optimised gradient of ammonium sulphate   
concentration from 0.7 M to 0 M in 50 ml (Figure 4.12). Peak fractions 15-19 were 
combined , V=12.5 ml, C=0.55 mg/ml, 6.8 mg. Proteins were precipitated with 2 M 
ammonium sulphate. The  pellet was spun down as above and dissolved in 1.5 ml 
of 50 mM tris-HCl buffer pH 8.0. The resulting sample, V=1.9 ml, C=5 mg/ml, 9.5 
mg was applied on a gel filtration column. Gel filtration was performed as 
described above. 12% SDS-PAGE was used to analyse the progress of BPSL2418 





































Figure 4.10: Gel filtration purification of BPSL2418. (A) a 16x60 HiLoad Superdex200 
gel filtration column loading and elution of BPSL2418. (B) the calibration plot for Hi-Load 
superdex 200 column chart shows that the BPSL2418 corresponding to apparent MW     
38 kDa, indicating its dimeric state in solution.        
Use the calibration plot 
for Hi-Load superdex 
200 column chart to 
calculate the protein 
MW: 
 
Ve/Vo=  84/45= 1.8 
logMW= 4.51 
MW= 38 KDa 
 
Note: 
Ve: Elution volume 


























Figure 4.11: 12% SDS-PAGE analysis of purification progress of BPSL2418 
preparation 1. Lane M: molecular weight marker; Lane 1: cell debris; Lane 3: CFE; Lane 




































Figure 4.12: A 5ml Hi Trap Phenyl-HP cartridge loading and elution of BPSL2418. 
The protein was eluted with optimised gradient of ammonium sulphate concentration from 












Figure 4.13: 12% SDS-PAGE analysis of purification progress of BPSL2418 
preparation 2. Lane M: molecular weight marker; Lane 1: sample applied on Phenyl-HP; 
































combined , V=6 ml, C=0.9 mg/ml, 5.4 mg/ml. The sample was concentrated to 30 
mg/ml and buffer exchanged as discribed above. This sample, preparation 2, was 
used for optimisation of the crystallisation conditions. 
 
4.5 Crystallization trials of BPSL2418 
In the first initial trials of BPSL2418 crystallization I found that most of the 
successful trials contained 2-(N-morpholine) etathanesullfonic acid (MES) buffer. 
However, as BPSL2418 is predicted to function as a methionine sulfoxide 
reductase and a MES molecule contains a sulfonic acid group. The formation of 
crystals of BPSL2418 in complex with MES buffer was encouraging.  
 
4.5.1 Crystallization of the BPSL2418 MES-bound form 
(BPSL2418MES)  
Six initial 96 condition robot screens, the PACT, JCSG, Classics, PEG, AmSO4, 
and pH clear suites were performed as described in section 2.15.1, using the sample 
of BPSL2418 preparation 1, with 20 mg/ml concentration. The initial screens were 
accomplished then were incubated at 17 ºC. Initial hits (microcrystals) were 
observed in five conditions: B7 in PACT (0.2 M NaCl, 0.1 M MES at pH 6 and 
20% w/v PEG 6000), B8 in PACT (0.2 M NH4Cl, 0.1 M MES at pH 6 and 20% 
w/v PEG 6000), B9 in PACT (0.2 M LiCl, 0.1 M MES at pH 6 and 20% w/v PEG 
6000) and B10 in PACT (0.2 M MgCl2, 0.1M MES at pH 6 and 20% w/v PEG 
6000) (Figure 4.14). Optimization of these conditions was made to produce large 
crystals, using the sample of BPSL2418 preparation 2, with 30 mg/ml 
concentration. Attempts of optimization were carried out by altering the PEG 6000 
concentration (10, 12, 14, 16, 18, 20, 22, 24, 26, 28 and 30 % w/v) and pH (5.0, 6.0 
and 7.0) for small crystals that were found in B7, B8, B9 and B10 in PACT. For 
the initial hit that appeared in B7 JCSG, the optimization was done by altering the 
























Figure 4.14: photographs of initial crystallization hits of BPSL2418MES in five 









0.2 M NaCl, 0.1 M MES at pH 6 and 
20% PEG 6000 0.2 M NH4Cl, 0.1 M MES at pH 6 and 
20% PEG 6000 
0.2 M LiCl, 0.1 M MES at pH 6 and 
20% PEG 6000 
0.2 M LiCl, 0.1 M MES at pH 6 and 
20% PEG 6000 
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The hanging-drop method (see sections 3.3.1.1) was utilized to optimize the initial 
hits and yield large crystals that were suitable for X-ray data collection. The droplet 
in the hanging-drop technique was made by combining 2 µl protein and 2 µl 
crystallization buffer and then hanging over a well of 1 ml of reservoir solution at 
17 ºC. Fortunately attempts to optimize crystallization conditions for BPSL2418 
produced crystals in many different conditions. The best crystals of BPSL2418MES 
were obtained with a rod shape in three concentrations of PEG 6000 conditions 
(18-20%), 0.2 M NaCl at pH 6 and 0.1 MES (Figure 4.15). Desirable, rod shaped 
crystals were also seen in these two conditions (0.2 M NH4Cl, 0.1 M MES at pH 6 
and 20% w/v PEG 6000) and (0.2 M LiCl, 0.1 M MES at pH 6 and 18% w/v PEG 
6000) (Figure 4.15).  
 
4.6 Crystallization of BPSL2418 unbound, reduced 
and substrate-bound forms           
 
4.6.1 Crystallization of BPSL2418 unbound form 
(BPSL2418unbound)  
It has been predicted from the sequence analysis that BPSL2418 may act as a free 
methionine-R-sulfoxide reductase. Therefore the crystallization buffers should 
contain no sulfoxide or sulfonic acid in order to produce an unbound form of 
BPSL2418. As mentioned above, most of the successful trials contained MES 
buffer and thus the only suitable condition that could produce unbound BPSL2418 
is B7 in the JCSG screen (0.1 M sodium acetate at pH 4.6 and 8% PEG 4000) 
(Figure 4.16). Optimization of this condition was run in order to obtain large 






























Figure 4.15: Photographs of BPSL2418MES crystals. (A) and (B) Most crystals had a rod 






0.2 M NaCl, 0.1 M MES at pH 6 and 
20% PEG 6000  
Drop size 2 µl protein + 2 µl well 
0.2 M NH4Cl, 0.1 M MES at pH 6 and 
20% PEG 6000 
Drop size 2 µl protein + 2 µl well 
0.2 M LiCl, 0.1 M MES at pH 6 and 
20% PEG 6000 

















Figure 4.16: Small crystals of BPSL2418unbound form produced from 0.1 M sodium 















4.6.2 Crystallization of BPSL2418 substrate-bound form 
(BPSL2418Met-SO)  
The structure analyses of BPSL2418 homologous proteins suggest that 
conformational changes occur in the active site (see Figure 1.7 and 1.8), where free 
methionine sulfoxide (Met-R-SO) is proposed to bind. In order to understand the 
role of BPSL2418, attempts to crystallize the BPSL2418 in complex with the free 
Met-R-SO substrate were performed. A mixture containing 20 mg/ml pure 
BPSL2418, 9 mM, free Met-R-SO was set up and incubated for 3 h at room 
temperature. Initial trials were carried out using this mixture, and hits were seen in 
0.2 M ammonium chloride 0.1 M sodium acetate pH 5 and 20% PEG 6000 (Figure 
4.17a). Crystals of the complex with free Met-R-SO were obtained from 0.2 M 
ammonium chloride, 0.1 M sodium acetate pH 6 and 18% PEG 6000 (Figure 
4.17b). One crystal was soaked in cryoprotectant solution containing 30% 
ethyleneglycol and 0.2 M ammonium chloride, 0.1 M sodium acetate pH 6 and 
18% PEG 6000. The crystal diffracted in-house to better then 2.5 Å resolution, and 
then it was frozen in liquid nitrogen to be sent to the Diamond Light Source.          
 
4.6.3 Crystallization of BPSL2418 reduced form 
(BPSL2418Reduced)       
Obtaining the structure of the reduced form of BPSL2418 can be valuable in 
understanding the role of BPSL2418. 10mM DTT (reducing agent) was added to a 
pure 20mg/ml BPSL2418 and the mixture was used to set up initial crystallization 
trials. Small crystals were found in 0.1M MIB buffer (this buffer is produced by 
mixing sodium malonate, imidazole and boric acid in the molar ratios 2:3:3- 
sodium malonate:imidazole:boric acid) pH 4, 25% PEG 1500 (Figure 4.18a), and 
then optimization trials were performed as previously described to achieve large 
crystals (Figure 4.18b). Crystals with a reasonable size were selected and soaked in 
a cryoprotectant of 30% ethyleneglycol and 0.1 M MIB buffer pH 4, 23% PEG 
1500. Crystal diffraction was initially tested in-house, where the best crystal 
diffracted to 3.1 Å. Best crystals were stored in liquid nitrogen and sent to the 


















Figure 4.17: Photographs of BPSL2418Met-SO complex crystals. A: Initial hits; B: 














0.2 M ammonium chloride, 0.1 M sodium 
acetate pH 5 and 20% PEG 6000 
0.2 M ammonium chloride, 0.1 M sodium 




























Figure 4.18: Photograph of crystals from BPSL2418Reduced form. A: Initial small 






0.1 M MIB buffer pH 4, 
25% PEG 1500 





4.7 Cryo-protection for BPSL2418 forms  
Cryoprotection as mentioned in section 3.4.2 is a very significant step that helps to 
reduce radiation damage. The exposure of the crystal to the X-ray radiation can 
produce free radicals, which distribute inside the crystal and damage the protein. 
Therefore, a cryoprotectant solution should be selected very carefully and different 
conditions need to be tested as described in section 2.15.2 to choose the optimum    
cryoprotectant condition. It was found that the best cryprotectant solution for the 
harvested crystals of the BPSL2418 forms is 30% ethylene glycol mixing with 
precipitant. The initial data collection for the BPSL2418 crystals were carried out 
on the in-house source utilizing the Rigaku Micromax 007 copper rotating anode 
generator with a Mar345 detector. In order to achieve higher resolution, the crystals 
were stored in liquid nitrogen at 100 k to send it to the Diamond Light Source in 


















Chapter 5: Structure determination of 
BPSL2418  
 
In this chapter a description of the structure solutions of BPSL2418MES, 
BPSL2418Met-SO and BPSL2418Reduced by molecular replacement will be provided. 
BPSL2418 shows a very high sequence similarity, 68% to the Staphyloccus aureus 
fRMsr, which allowed the use of this protein as a model in initial phasing by 
molecular replacement.      
 
5.1 Experimental structure determination of 
BPSL2418MES by molecular replacement using PDB 
entry: 3ksf.  
 
5.1.1 Space group determination and indexing 
Initial diffraction analysis of BPSL2418MES crystals was carried out in Sheffield 
using the Rigaku Micromax 007 copper rotating anode generator with MAR 345 
image plate, in order to evaluate the diffraction quality. 1.542 Å wavelength X-rays 
were used and the crystal diffracted to 2.0 Å. Two images were collected of 1° 
oscillations separated by 90° with 20 minutes exposure each. These initial test 
images were used to find out the lattice type by auto-indexing using MOSFLM 
(Leslie, 1994). This was confirmed by collecting three test images 45° apart with 
1° oscillation at the Diamond Light Source in Oxford using the auto-indexing and 
collection strategy components of MOSFLM. BPSL2418MES belongs to the 
primitive orthorhombic crystal system, which is distinguished by unequal length of 
the three axes a, b and c and the three interaxial angles equal to 90°, (a≠b≠c, 
α=β=γ=90°). The Laue group is P 2 2 2 and the crystal had a cell dimensions 
a=53.48 Å, b=60.54 Å, c=42.24 Å, α=90°, β= 90° and γ= 90°.   
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5.1.2 Data collection and processing 
The BPSL2418MES crystals, were saved in liquid nitrogen and data were collected 
at 100 k on the I04 beamline of the Diamond Light Source, Oxford. Three test 
images 45° apart with 1° oscillation were collected as described in section 5.1.1 to 
confirm crystal centering and to obtain a collection strategy using MOSFLM 
(Leslie, 1994). A total of 360 images were collected with 0.5° rotation per image at 
a crystal-to-detector distance of 250 mm at a wavelength 0.9795 Å. The exposure 
time was 0.5 second per image at 40% beam-transmission. Data extending to 1.18 
Å were collected (Figure 5.1), and the data were processed using xia2 (Winter, 
2010), indexed and integrated by XDS (Kabsch, 2010a) and scaled by XSCALE 
(Kabsch, 1988). The processing data collection statistics of BPSL2418MES at 1.18 Å 
resolution are shown in table 5.1. The result of data collection and processing gave 
the overall Rmerge 0.072 (0.566 for the outer shell), the I/σI was overall 16.3 (2.6 for 
the outer shell) and the completeness was overall 97.3%. Also the data do not 
appear to be twinned and there was no sign of significant radiation damage.           
 
5.1.3 Matthews Coefficient (Vm) calculation 
Matthews Coefficient calculations allow an estimation of the number of molecules 
in the asymmetric unit (Matthews, 1968). The Matthews Coefficient was estimated 
using Mattprob (http://www.ruppweb.org/Mattprob/) (Kantardjieff & Rupp, 2003). 
This calculated value depends on the unit cell volume and the molecular weight of 
BPSL2418MES. Mattprob showed one possible solution of one protein molecule in 
the asymmetric unit with a solvent content of 35.2% and a Vm of 1.9 Å3/Da (Figure 
5.2).        
 
5.1.4 Structure determination of BPSL2418MES  
As described in section 1.2.4 BPSL2418MES shows high homology with the GAF 
domain fRMsr enzymes, which made phase determination by molecular 















Figure 5.1: X-ray diffraction image of BPSL2418MES crystal to 1.18 Å resolution using 












Data collection statistics  
Beamline at DLS,Oxford, UK I04 
Detector ADSC Q315r detector 
The crystal-to-detector distance 250 mm 
Space group P 21 21 21 
Crystal system orthorhombic 














Wavelength (Å) 0.97950 
Resolution range (Å) 60.5-1.18 (1.21-1.18) 
No. of unique reflections 40778 (1566) 
Rmerge 0.07 (0.57) 
Rpim 0.03 (0.29) 
Mean (I)/σ(I) 16.3 (2.6) 
Completeness (%) 97.3 (89.3) 
Multiplicity 7.0 (5.4) 
Mosaicity (°) 0.1 




Table 5.1: Data collection statistics for the BPSL2418MES number in parentheses 






























Figure 5.2: Matthews coefficient calculations and probabilities for BPSL2418MES 
using Mattprob http://www.ruppweb.org/Mattprob/. (A) This indicates the possibility of 
one protein molecule in the asymmetric unit with a Vm of 1.9 Å/Da (B) and a solvent 






The Phyre2 server (Kelley & Sternberg, 2009) was used to obtain a search model. 
A Staphyloccus aureus fRMsr structure (PDB 3KSF) with 49% identity and 68% 
similarity was selected and use for an automated search in Phaser (McCoy et al, 
2007). No modification was done before using the template structure. The 1.18 Å 
dataset (the scaled mtz file) was input and Phaser was run in     P 2 2 2 with the all 
alternative space groups, searching for one molecule in the asymmetric unit. A 
single solution was obtained in space group P 21 21 21 with one molecule in the 
asymmetric unit, which correlated to the single model predicted by the Matthews 
probability calculations. This molecular replacement solution produced the rotation 
and translation function Z-scores of 8.1 and 13.1, respectively, which suggested the 
model was correct.       
 
5.1.5 Model building and refinement    
The model of BPSL2418MES obtained by molecular replacement was viewed in 
COOT (Emsley & Cowtan, 2004) and immediately it was clear that the majority of 
the BPSL2418MES sequence fitted well to the electron density. The molecular 
replacement solution produced R-factor and Rfree of 0.409 and 0.428, respectively 
and after one round of refinement using REFMAC5 (Murshudov et al, 1997) the R-
factor and Rfree showed an improvement to 0.352 and 0.402, respectively. The 
refinement statistics exhibit a reduction in R-factor and Rfree over 29 rounds of 
refinement and the model was rebuilt, refined and assessed using REFMAC5 and 
COOT (Figure 5.3). The refinement was carried on until there was no improvement 
could be seen. The final model composed of 162 residues, 180 water molecules and 
one MES molecule. The final refinement statistics for BPSL2418MES structure are 
shown in table 5.2.        
 
5.1.6 3D structure of BPSL2418MES   
The crystal structure of BPSL2418MES shows that the protein has one molecule in 
the asymmetric unit as predicted by the Matthews coefficient calculations. This 
molecule was named chain A and the electron density of this molecule is well 
determined except for the first five residues at the N-terminus and the last three  
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Figure 5.3: Sample regions of electron density for BPSL2418MES at 1.18 Å show the 
structure improvement over 29 refinement cycles. (A) Shows three regions of electron 
density around residues 16,45 and 58 after one refinement. (B) Shows the same three 
regions after 29 cycles of rebuilding and refinement. Blue map calculated using coefficients     








Refinement statistics   
Resolution 1.18 Å 
Protein molecules in asymmetric 
unit 
1 
Number of residues 162 
Number of waters 180 
Number of atoms 1383 
Average B values (Å2): 
Whole chain A 
Main chain 

















Most favored regions 
 
 
MolProbity score:  
 
98.75% 
                    






Table 5.2: Refinement statistics for BPSL2418MES after 29 cycles of rebuilding in 
COOT and refinement in REFMAC5. The Ramachandran scores were produced using 






residues at the C-terminus. The refined electron density map shows a MES 
molecule binding the BPSL2418 close to CYS75 and CYS109 where a disulfide 
bond is formed between these two cysteines (Figure 5.4). BPSL2418MES structure 
description and analysis will be discussed in chapter 6. The final model was 
validated using PROCHECK (Laskowski, 1993), and MOLPROBITY program 
(http://molprobity.biochem.duke.edu) (Chen et al, 2010). This shows that all 
residues fell within allowed regions of Ramachandran plot (Figure 5.5) and all 
main chain and side chain parameters were better or within the expected range for 
the resolution of data (Figure 5.6). These results reveal that the overall structure is 
of very good quality.                                  
The PISA webserver http://pdbe.org/PISA (Krissinel & Henrick, 2007) was used to 
investigate the assemblies and interface between monomers in BPSL2418MES.  
PISA was run using a model containing the BPSL2418 protein chain binding MES 
molecule and symmetry-related molecules generated by the three 2-fold screw 
symmetry axes in space group P 21 21 21. The PISA analysis shows that 
BPSL2418MES monomers interact to form dimers (Figure 5.7) (this discussed in 
more details in chapter 6). The BPSL2418MES crystal belongs to space group          
P 21 21 21 and the unit cell therefore contains four identical monomers, which 




































Figure 5.4: Electron density map of BPSL2418MES at 1.18 Å shows a MES molecule 
binding the BPSL2418 close to CYS75 and CYS109 where a disulfide bond is formed 
between these two cysteines. Blue map calculated using coefficients 2mFo-dFc and contoured at 0.5 σ. 
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Disulfide bond  
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Figure 5.5: Result of MOLPROBITY and Ramachandran plot of BPSL2418MES 
structure. (A) The Ramachandran plot shows that all residues are within the favored 
region. (B) Overall the MOLPROBITY score is in the 93rd percentile (100% being the best 





Figure 5.6: Main chain and side chain parameters of BPSL2418MES. (A) Showing all the 





(B) Showing all the side chain parameters values are better than the average for a 
structure at this resolution. Produced by the programme PROCHECK (Laskowski et al, 




























Figure 5.7: Dimeric BPSL2418MES. (A) Cartoon model. (B) space-filling model. The Figure 





































Figure 5.8: Four BPSL2418MES molecules in a unit cell (space group P 21 21 21) of the 
crystal. (A) Spacefil model. (B) Cartoon model. The unit cell has two biological dimers and 
interaction between them is crystallographic interaction.  The Figure was produced using 







1 unit cell 
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5.2 Experimental structure determination of 
BPSL2418Met-SO by molecular replacement using 
BPSL2418MES  
 
The best crystals of BPSL2418 in complex with the Met-SO substrate were 
selected from the optimization trial for data collection (section 4.6.2).  
 
5.2.1 Space group determination and indexing 
The initial data collection was carried out in Sheffield to estimate the diffraction 
quality. The best in-house diffraction of BPSL2418Met-SO was 2.5 Å and to obtain 
better diffraction the crystal was sent to the Diamond Light Source at the I02 
beamline. To obtain a collection strategy, three initial test images were collected 
45° apart with 0.2° oscillation and analyzed using MOSFLM. BPSL2418Met-SO 
belongs to the primitive monoclinic crystal system, which is distinguished by 
unequal length of the edges of the unit cell (a≠b≠c) and the equal α and γ angles of 
90° and β unequal to 90° (α = γ=90°, β≠90°). BPSL2418Met-SO data was indexed in 
P 1 2 1 space group with unit cell dimensions; a= 35.90 Å, b= 92.27 Å, c= 42.65 Å, 
α= 90°, β=102.42° and γ=90°.          
 
5.2.2 Data collection and processing 
The BPSL2418Met-SO data were collected at the I02 beamline of the Diamond Light 
Source, Oxford. 900 images were collected for the data set with 0.2° oscillation per 
image using X-ray of wavelength 0.97949 Å and using an Pitatus 6M detector with 
a crystal-to-detector distance of 246.4 mm. The crystal diffracted to 1.4 Å 
resolution (Figure 5.9). The collected images were processed using xia2 system 
and were indexed and integrated by XDS and scaled by XSCALE. All statistics of 
processed data collection of BPSL2418Met-SO at 1.4 Å resolution are described in 
















Figure 5.9: X-ray diffraction image of BPSL2418Met-SO crystal to 1.4 Å using the I02 













Data collection statistics  
Beamline at DLS,Oxford, UK I02 
Detectore Pitatus 6M 
The crystal-to-detector distance 246.40  mm 
Space group P21  
Crystal system monoclinic 














Wavelength (Å) 0.97949 
Resolution range (Å) 32.8-1.42 (1.46-1.42) 
No. of unique reflections 49084 (3603) 
Rmerge 0.08 (0.9) 
Rpim 0.06 (0.63) 
Mean (I)/σ(I) 9.7 (2.0) 
Completeness (%) 96.2 (95.6) 
Multiplicity 3.3 (3.4) 
Mosaicity (°) 0.4 




Table 5.3: Data collection statistics for the BPSL2418Met-SO. Number in 




the I/σI was overall 9.7 (2 for the outer shell) and the completeness was overall 
96.3%. Also the data do not appear to be twinned and there was no sign of 
radiation damage.     
 
5.2.3 Matthews Coefficient (Vm) calculation 
The Matthews Coefficient number Vm for BPSL2418Met-SO was calculated using 
Mattprob webserver. The Matthews Coefficient calculation shows the asymmetric 
unit was estimated to include one or two protein molecules, with two being the 
most likely solution, producing a Matthews coefficient of 1.92 Å3/Da and a solvent 
content of 35.8% (Figure 5.10). 
 
5.2.4 Structure determination of BPSL2418Met-SO   
The structure of BPSL2418MES solved as part of this thesis was used as a search 
model for molecular replacement utilizing the diffraction data of BPSL2418Met-SO. 
The 1.4Å dataset was input and Phaser was run in P2 with all alternative space 
groups, searching for two molecules in the asymmetric unit. A single solution was 
found in space group P21. This molecular replacement solution produced rotation 
and translation function Z-scores of 8.8 and 40.2 respectively, which suggested the 
model was correct.       
 
5.2.5 Model building and refinement   
The electron density map of BPSL2418Met-SO produced by molecular replacement 
was viewed in COOT. The molecular replacement gave a model with an initial R-
factor of 0.290 and Rfree of 0.323. Reductions in R-factor and Rfree to 0.18 and 0.20 
respectively were achieved using 38 cycles of rebuilding and refinement and 
showed an improvement in the fit of the model to the map (Figures 5.11 & 5.12). 
The refinement was carried on until there was no possible structure improvement. 
The final model was composed of two molecules chain A and chain B, which 
consist of 155 residues and 156 residues, respectively The final refinement 































Figure 5.10: Matthews coefficient calculations and probabilities for BPSL2418Met-SO 
using Mattprob http://www.ruppweb.org/Mattprob/. This indicates the possibility of two 
protein molecules in the asymmetric unit (A) with a Vm of 1.92 Å3/Da (B) and a solvent 































Figure 5.11: Sample regions of electron density for BPSL2418Met-SO chain A at 1.4 Å 
show the structure improvement over 38 refinement cycles. On the left side three 
regions of electron density around residues 17,90 and 98 after one cycle of refinement. On 
the right side the same three regions after 38 cycles of rebuilding in COOT and refinement 
in REFMAC5. Blue map calculated using coefficients 2mFo-dFc and contoured at 0.4 σ. Green map 

























Figure 5.12: Sample regions of electron density for BPSL2418Met-SO chain B at 1.4 Å 
show the structure improvement over 38 refinement cycles. (A),(B) and (C) Three 
regions of electron density around residues 12,24 and 31 after one cycle refinement. 
(D),(E) and (F) The same three regions after 38 cycles of rebuilding in COOT and 
refinement in REFMAC5. Blue map calculated using coefficients 2mFo-dFc and contoured at 0.4 σ. Green 










5.2.6 3D structure of BPSL2418Met-SO   
The crystal structure of BPSL2418Met-SO shows that the protein has two molecules 
in the asymmetric unit as predicted by the Matthews coefficient calculations. The 
electron density of these molecules is well determined except for ten residues in the 
N-terminus for both molecules and the last four or five residues in the C-terminus 
for chain A and chain B, respectively. The electron density map shows a Met-SO 
molecule binding the BPSL2418 in the active site close to CYS75 and CYS109 in 
both chain A and chain B. A disulfide bond is formed between these two cysteines 
in both molecules A and B (Figure 5.13). BPSL2418Met-SO structure description and 
analysis will be discussed in chapter 6. The final model was validated using 
PROCHECK (Laskowski, 1993), and MOLPROBITY program (Chen et al, 2010). 
This shows that all residues fell within allowed regions of Ramachandran plot 
(Figure 5.14) and all main chain and side chain parameters were better or within 
the expected range for the resolution of data (Figure 5.15). These results reveal that 
the overall structure is of very good quality.                                  
To identify the assemblies and interface between monomers in BPSL2418Met-SO the 
PISA webserver was used. PISA was run using a model involving the BPSL2418 
chain binding Met-SO substrate and it indicates the presence of a dimer interface 
between the two monomers of BPSL2418Met-SO A and B (this is discussed in more 
chapter 6) (Figure 5.16). The BPSL2418Met-SO crystal belongs to space group         
P21 which has one 2-fold screw axis and thus the unit cell contains two dimers of 
BPSL2418Met-SO (Figure 5.17).                               
 








Refinement statistics   
Resolution 1.4 Å 
Protein molecules in asymmetric 
unit 
2 
Number of atoms 2542 
Number of residues 311 
Number of waters 390 
Average B values (Å2): 
Whole chain A 
Main chain A 
Side chain A 
Met-SO molecule 
Whole chain B 
Main chain B 





















Most favored regions 
 
 
MolProbity score:  
 
98.75% 
                    






Table 5.4: Refinement statistics for BPSL2418Met-SO after 38 cycles of rebuilding 
in COOT and refinement in REFMAC5. The Ramachandran scores were 
produced using MolProbity.    
 




























Figure 5.13: Electron density map of BPSL2418Met-SO at 1.4 Å shows a Met-SO 
molecule binding the BPSL2418 close to CYS-75 and CYS-109 where a disulfide 
bond is formed between these two cysteines. Blue map calculated using coefficients 2mFo-dFc 
and contoured at 0.4 σ. Green map calculated using coefficients mFo-dFc and contoured at 2.4 σ.    
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Figure 5.14: Result of MOLPROBITY and Romachandran plot of BPSL2418Met-SO 
structure. (A) The Romachandran plot shows that all residues are within the favored 
region. (B) Overall the MOLPROBITY score is in the 78th percentile (100% being the best 
amongst structures of comparable resolution). MOLPROBITY (Chen et al, 2010).    
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Figure 5.15: Main chain and side chain parameters of BPSL2418Met-SO. (A) Showing all 
the main chain parameters values are better or within the average for a structure at this 





(B) Showing all the side chain parameters values are better than the average for a 
structure at this resolution. Produced by the programme PROCHECK (Laskowski et al, 































Figure 5.16: Dimeric BPSL2418Met-SO. (A) Cartoon model. (B) Space-filling model. The 






























Figure 5.17: Two BPSL2418Met-SO dimers in a unit cell (space group P21) of the 
crystal. (A) Spacefil model. (B) Cartoon model.  The Figure was produced using PISA 
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5.3 Experimental structure determination of 
BPSL2418Reduced by molecular replacement using 
BPSL2418MES  
 
The best crystals of reduced BPSL2418 were selected from the optimization trial 
for data collection (section 4.6.3).  
 
5.3.1 Space group determination and indexing 
The X-ray source in Sheffield was used for initial X-ray diffraction determination. 
The best diffraction of BPSL2418Reduced was 3.1Å and in order to achieve higher 
resolution diffraction the crystal was sent to the Diamond Light Source at the I02 
beamline. To obtain a collection strategy, three initial test images 45° apart, 0.2° 
oscillation were collected using MOSFLM. BPSL2418Reduced was indexed to the 
primitive monoclinic crystal system P2, with unit cell parameters: a= 35.99 Å, b= 
92.28 Å, c= 42.75 Å, α= 90°, β= 102.72° and γ=90°; i.e. essentially isomorphous 
with BPSL2418Met-SO.           
 
5.3.2 Data collection and processing 
The data from BPSL2418Reduced crystal were collected using the I02 beamline of the 
Diamond Light Source. For the data set 900 images were collected with 0.2 
oscillation per image using X-ray of wavelength 0.97949Å and using a Pitatus 6M 
detector with a crystal-to-detector distance of 395.28 mm. Data were collected to 
2.0 Å resolution (Figure 5.18). The images were processed using xia2 system and 
were indexed and integrated by XDS and scaled by XSCALE. All statistics of the 
processed data of BPSL2418Reduced at 2.0 Å resolution are described in table 5.5. 
The processing gave overall Rmerge   0.129 (0.522 for the outer shell) and the I/σI 


















Figure 5.18: X-ray diffraction image of BPSL2418Reduced crystal to 2.0 Å using the I02 














Data collection statistics  
Beamline at DLS,Oxford, UK I02 
Detectore Pitatus 6M 
The crystal-to-detector distance 395.28 mm 
Space group P21  
Crystal system monoclinic 














Wavelength (Å) 0.97949 
Resolution range (Å) 38-2.21 (2.27-2.21) 
No. of unique reflections 13602 (998) 
Rmerge 0.13 (0.52) 
Rpim 0.1 (0.41) 
Mean (I)/σ(I) 6.3 (2.3) 
Completeness (%) 99.4 (98.7) 
Multiplicity 3.3 (3.1) 
Mosaicity (°) 0.2 




Table 5.5: Data collection statistics for the BPSL2418Reduced. Number in 




5.3.3 Matthews Coefficient (Vm) calculation 
The Matthews calculation for BPSL2418Reduced using Mattprob webserver shows 
the possibility of one or two molecules in the asymmetric unit, with two as the 
most likely solution. The Matthews coefficient of the protein is 1.92 and estimated 
solvent content is 36.1% (Figure 5.19). 
 
5.3.4 Structure determination of BPSL2418Reduced 
BPSL2418Reduced structure was solved by molecular replacement using the model of 
BPSL2418MES in PHASER. The 2.0 Å dataset of BPSL2418Reduced were input and 
Phaser searched for two molecules in the asymmetric unit. A single solution was 
found using space group P21 giving rotation and translation function Z-scores of 
10.1 and 32.7 respectively, which suggested the model was correct.       
 
5.3.5 Model building and refinement   
The obtained electron density map of BPSL2418Reduced generated by molecular 
replacement was viewed in COOT. The initial model produced has an R-factor of 
0.271 and Rfree of 0.328. An improved model with a reduction in R-factor and Rfree 
to 0.19 and 0.214, respectively was obtained by using repetitive cycles of model 
building and refinement (Figures 5.20 & 5.21). The refinement was carried on until 
there was no possible structure improvement. The final model consists of two 
molecules chain, A which consist of 156 residues, chain B with 155 residues and 
116 water molecules.  
 
5.3.6 3D structure of BPSL2418Reduced   
The crystal structure exhibits two molecules in the asymmetric unit of 
BPSL2418Reduced, which agrees with the Matthews coefficient prediction. The 
electron density of these two molecules is well determined except 11 and 9 
residues from the N termini and 3 and 6 residues from the C termini of chain A and 



































Figure 5.19: Matthews coefficient calculations and probabilities for    
BPSL2418Reduced using Mattprob http://www.ruppweb.org/Mattprob/. This indicates the 
possibility of two protein molecules in the asymmetric unit (A) with a Vm of 1.92 Å3/Da (B) 































Figure 5.20: Sample regions of electron density for BPSL2418Reduced chain A at 2.0 Å 
show the structure improvement over 18 refinement cycles. On the left three regions 
of electron density around residues 24, 40 and 49 after one cycle of refinement. On the 
right the same three regions after 18 refinement cycles. Blue map calculated using coefficients 




























Figure 5.21: Sample regions of electron density for BPSL2418Reduced chain B at 2.0 Å 
show the structure improvement over 18 refinement cycles. On the left side three 
regions of electron density around residues 46,60 and 159 after one cycle of refinement. 
On the right side the same three regions after 18 refinement cycles. Blue map calculated using 
coefficients 2mFo-dFc and contoured at 0.69 σ. Green map calculated using coefficients mFo-dFc and contoured 
at 2.63 σ.      
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of the active site of  BPSL2418, where no disulfide bridge (S-S) is formed between 
CYS75 and CYS109 and the two cysteines are maintained in the sulphydryl (-SH) 
form (Figure 5.22). BPSL2418Reduced structure description and analysis will be 
discussed in chapter 6. The final model was validated using PROCHECK 
(Laskowski, 1993), and MOLPROBITY program (Chen et al, 2010). This shows 
that all residues fell within allowed regions of Ramachandran plot (Figure 5.23) 
and all main chain and side chain parameters were better or within the expected 
range for the resolution of data (Figure 5.24). These results reveal that the overall 
structure is of very good quality.                                    
To determine the assemblies and interface between monomers in BPSL2418Reduced 
the PISA webserver was applied. PISA was run using the reduced model of 
BPSL2418 which indicates a dimer interfaces between the two BPSL2418Reduced 
monomers A and B (this is discussed in more details in chapter 6) (Figure 5.25). 
The BPSL2418Reduced crystal belongs to space group P21 which has one 2-fold 
screw axis and this suggests that the unit cell contains two dimers of 




























Figure 5.22: Electron density map of BPSL2418Reduced at 2.0 Å shows no disulfide 
bond is formed between CYS75 and CYS109. Blue map calculated using coefficients 2mFo-dFc 

















Refinement statistics   
Resolution 2.0 Å 
Protein molecules in asymmetric 
unit 
2 
Number of atoms 2403 
Number of residues 311 
Number of waters 116 
Average B values (Å2): 
Whole chain A 
Main chain A 
Side chain A 
Whole chain B 
Main chain B 






























Table 5.6: Refinement statistics for BPSL2418Reduced after 18 cycles of rebuilding 
in COOT and refinement in REFMAC5. The Ramachandran scores were 































Figure 5.23: Result of MOLPROBITY and Romachandran plot of BPSL2418Reduced 
structure. (A) The Romachandran plot shows that all residues are within the favored 
region. (B) Overall the MOLPROBITY score is in the 79th percentile (100% being the best 




























Figure 5.24: Main chain and side chain parameters of BPSL2418Reduced. (A) Showing 
all the main chain parameters values are within the average for a structure at this 






























(B) Showing all the side chain parameters values are within the average for a structure at 
this resolution. Produced by the programme PROCHECK (Laskowski et al, 1993)  
 
 


























Figure 5.25: Dimeric BPSL2418Reduced. (A) Cartoon model. (B) Space-filling model. The 





























Figure 5.26: Two BPSL2418Reduced dimers in a unit cell (space group P21) of the 
crystal. (A) Spacefil model. (B) Cartoon model.  The Figure was produced using PISA 
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Chapter 6: BPSL2418 structure analysis 
 
This chapter represents the analyses of the structures of MES-bound, Met-SO 
bound and reduced forms of BPSL2418, which were produced in this project. Also 
the chapter describes the putative active site and BPSL2418 is possible role in 
Burkholderia pseudomallei. 
 
6.1 BPSL2418 structure description  
This section describes in detail the structure analysis of BPSL2418MES, 
BPSL2418Met-SO and BPSL2418Reduced.    
 
6.1.1 Features of BPSL2418 structure 
 
6.1.1.1 BPSL2418MES 
The structure of BPSL2418MES was determined from crystals grown in 
orthorhombic spacegroup the P 21 21 21 and it comprises one subunit in the 
asymmetric unit. A Dali search suggests that the BPSL2418MES subunit structure 
shares the overall topology of the GAF domain and it consists of six antiparallel β-
strands (β1- β6) and four α-helices (α1- α4) with connecting loops (Figure 6.1). 
The antiparallel β-strands (β1, β2, β5 and β6) are located in the center of the 
BPSL2418MES structure flanked on one side by three α-helices (α1,α2 and α4). On 
the other side a construct of loop1(β2β3 loop), β3, loop2(β3α3 loop), α3, 
loop3(α3β4 loop), β4 and loop4(β4β5 loop) unit, where loop 4 forms a capping 
flap, which covers the active site (Figure 6.2 a).  
The Active Site: The active site consists of residues from the four β-strands (β1, 
β2, β5, β6) and the loop1- β3- loop2- α3- loop3- β4- loop4 unit that surrounds the 
active site forming a small cavity (Figure 6.2b). It contains TRP53 and TYR57 
from β1, ALA74 and CYS75 from loop1, ILE 78 from β3, GLY83 from loop2, 
VAL84 and CYS85 from α3 and ILE107, ALA108, CYS109, SER 111, SER113 






















Figure 6.1: Cartoon representation of the overall fold structure of BPSL2418MES. The 
structure consists of six β-strands and four α-helices with connecting loops. The disulfide 
S-S bond between CYS75 and CYS109 is shown in orange color and MES molecule in 











































Figure 6.2: Cartoon representation of the BPSL2418MES showing the active site. (A) 
The β-strands (β1, β2, β5 and β6) of BPSL2418MES are located in the center of the 
structure flanked on one side by three α-helices (α1, α2 and α4), and on the other side by 
loop1, β3, loop2, α3, loop3, β4 and loop4 construct. (B) loop4 forms a capping flap, which 











































Figure 6.3: (A) Electron density map of 2-(N-morpholino)ethanesulfonic acid [MES] 
structure at 1.18 Å. (oxygen atom in red, nitrogen in blue and sulfur in green) (B) The 
binding site of BPSL2418MES molecule with the MES bound. Residues involved in 
BPSL2418-MES binding are shown as sticks. The Figures were created by PyMol 
(DeLano & Lam, 2005). Blue map calculated using coefficients 2mFo-dFc and contoured at 0.5 σ.  

























BPSL2418MES structure is an oxidized form where a disulfide bond is formed 
between CYS75-CYS109, binding loop1 and loop4 together and tightening the 
active site cavity (Figure 6.3b). The MES molecule (Figure 6.3a) lies inside the 
cavity with a MES sulfonic acid group being close to CYS85 in α3 (Figure 6.3b). 
To analyze the interaction between MES and the active site of BPSL2418 protein, 
LigPlot (Wallace et al, 1995) was used. Hydrogen bonds are formed between O1 of 
the sulfonic acid group and the peptide nitrogen atoms of ALA108 and CYS109 
residues, which are both located in loop4. Further hydrogen bonds are formed 
between O2 and O3 of the sulfonic acid group and the NH of VAL84 and CYS85 
respectively, where VAL84 and CYS85 are both situated at α3. TYR57 and TRP53 
were thought to provide the hydrophobic contact to the morpholine ring of MES, 
where both residues are situated in β1. CYS85 and VAL84 in α3 and ALA108 in 
loop4 were proposed to form hydrophobic interactions with the sulfonic acid group 
of MES. In addition to ILE78, GLY83, ILE107 and SER111 residues, which 
predicted to form a hydrophobic pocket in the active site seems important in ligand 
binding (Figure 6.4).   
Similar 3D structures: A search of the Dali database (Holm & Rosenstrom, 2010) 
with the BPSL2418MES structure indicates several homologs with high Z-scores 
and high sequence identity. It shows that BPSL2418MES belongs to a GAF domain 
family that acts as free methionine sulfoxide reductase, as also has been predicted 
before from protein sequence (see section 1.2.4). Dali suggests several homologs to 
BPSL2418MES (table 6.1), but the top of the list is the E. coli fRMsr structure (PDB 
code 1VHM) (Badger et al, 2005) (Figure 6.5). Dali superimposed the 
BPSL2418MES and the E. coli fRMsr over 151 α-carbon atom pairs with a Z-score 
of 26.8, sequence identity 49% and a root mean-square deviation (RMSD) of 1.1 
Å. The E. coli fRMsr structure consists of two chains A and B, both have high 
identity to BPSL2418MES. Similar to BPSL2418MES, the E. coli fRMsr subunits have 
a GAF domain topology composing of four six antiparallel β-strands and four α-
helices with connecting loops. BPSL2418MES and the E. coli fRMsr each have three 
cysteines and a disulfide bond in the active site pocket, which are conserved in all 
of the fRMsr family (see section 1.2.2.3 and Figure 1.12). Also the E. coli fRMsr 
























































1 1vhm-A 26.8 1.1 151 159 49 Structure of fRMsr of E. coli  (Badger et 
al, 2005) 
Method: X-ray diffraction 
Resolution: 2.1 Å 
Ligand: MES  
2 1vhm-B 26.6 1.3 152 160 49 Structure of fRMsr of E. coli  (Badger et 
al, 2005) 
Method: X-ray diffraction 
Resolution: 2.1 Å 
Ligand: MES 
3 3 ksf-G 25.7 2.1 151 152 44 Structure of fRMsr of Staphylococcus 
aureus (Bong et al, 2010) 
Method: X-ray diffraction 
Resolution: 1.9 Å 
Ligand: PEG  
4 3 rfb-A 25.6 1.2 151 161 40 Structure of fRMsr of Streptococcus 
pneumonia (To be published) 
 Method: X-ray diffraction 
Resolution: 2.3 Å 
Ligand: Met-R-SO 
5 3 ksh-A 25.6 1.8 151 152 48 Structure of fRMsr of Staphylococcus 
aureus (Bong et al, 2010) 
Method: X-ray diffraction 
Resolution: 1.5 Å 
Ligand: SO4 
 
Table 6.1: Dali server results for the model of BPSL2418MES. The top five hits 
are listed alongside their related Zscores, RMSD scores, alignment statistics and a 



















Figure 6.4: The binding site interaction of BPSL2418MES with the MES buffer. The 
Figure shows the residues, are involved in hydrogen bonds and hydrophobic interactions. 
Hydrogen bonds are shown as green dashed lines between atoms. Hydrophobic 
interactions are indicated by a red lashes-like symbol pointing towards the ligand atom 
they contact. The MES atoms that are involved in hydrophobic interaction are represented 
by a red spokes pointing back. (oxygen atom in red, nitrogen in blue, carbon in black, 


































Figure 6.5: Superimposition of BPSL2418MES (green) and E. coli fRMsr  
(gray). (A) Overall fold of BPSL2418MES and E. coli fRMsr. (B) The active sites of the two 
structures showing the binding residues and MES ligand as sticks. It is clear that the 
overall structures and the active sites of both structures are almost identical. The Figure 












providing hydrogen bonds and hydrophobic surface (Figure 6.6). Similar to 
BPSL2418MES, the sulfonic acid group of the MES ligand in E. coli fRMsr active 
site is situated close to CYS94, the corresponding residue to CYS85 in 
BPSL2418MES. The proximity of the MES sulfonic acid group to the third cysteine, 
which does not participate in the disulfide bond, is constant in the arrangement of 
the active site residues in the MsrA family and in the E. coli fRMsr the only known 
structure from the fRMsr family that has a MES molecule in the active site (Lin et 























































Figure 6.6: LigPlot diagrams of the binding site interaction of E.coli fRMsr and 
BPSL2418MES. Hydrogen bonds are shown as green dashed lines between atoms. 
Hydrophobic interactions are indicated by a red lashes-like symbol pointing towards the 
ligand atom they contact. The MES atoms that are involved in hydrophobic interaction are 
represented by red spokes pointing back. (oxygen atom in red, nitrogen in blue, carbon in 







The crystal structure of BPSL2418 in complex with the substrate free Met-R-SO 
was solved at 1.4 Å. This structure belongs to the space group P21 and it consists of 
a dimer in the asymmetric unit with the substrate in bound to subunit. The overall 
structure and the active site of each BPSL2418Met-SO subunit (Figure 6.7) is almost 
identical to BPSL2418MES except for a slight change in loop 4 in the active site; the 
comparison between the two structures will be discussed later on in this chapter.   
The Active Site: Each active site of the BPSL2418Met-SO dimer is composed of the 
same BPSL2418MES active site structure of four β-strands (β1, β2, β5 and β6) that 
are located in the center of the subunit and the (loop1- β3- loop2- α3- loop3- β4- 
loop4) construct that shields the binding ligand forming a small cavity. This cavity 
is made more tightened by the formation of the disulfide bond (CYS75-CYS109) 
that binds loop1 with loop4. The formation of this cavity in BPSL2418MES and   
BPSL2418Met-SO might ensure tight binding for the ligand. One molecule of free 
Met-R-SO substrate (Figure 6.8a) is bound within each active sites of the 
BPSL2418Met-SO dimer identically. The substrate lies along the full-length of the 
central β-strands and the carboxylate group is located close to CYS85 in α3 (Figure 
6.8b). The orientation of the free Met-R-SO carboxylate toward the free cysteine in 
α3 is also seen in the N. meningitides fRMsr (PDB code 3MMH) (Gruez et al, 
2010) and the S. pneumoniae fRMsr (PDB code 3RFB) (Bong & Chi, 2011) 
structures. LigPlot (Figure 6.9) was used to investigate the interaction of the 
BPSL2418 protein and the free Met-R-SO substrate. These analyses indicate the 
residues in the active site that interact with the ligand: CYS109, ILE107 and 
HIS106 in loop4, VAL84 and CYS85 in α3, ILE78 and CYS75 in loop1, TRP53 
and TYR57 in β1, ASP133 and ASP135 in β5, GLU116 in β4 and GLY83 in 
loop2. Hydrogen bonds occur between the amino nitrogen atom of Met-R-SO 
substrate and the OE1 and O atoms of GLU116 and ILE107 respectively (Figure 
6.9). Also between the peptide nitrogens of ILE107 and VAL84 and the oxygen 
atom O of the Met-R-SO carboxylate group (Figure 6.9). Another hydrogen bond 
was predicted between the OXT of the Met-R-SO carboxylate and the peptide 
nitrogen of CYS85 in α3 (Figure 6.9). Other residues in the active site provide 



















Figure 6.7: Cartoon representation of the overall fold structure of BPSL2418Met-SO. 
The structure consists of a dimer with the free Met-SO (blue) substrate bound in each 
subunit of the asymmetric unit (on the right side chain A of BPSL2418Met-SO dimer and on 
the left side chain B). Each subunit is composed of six β-strands and four α-helices with 
connecting loops. The disulfide S-S bond between CYS75 and CYS109 is shown in yellow 
color and free Met-SO molecules in blue color. The Figure was created by PyMol (DeLano 
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  Figure 6.8: (A) Electron density map of free L-Methionine sulfoxide [free Met-R-SO] 
structure at 1.4 Å. (oxygen atom in red, nitrogen in blue and sulfur in green) (B) The 
binding site of BPSL2418Met-SO with free Met-SO substrate bound. Residues that are 
involved in BPSL2418-Met-SO binding are shown as sticks, the Figures were created by 








































Figure 6.9: The binding site interaction of BPSL2418Met-SO with the free Met-SO 
substrate. The Figure shows the residues, which involved in hydrogen bonds and 
hydrophobic interactions. Hydrogen bonds are shown as green dashed lines between 
atoms. Hydrophobic interactions are indicated by a red lashes-like symbol pointing towards 
the ligand atom they contact. The Met-SO atoms that involved in hydrophobic interaction 
are represented by a red spokes pointing back. (oxygen atom in red, nitrogen in blue, 
carbon in black, sulfur in yellow). This Figure was produced by LigPlot (Wallace et al, 











tight binding of the substrate (Figure 6.9).  
 
Similar 3D structures: Several homologs with high Z-scores and sequence 
identity have been predicted using the Dali server. As expected the Dali search 
revealed that BPSL2418Met-SO belongs to the GAF domain fRMsr family (table 
6.2). The first two hits are the S. pneumonia fRMsr (PDB code 3RFB) (Bong & 
Chi, 2011) and the N. meningitides fRMsr (PDB code 3MMH) (Gruez et al, 2010). 
The search gave a superposition of BPSL2418Met-SO with S. pneumonia fRMsr with 
a Z-score of 27.3, sequence identity 42% and a root mean-square deviation 
(RMSD) of 1.2 Å between 153 α-carbon atom pairs (Figure 6.10). The 
superposition of  BPSL2418Met-SO was with N.  meningitides fRMsr and gave a Z-
score of 27.2, sequence identity 46% and a root mean-square deviation (RMSD) of 
0.9 Å between 152 α-carbon atom pairs (Figure 6.11). The overall structure of 
BPSL2418Met-SO, S. pneumonia fRMsr and N. meningitides fRMsr subunits are 
almost identical and share the GAF domain topology of four six antiparallel β-
strands and four α-helices with connecting loops. An additional small alpha helix 
(ASP99, VAL100, ASP101, ALA102 and HIS103) in loop4 in N. meningitides 
fRMsr was the only difference between the three overall structures (Figure 6.10). 
The three structures have the three cysteines, which are conserved in all fRMsr 
family and a disulfide bond in the active site pocket. Like BPSL2418Met-SO, each of 
the two homologs’ structures consists of a dimer with the Met-SO substrate in each 
subunit of the asymmetric unit. The active sites of S. pneumonia fRMsr and N. 
meningitides fRMsr have a similar set of residues to the BPSL2418Met-SO active site 
residues that provides hydrogen bonds and hydrophobic surface (Figure 6.10 & 
6.12). The Met-R-SO lies inside the active sites of BPSL2418Met-SO, S. pneumonia 
fRMsr and N. meningitides fRMsr identically, where the carboxylate of the 
substrate is close to the free cysteine in α3 (Figure 6.11). It has been mentioned in 
section 1.2.3 (2)&(3) the difference of the orientation of the position of Met-R-SO 
between the substrate bound form of Staphylococcus aureus fRMsr and the 
Neisseria meningitides fRMsr, where the sulfoxide moiety in the Staphylococcus 
aureus fRMsr replaces the position of the carboxylate group in Neisseria 
meningitides fRMsr and vice versa. This thesis shows that BPSL2418Met-SO has the 























































1 3 rfb-A 27.3 1.2 153 161 42 Structure of fRMsr of Streptococcus 
pneumonia (To be published) 
 Method: X-ray diffraction 
Resolution: 2.3 Å 
Ligand: Met-R-SO 
2 3 mmh-B 27.2 0.9 152 168 46 Structure of fRMsr of neisseria 
meningitides (Gruez et al, 2010). 
Method: X-ray diffraction 
Resolution: 1.25 Å 
Ligand: Met-R-SO 
3 3 mmh-A 27.1 1.0 152 168 46 Structure of fRMsr of neisseria 
meningitides (Gruez et al, 2010). 
Method: X-ray diffraction 
Resolution: 1.25 Å 
Ligand: Met-R-SO 
4 1vhm-A 26.8 1.1 152 159 46 Structure of fRMsr of E. coli  (Badger et 
al, 2005) 
Method: X-ray diffraction 
Resolution: 2.1 Å 
Ligand: MES  
4 3 rfb-B 26.7 1.3 153 164 42 Structure of fRMsr of Streptococcus 
pneumonia (To be published) 
 Method: X-ray diffraction 
Resolution: 2.3 Å 
Ligand: - 
 
Table 6.2: Dali server results for the model of BPSL2418Met-SO. The top five hits 
are listed alongside their related Zscores, RMSD scores, alignment statistics and a 

























Figure 6.10: Superimposition of BPSL2418Met-SO (gold), N. meningitides fRMsr (PDB 
code 3MMH) (green) and S. pneumonia fRMsr (PDB code 3RFB) (blue). (A) Overall 
fold of BPSL2418Met-SO, 3MMH and 3RFB dimers. (B) The active sites of the three 
structures showing the binding residues and Met-SO ligand as sticks. The names of the 
corresponding residues are ordered as BPSL2418Met-SO then 3MMH then 3RFB.   Met-SO 
substrates are shown in red, grey and navy respectively.  It is clear that the overall 
structures and the active sites of the three structures are almost identical except the small 
alpha helix in N. meningitides fRMsr pointed by black arrow. The Figure produced by 
PyMol (DeLano & Lam, 2005).          
TRP53/  













































Figure 6.11: Close view of the Met-SO substrate that lies inside the active sites of 
BPSL2418Met-SO (gold), N. meningitides fRMsr (PDB code 3MMH) (green) and S. 
pneumonia fRMsr (PDB code 3RFB) (blue). The Figure shows that the carboxylate 
groups of the substrate inside the three active sites are located close to the free cysteine in 










































Figure 6.12: LigPlot diagrams of the binding site interaction of BPSL2418Met-SO, N. 
meningitides fRMsr and S. pneumonia fRMsr. Hydrogen bonds are shown as green 
dashed lines between atoms. Hydrophobic interactions are indicated by a red lashes-like 
symbol pointing towards the ligand atom they contact. The Met-SO atoms that involved in 
hydrophobic interaction are represented by a red spokes pointing back. (oxygen atom in 
red, nitrogen in blue, carbon in black, sulfur in yellow). This Figure was produced by 
LigPlot (Wallace et al, 1995).   
BPSL2418Met-SO 
S. pneumonia fRMsr 





S. pneumonia fRMsr and N. meningitides fRMsr and only the Staphylococcus 
aureus fRMsr has different orientation. It’s not clear why the Staphylococcus 
aureus fRMsr structure binds the substrate in different orientation, but this might 
be because it was obtained using C68S mutant (CYS68 corresponding to CYS75 in 
BPSL2418). This feature is different from the other fRMsr-substrate complex are 
oxidized forms with a disulfide bond between two cysteines in the active site.             
 
6.1.1.3 BPSL2418Reduced 
In order to investigate changes in the active site of the BPSL2418 protein that 
predicted to act as free methionine sulfoxide reductase, a reduced form of 
BPSL2418 was produced. The BPSL2418Reduced crystal, which diffracted to 2.0 Å, 
comprised two subunits in the asymmetric unit. The structure of the BPSL2418 
protein has changed in the active site of the different forms. A comparison between 
the reduced BPSL2418 and the other two oxidized forms BPSL2418MES and 
BPSL2418Met-SO will be illustrated in the following sections.  
The Active Site: The overall structure of one subunit involved six β strands and 
four α helices (Figure 6.13). The active site as in the other forms of BPSL2418 is 
composed of the four β-strands (β1, β2, β5 and β6) bounded by (α1, α2 and α4) 
helices from one side and the (loop1- β3- loop2- α3- loop3- β4- loop4) unit from 
the other side. The reduced form has no bound ligand in either active sites, and has 
no disulfide bond between CYS75-CYS109 due to the addition of the DTT 
reductant in the crystallization solution (Figures 5.22 & 6.14).  
Similar 3D Structures: Like the other two forms of BPSL2418, a search with Dali 
server with BPSL2418Reduced shows several homologs belonging to fRMsr family 
(table 6.3) with a GAF domain topology. The search gave a best superimposition of 
BPSL2418Reduced with the reduced form of S. aureus fRMsr (PDB code 3KSG) 
(Bong et al, 2010) with a Z-score of 26.5, sequence identity 44% and a root mean-
square deviation (RMSD) of 1.0 Å between 151 α-carbon atom pairs (Figure 6.15). 
The superimposition reveals that the BPSL2418Reduced and S. aureus fRMsr share a 
similar fold except the present of an extra small helix between β4 and β5 in S. 























































1 3 mmh-B 26.5 1.0 151 168 44 Structure of fRMsr of neisseria 
meningitides (Gruez et al, 2010). 
Method: X-ray diffraction 
Resolution: 1.25 Å 
Ligand: Met-R-SO 
2 3 mmh-A 26.4 1.0 151 168 44 Structure of fRMsr of neisseria 
meningitides (Gruez et al, 2010). 
Method: X-ray diffraction 
Resolution: 1.25 Å 
Ligand: Met-R-SO 
3 3 rfb-A 26.3 1.5 151 161 40 Structure of fRMsr of Streptococcus 
pneumonia (To be published) 
 Method: X-ray diffraction 
Resolution: 2.3 Å 
Ligand: Met-R-SO 
4 1vhm-A 26.3 1.1 151 159 48 Structure of fRMsr of E. coli  (Badger et 
al, 2005) 
Method: X-ray diffraction 
Resolution: 2.1 Å 
Ligand: MES  
5 1vhm-B 26.0 1.2 151 160 48 Structure of fRMsr of E. coli  (Badger et 
al, 2005) 
Method: X-ray diffraction 
Resolution: 2.1 Å 
Ligand: MES  
 
Table 6.3: Dali server results for the model of BPSL2418Reduced. The top five 
hits are listed alongside their related Zscores, RMSD scores, alignment statistics 

















Figure 6.13: Cartoon representation of the overall fold structure of   BPSL2418Reduced. 
The structure consists of a dimer with no disulfide bond formed in any of each subunit (on 
the right side chain A of BPSL2418Reduced dimer and on the left side chain B). Each subunit 
is composed of six β-strands and four α-helices with connecting loops. The Figure was 




























N-terminal of chain A 
 



















Figure 6.14: Cartoon representation of BPSL2418Reduced structure showing the active 
site. The active site contains the three conserved cysteines of the fRMsr family as sticks. 




































Figure 6.15: Superimposition of BPSL2418Reduced (green) chain A and S. aureus 
fRMsr (PDB code 3KSG)  (light blue) chain A. (A) Side view, (B) active site of the 
BPSL2418Reduced and S. aureus fRMsr. The superimposition shows that the overall 
structures and the active sites of the two structures are matching well except the extra 
alpha helix between β4 and β5 in S. aureus fRMsr (pointed by a black arrow). The three 
cysteines residues in the active site of the two proteins are shown as sticks. The Figure 
















6.1.2 Comparison and conformational changes of MES-
bound, Met-SO-bound and reduced forms of BPSL2418 
In this section a comparison between the BPSL2418MES, BPSL2418Met-SO and 
BPSL2418Reduced  structures, which are expected to represent the catalytic steps of 
the BPSL2418 reaction will be described. 
 
6.1.2.1 Comparison of the overall structures of BPSL2418 forms 
The overall structural alignment of BPSL2418MES, BPSL2418Met-SO and 
BPSL2418Reduced was produced using PyMol to compare the three forms of 
BPSL2418 (Figure 6.16). The alignment shows significant conformational changes 
between the three forms in the active site. No change was observed in loop1 of 
BPSL2418MES, BPSL2418Met-SO and BPSL2418Reduced and the position of CYS75 
residues of the three forms was unchanged (Figure 6.17). A conformational change 
was shown in loop4, which is composed of residues 98-113 including CYS109 
(Figure 6.17). It is clear that the CYS109 residue of each loop4 of the three 
structures is located at a different position. The Cα of the CYS109 residue of 
BPSL2418MES, BPSL2418Met-SO and BPSL2418Reduced  resides at a distance of 6.0 Å, 
5.7 Å and 10.0 Å, respectively from the Cα of the CYS75 residue in loop1 of each 
form. This indicates that the loop4 of BPSL2418Met-SO moves toward the entrance 
of the active site, where a disulfide bond is produced between CYS109 and 
CYS75, leading to closure of the active site pocket. The BPSL2418MES structure is 
an oxidized form and the distance between the Cα of CYS109 and CYS75 is 
slightly longer compared with the Cα- Cα distance between the two cysteines in 
BPSL2418Met-SO. Also the CYS109 residue in BPSL2418MES pulls loop4 to the 
entrance of the active site producing a cavity, but it seems to be less tight then the 
BPSL2418Met-SO pocket (Figure 6.17). A large movement far from the entrance of 
the cavity occurs in loop4 of the reduced form. The Cα of CYS109 in loop4 of 
BPSL2418Met-SO and BPSL2418Reduced reside at a distance of 4.6 Å from each other 
(Figure 6.18). Also the sulfur atom of CYS109 in the reduced form points toward 
the opposite side of the active site cavity (Figure 6.17). The volume of the active 
site pocket of the three forms was calculated using CASTp http://sts-










































Figure 6.16: Different views of the superimposition of BPSL2418MES (gold), 
BPSL2418Met-SO chain A (blue) and BPSL2418Reduced chain A (green) with disulfide 
bonds in yellow. (A) The alignment shows an overall very good superimposition but with 
a significant change in loop4 (defined by black circle). (B) RMSD between subunits after 
superimposition. The Figure produced by PyMol (DeLano & Lam, 2005).                 
 























Figure 6.17: Superimposition of the three forms of BPSL2418 shows the change in 
the active site, BPSL2418MES (gold), BPSL2418Met-SO (blue) and BPSL2418Reduced 
(green). The Figure shows the positions of the three conserved cysteines CYS75, CYS85 
and CYS109 in the active sites. The cysteines side chains are shown as sticks. The Figure 






































Figure 6.18: Calpha-Calpha distance (Y-axis) of residues of loop4 between 
BPSL2418Met-SO and BPSL2418Reduced (blue line) and between BPSL2418MES and 
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445.5 Å3, the BPSL2418MES has a pocket volume of 204.2 Å3 and the   
BPSL2418Met-SO has the smallest pocket volume of 167.3 Å3.  The B-value 
(temperature-factor) for the atoms of the loop4 compared to the rest of the structure 
in each form was calculated. Atoms with low B-factors indicate a well-ordered part 
of the structure. Atoms with high B-factors belong to a part of the structure that has 
a higher degree of mobility and flexibility. The B-factors of loop4 of subunit A of 
BPSL2418MES, BPSL2418Met-SO and BPSL2418Reduced are (14.27, 19.5 and 32.8 Å2 
respectively), which are significantly higher then the overall B-factors of the 
subunit A of each form (8.52, 14.6 and 27.2 Å2 respectively). It has been shown 
also that the B-factor of the main chain residues of BPSL2418Reduced is higher than 
the main chain residues of BPSL2418MES and BPSL2418Met-SO (Figure 6.19).  In 
sum the movement of the loop4, particularly CYS109, determines the 
conformational changes of the reduced form and the oxidized form (BPSL2418Met-
SO and BPSL2418MES) by creating a closed conformation in BPSL2418Met-SO and 
BPSL2418MES and an open conformation in BPSL2418Reduced. This result is 
consistant with the comparison between the reduced and oxidized forms of fRMsr 
from S. aureus (Bong et al, 2010). The conformational changes can also be 
observed by comparing the molecular surface of the three forms.    
 
6.1.2.2 Comparison of the molecular surface of the different forms 
of BPSL2418  
The electrostatic surfaces of the three different BPSL2418 forms were calculated 
using Pymol (DeLano & Lam, 2005). The two subunits for each BPSL2418Met-SO 
and BPSL2418Reduced dimers are identical, therefore only one subunit of each form 
will be used in the comparison. The models show the charge distribution on the 
surface of BPSL2418 forms (Figure 6.20). A fairly negatively charged depression 
appears in the entrance of the active site clearly shown in the reduced form (Figure 
6.20 c). The negative potential in the active site possibly indicates the substrate-
binding site. It is formed by the side chains of residues (ASP60, GLU63, ASP99, 
ASP110, GLU116, ASP125, ASP133, ASP135 and ASP143) in the active site. The 
negatively charged pocket might be significant in terms of the substrate binding,   





Figure 6.19: B-factors (Å2) of main chain residues of BPSL2418 different forms 
plotted against residues numbers (X-axis). The blue, red and green lines represent 
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by site-directed mutagenesis, kinetic characterization and crystallographic analysis.  
In these Positive charge is distributed randomly on the surface of BPSL2418, 
provided by the side chains of LYS and ARG residues. The comparison of the 
molecular surface of BPSL2418 forms reveals that the reduced form creates an 
opened conformation (Figure 6.20 c) while the MES and the Met-SO complex 
forms produce a closed conformation of the active site cavity (Figure 6.20 b). 
However the molecular surface model shows that the BPSL2418Met-SO form 
generates a more closed conformation and this might indicate that the free Met-R-
SO is the most preferable ligand. The closed conformation status of the two 
oxidized forms (BPSL2418Met-SO and BPSL2418MES) supports the role of the 
disulfide bond in providing tight binding for the ligand in a small cavity that is 
covered by the flap (loop1- β3- loop2- α3- loop3- β4- loop4 unit). In addition to 
offering tight binding to the substrate, this covered small cavity protects the active 
site from the solvent. The active site of many enzymes must protect their substrate 
from water because the reactions cannot proceed rapidly or even at all in an 
aqueous environment. The ability of some enzymes to shield their substrate from 
aqueous solvent by taking advantage of conformational changes that close off the 
active site from contact with bulk solvent is important in enabling them to 







































Figure 6.20: Comparison of electrostatic surface potential of BPSL2418 forms 
showing the conformational changes in the active site. (A) BPSL2418MES creates a closed 
conformation. (B) BPSL2418Met-SO creates a more closed conformation. (C) BPSL2418Reduced creates 
an open conformation; the model shows the putative binding site inside the cavity. On the left side 
the subunits of the three forms are shown as solid electrostatic surface model, on the right side the 
subunit are shown as semi-transparent electrostatic surface and ribbon models. The Figures 





6.2 BPSL2418 interfaces, surfaces and assemblies 
In protein crystallization, the molecules pack together in a regular array (Rhodes, 
2006). In crystals, the interactions between protein molecules and their binding 
energy, interface area, hydrogen bonds, hydrophobic interactions, solvation energy 
and salt bridges across the various interfaces can be examined using PDBePISA 
webserver http://pdbe.org/PISA (Krissinel & Henrick, 2007). This is a web service 
for analyzing the macromolecular surfaces, interfaces, interactions and assemblies. 
The crystal packing analysis of the three forms of BPSL2418 using PDBePISA 
webserver shows that the subunits form dimers. This result corresponds with the 
apparent dimeric state indicated from the gel filtration profile of BPSL2418 (Figure 
4.10).  
 
6.2.1 BPSL2418MES analysis   
The BPSL2418MES crystal contacts and molecular interactions, which maintain the 
molecules together in the crystal, were investigated using PDBePISA with a model 
containing the protein chain and the MES molecule. 
 
6.2.1.1 BPSL2418MES monomers 
Chain A, binding MES ligand which represents the BPSL2418MES protein structure 
was calculated using PISA to has a total of 162 residues, 146 of them are surface 
exposed residues. The solvent accessible area for chain A is 8000 Å2 approximately 
and the solvation free energy gain from interface formation  (ΔG) is estimated as -
149.5 Kcal/mol.   
6.2.1.2 Monomer-monomer interface forming dimeric 
BPSL2418MES  
The PISA analysis indicates that the most extensive crystal packing appears 
between BPSL2418MES molecules related to each other by a 2-fold axis symmetry 
(Figure 6.21). PISA estimates a dimeric state for BPSL2418MES where the 






















Figure 6.21: The dimeric structure model of BPSL2418MES. On the left side the space-
filling model and on the right side the cartoon model, each has three images taken 90°	  
apart	  about	  the	  Y-­‐axis.	  The	  two	  molecules	  forming	  the	  dimer	  are	  in	  blue	  	  	  	  	  	  	  	  and	  tiffany	  	  	  	  	  	  	  	  colors	  








significant is the interface for assembly formation and it ranges from 0 to 1 as 
interface relevance to complex formation increases. The monomer-monomer 
interface forming dimeric BPSL2418MES has a buried surface area of 
approximately 800 Å2 including 27 residues from each molecule (table 6.4). The 
dimer interface involves 7 hydrogen bonds, 4 salt bridges (table 6.5) (Figures 6.22) 
and no disulfide bonds or covalent bonds. The estimated interface area represents 
9.9% of the total surface area and lies in the normal buried surface area range of 
protein-protein interactions (5-25%) (Jones & Thornton, 1995). The PISA analysis 
is in a good agreement with the result from gel filtration (Figure 4.10) thus, it is 
most likely that BPSL2418MES occurs as a dimer. The dimer interface is made up of 
residues in α2, α1- α2 loop, β2 and β2- β3 loop interact with residues in α2, α1- α2 








































1 LEU 26 67.16 16.77 
2 GLU 30 77.83 58.61 
3 THR 31 59.31 3.68 
4 ASP 32 43.94 21.45 
5 VAL 34 92.70 57.89 
6 ALA 35 39.77 39.77 
7 ASN 36 2.38 1.84 
8 ALA 38 42.51 40.18 
9 ASN 39 71.65 70.77 
10 SER 42 33.04 33.04 
11 LEU 43 38.53 11.34 
12 TYR 45 52.32 0.89 
13 HIS 46 134.07 36.99 
14 PHE 58 42.60 0.63 
15 VAL 65 30.97 20.92 
16 VAL 66 29.86 28.02 
17 GLY 67 17.87 17.03 
18 PRO 68 27.72 26.55 
19 PHE 69 60.96 56.89 
20 GLN 70 45.19 27.74 
21 GLY 71 36.60 14.17 
22 LYS 72 160.16 36.19 
23 PRO 73 128.65 70.64 
24 ALA 74 30.41 11.54 
25 VAL 76 74.75 53.69 
26 ARG 77 128.82 36.84 
27 THR 166 69.20 1.35 
 
Table 6.4: Accessibility and buried surface areas of 27 residues involved in the 
BPSL2418MES monomer-monomer interface calculated by PISA 
http://pdbe.org/PISA (Krissinel & Henrick, 2007).    
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1 ARG 77 [ NE ] 2.81 GLU 30 [ OE1 ] 
2 ARG 77 [ NH2 ] 2.93 GLU 30 [ OE2 ]  
3 ALA 74 [ N ] 2.94 ASN 39 [ OD1 ] 
4 GLN 70 [ NE2 ] 3.15 PHE 69 [ O ] 
5 SER 42 [ OG ] 2.65 GLY 71 [ O ] 
6 GLN 70 [ NE2 ] 3.44 GLY 71 [ O ] 
7 ASN 39 [ ND2 ] 3.02 ALA 74 [ O ] 
                                               








1 ARG 77 [ NE ] 2.81 GLU 30 [ OE1 ] 
2 ARG 77 [ NH2 ] 3.72 GLU 30 [ OE1 ]  
3 ARG 77 [ N ] 3.55 GLU 30 [ OE2 ] 
4 ARG 77 [ NE2 ] 2.93 GLU 30 [ OE2 ] 
   
Table 6.5: The hydrogen bonds and salt bridges formed in BPSL2418MES 
monomer-monomer interface calculated by PISA http://pdbe.org/PISA 


































Figure 6.22: Residues positioned in BPSL2418MES monomer-monomer interface. The 
residues highlighted by the PISA analysis are shown in stick form. (A) Hydrogen bonds 
and salt bridges involved in the interface shown as dashed lines. (B) Close view of the 
dimer interface. The two MES molecules of the two monomers are shown in light pink 





















6.2.2 BPSL2418Met-SO analysis   
The PISA webserver was used with a model containing two molecules of    
BPSL2418Met-SO each binding a substrate Met-SO molecule in the asymmetric unit.  
 
6.2.2.1 BPSL2418Met-SO monomers 
The two molecules of BPSL2418Met-SO were labeled as chain A and chain B. Chain 
A contains 152 residues, 132 of them are surface exposed residues as defined by 
PISA. It has a solvent accessible area of approximately 7100 Å2 and estimated 
solvation free energy gain upon formation of the interface (ΔG) of -144.8 
Kcal/mol. Chain B has 133 residues and there are surface exposed residues. The 
solvent accessible area for chain B is approximately 7000 Å2 and the solvation free 
energy gain (ΔG) is estimated as -146.4 Kcal/mol.   
 
6.2.2.2 Monomer-monomer interface forming dimeric 
BPSL2418Met-SO  
PISA analysis for BPSL2418Met-SO predicts an interaction between the two 
molecules (A and B) in the asymmetric unit forming a dimeric state with CSS =1. 
It shows that the crystal packing appears between BPSL2418Met-SO molecules 
related by a 2-fold axis (Figure 6.23). PISA analysis does not suggest any 
interaction between the asymmetric unit dimers to form tetramers. The dimer 
interface has a total of 25 residues from each molecule (table 6.6) and a buried 
surface area of 850 Å2 and it contains 15 hydrogen bonds and 8 salt bridges (table 
6.7). The interface area approximately includes 12% of the total surface area of 
BPSL2418Met-SO molecule, and this percentage confirms the dimeric state of the 
protein (Jones & Thornton, 1995). Also the gel filtration analysis (Figure 4.10) 
agrees with the PISA prediction. BPSL2418Met-SO dimeric interface (Figure 6.24) is 
very similar to the interface of BPSL2418MES dimer except a HIS46[NE2]-
GLY71[O] hydrogen bond occurs in BPSL2418Met-SO dimer, where BPSL2418MES 
dimer has PHE69[O]-GLN70[NE2] hydrogen bond instead. PHE69and GLN70 




   

















Figure 6.23: The dimeric structure model of BPSL2418Met-SO. On the left side the space-
filling model and on the right side the cartoon model, each has three images taken 90°	  
apart	  about	  the	  X-­‐axis.	  The	  two	  molecules	  forming	  the	  dimer	  are	  in	  blue	  	  	  	  	  	  and	  tiffany	  	  	  	  	  	  colors	  
and	  the	  interface	  area	  in	  green	  	  	      and red     colors. The Figure was produced using PISA 
































1 LEU 26 63.88 19.43 70.64 15.96 
2 GLU 30 65.12 49.60 76.10 63.97 
3 THR 31 87.61 5.64 81.79 7.24 
4 ASP 32 74.33 21.41 72.20 20.94 
5 VAL 34 91.96 56.24 86.28 56.56 
6 ALA 35 41.67 41.67 40.91 40.91 
7 ASN 36 3.06 1.60 1.72 1.35 
8 ALA 38 43.27 41.44 44.60 41.56 
9 ASN 39 77.40 75.87 75.00 73.96 
10 SER 42 37.00 37.00 34.15 34.15 
11 LEU 43 38.80 14.97 39.88 13.82 
12 HIS 46 130.72 46.89 131.40 49.62 
13 PHE 58 42.30 0.47 39.34 1.72 
14 VAL 65 36.79 28.95 33.37 25.59 
15 VAL 66 32.68 30.44 34.64 32.19 
16 GLY 67 17.52 16.39 16.94 16.13 
17 PRO 68 29.03 27.69 26.45 25.77 
18 PHE 69 59.61 55.35 63.76 59.15 
19 GLN 70 54.28 48.15 44.26 40.18 
20 GLY 71 36.06 31.02 41.49 36.67 
21 LYS 72 148.40 28.78 150.48 30.90 
22 PRO 73 123.35 77.27 117.53 74.766 
23 ALA 74 23.22 10.23 22.81 8.30 
24 VAL 76 90.21 51.55 84.79 54.58 
25 ARG 77 127.05 38.36 132.00 36.16 
 
Table 6.6: Accessibility and buried surface areas of 25 residues involved in the 
BPSL2418Met-SO monomer-monomer interface calculated by PISA 
http://pdbe.org/PISA (Krissinel & Henrick, 2007).    
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1 ARG 77 [ NE ] 2.94 GLU 30 [ OE1 ] 
2 ARG 77 [ NH2 ] 2.85 GLU 30 [ OE2 ]  
3 ALA 74 [ N ] 2.87 ASN 39 [ OD1 ] 
4 GLY 71 [ N ] 3.81 GLN 70 [ OE1 ] 
5 HIS 46 [ NE2 ] 3.16 GLY 71 [ O ] 
6 SER 42 [ OG ] 2.68 GLY 71 [ O ] 
7 GLN 70 [ NE2 ] 3.36 GLY 71 [ O ] 
8 ASN 39 [ ND2 ] 3.34 ALA 74 [ O ] 
9 GLU 30 [ OE1 ] 2.87 ARG 77 [ NE ] 
10 GLU 30 [ OE2 ] 2.82 ARG 77 [ NH2 ] 
12 ASN 39 [ OD1 ] 3.12 ALA 74 [ N ] 
13 GLY 71 [ O ] 2.65 SER 42 [ OG ] 
14 GLY 71 [ O ] 3.44 GLN 70 [ NE2 ] 
15 ALA 74 [ O ] 3.02 ASN 39 [ ND2 ] 
                                                      








1 ARG 77 [ NE ] 3.93 GLU 30 [ OE1 ] 
2 ARG 77 [ NH ] 2.94 GLU 30 [ OE1 ]  
3 ARG 77 [ NH2 ] 2.85 GLU 30 [ OE2 ] 
4 ARG 77 [ NE ] 3.40 GLU 30 [ OE2 ] 
5 GLU 30 [ OE1 ] 2.87 ARG 77 [ NE ] 
6 GLU 30 [ OE1 ] 3.71 ARG 77 [ NH2 ] 
7 GLU 30 [ OE2 ] 3.53 ARG 77 [ NE ] 
8 GLU 30 [ OE2 ] 2.82 ARG 77 [ NH2 ] 
 
Table 6.7: The hydrogen bonds and salt bridges formed in BPSL2418Met-SO 
monomer-monomer interface calculated by PISA http://pdbe.org/PISA 




























Figure 6.24: Residues positioned in BPSL2418Met-SO monomer-monomer interface. 
The residues highlighted by the PISA analysis are shown in stick form (A) Hydrogen bonds 
and salt bridges involved in the interface shown as dashed lines. (B) Close view of the 
dimer interface. The two Met-SO molecules of the two monomers are shown in pink color 
and the CYS75-CYS109 disulfide is shown in yellow. The images were created by PyMol 




















hydrogen bond between these two residues occasionally. Similar to BPSL2418MES, 
the dimer interface of BPSL2418Met-SO consists of residues in α2, α1- α2 loop, β2 
and β2- β3 loop interact with residues in α2, α1- α2 loop, β2 and β2- β3 loop of the 
symmetry related molecule. 
 
6.2.3 BPSL2418Reduced analysis 
A model of BPSL2418Reduced structure containing 2 molecules in the asymmetric 
unit was used to run PISA analysis.  
 
6.2.3.1 BPSL2418Reduced monomers 
Chain A and chain B of BPSL2418Reduced dimer have 154 and 152 residues 
respectively. There are 136 and 133 surface exposed residues are 136 residues from 
chain A and 133 from chain B, with solvent accessible area of 7300 Å2 and      
7100 Å2 and estimated solvation free energy gain upon formation of the interface 
(ΔG) -140.6 Kcal/mol and -143.4 Kcal/mol respectively.   
 
6.2.3.2 Monomer-monomer interface forming dimeric 
BPSL2418Reduced  
PISA analysis indicates a dimeric state with CSS equal to 0.75, which also agreed 
with gel filtration (Figure 4.10). The dimeric interface includes 25 residues from 
chain A and 24 residues from chain B (table 6.8), a buried surface area of 830 Å2, 
and it contains 15 hydrogen bonds and 8 salt bridges (table 6.9). The interface area 
presents 12% of the total surface area of the protein molecule. This interface has 
PHE69[O]-GLN70[NE2] similar to BPSL2418MES dimer.  Similar to BPSL2418MES 
and BPSL2418Met-SO the dimer interface of BPSL2418Reduced consists of residues in 
α2, α1- α2 loop, β2 and β2- β3 loop interact with residues in α2, α1- α2 loop, β2 
and β2- β3 loop of the symmetry related molecule. The images of BPSL2418Reduced 
dimer produced using PISA are identical to the images of BPSL2418Met-SO dimer 
(Figure 6.25). 


























1 LEU 26 73 19.00 75.24 14.34 
2 GLU 30 66.62 52.32 73.91 57.59 
3 THR 31 83.95 5.30 80.69 10.55 
4 ASP 32 71.66 21.59 71.82 19.78 
5 VAL 34 90.96 59.26 88.43 56.05 
6 ALA 35 39.90 39.58 39.72 39.72 
7 ASN 36 3.22 0.74 3.64 1.56 
8 ALA 38 37.99 37.15 42.34 39.42 
9 ASN 39 82.92 70.72 81.93 77.84 
10 SER 42 34.50 34.50 31.49 31.49 
11 LEU 43 38.70 13.10 37.31 14.63 
12 HIS 46 131.48 26.77 138.53 56.16 
13 PHE 58 43.39 0.63 40.95 2.34 
14 VAL 65 35.13 25.60 35.15 25.73 
15 VAL 66 27.62 26.11 31.68 30.57 
16 GLY 67 21.27 19.46 16.80 15.98 
17 PRO 68 29.03 27.70 27.25 26.42 
18 PHE 69 63.12 58.48 60.53 57.69 
19 GLN 70 46.89 43.56 51.67 45.59 
20 GLY 71 45.45 40.90 54.12 40.05 
21 LYS 72 163.59 32.77 - - 
22 PRO 73 127.49 71.70 137.04 67.76 
23 ALA 74 27.84 8.50 25.41 8.95 
24 VAL 76 78.89 52.59 87.71 53.89 
25 ARG 77 133.31 36.84 129.81 35.99 
 
Table 6.8: Accessibility and buried surface areas residues involved in the 
BPSL2418Reduced monomer-monomer interface calculated by PISA 
http://pdbe.org/PISA (Krissinel & Henrick, 2007).  
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1 ARG 77 [ NE ] 2.96 GLU 30 [ OE1 ] 
2 ARG 77 [ NH2 ] 3.12 GLU 30 [ OE2 ]  
3 ARG 77 [ NH2 ] 3.74 THR 31 [ OG1 ] 
4 ALA 74 [ N ] 2.94 ASN 39 [ OD1 ] 
5 GLN 70 [ NE2 ] 2.90 PHE 69 [ O ] 
6 GLY 71 [ N ] 3.29 GLN 70 [ OE1 ] 
7 SER 42 [ OG ] 2.69 GLY 71 [ O ] 
8 ASN 39 [ ND2 ] 3.19 ALA 74 [ O ] 
9 GLU 30 [ OE1 ] 2.83 ARG 77 [ NE ] 
10 GLU 30 [ OE2 ] 2.70 ARG 77 [ NH2 ] 
11 ASN 39 [ OD1 ] 3.15 ALA 74 [ N ] 
12 PHE 69 [ O ] 3.03 GLN 70 [ NE2 ] 
13 GLN 70 [ OE1 ] 3.22 GLY 71 [ N ] 
14 GLY 71 [ O ] 2.54 SER 42 [ OG ] 
15 ALA 74 [ O ] 3.02 ASN 39 [ ND2 ] 
 








1 ARG 77 [ NE ] 3.94 GLU 30 [ OE1 ] 
2 ARG 77 [ NE ] 2.96 GLU 30 [ OE1 ]  
3 ARG 77 [ NH2 ] 3.12 GLU 30 [ OE2 ] 
4 ARG 77 [ NE ] 3.59 GLU 30 [ OE2 ] 
5 GLU 30 [ OE1 ] 2.83 ARG 77 [ NE ] 
6 GLU 30 [ OE1 ] 3.75 ARG 77 [ NH2 ] 
7 GLU 30 [ OE2 ] 3.36 ARG 77 [ NE ] 
8 GLU 30 [ OE2 ] 2.70 ARG 77 [ NH2 ] 
Table 6.9: The hydrogen bonds and salt bridges formed in BPSL2418Reduced 
monomer-monomer interface calculated by PISA http://pdbe.org/PISA 


























Figure 6.25: Residues positioned in BPSL2418Reduced monomer-monomer interface. 
The residues highlighted by the PISA analysis are shown in stick form (A) Hydrogen bonds 
and salt bridges involved in the interface shown as dashed lines. (B) Close view of the 



















6.3 Functional prediction  
The structures of the BPSL2418 forms can be used to predict the function of the 
BPSL2418 protein. The determination of the protein family that BPSL2418 
belongs to and the high identity of BPSL2418 with known function homologs can 
provide useful information for understanding the protein.  
 
6.3.1 Structure comparisons 
All the final refined structures of BPSL2418 forms were analyzed with the Dali 
server as described in section 6.1. The Dali search shows that BPSL2418 belongs 
to the GAF domain free methionine sulfoxide reductase (fRMsr) family. In the 
database only four structures of fRMsr are known so far: Escherichia coli fRMsr 
(PDB code 1VHM), Staphyloccus aureus fRMsr (PDB code 3KSF), Neisseria 
meningitidis fRMsr (PDB code 3MMH) and Streptococcus pneumoniae fRMsr 
(PDB code 3RFB). As demonstrated in section 6.1, each structure of the 
BPSL2418 forms superimposed very well with structures from the fRMsr family. 
However in order to obtain the sequence similarity and conserved residues between 
BPSL2418 and fRMsr proteins, they were also aligned using PROMALS3D (Pei et 
al, 2008). The alignment was run using the 3D models of these proteins (Figure 
6.26). 12 residues of 13 residues composing the active site are conserved among 
the aligned proteins. The three cystienes in loop1, α3 and loop4 are conserved 
where a disulfide bond is formed between the cysteine in loop1 and the cysteine in 
loop4. The third cysteine located in α3 provides a hydrogen bond via its main chain 
amide nitrogen in the ligand interaction (see section 6.2). Like all GAF domains, 
BPSL2418 and the fRMsr known structures are dimeric that also superimposed 
very well (Figure 6.27). 
 
                       


















6.26: Structure based alignment of BPSL2418 (s001), N. meningitidis fRMsr (S004), S. 
pneumoniae  fRMsr (S005), E. coli fRMsr (S006) and S. aureus fRMsr (S007). The β-
strands and α-helices are represented as blue and red residues, respectively. The active 
site consisting of (β1, β2,loop1, β3,loop2,α3,loop3, β4  and loop4) is defined by black 





































6.27: structural alignment of BPSL2418 structure and fRMsr structures (N. 
meningitidis fRMsr S. pneumoniae  fRMsr, E. coli fRMsr and S. aureus fRMsr). The 
Figure shows an alignment of dimeric structures of BPSL2418 with fRMsr proteins. The 
images were created by PyMol (DeLano & Lam, 2005).      















6.3.2 Catalytic Mechanism of BPSL2418 
All the structural analyses of BPSL2418 indicate that this protein is most likely a 
new member in the GAF domain fRMsr family. The crystal structures of 
BPSL2418MES, BPSL2418Met-SO and BPSL2418Reduced help in describing the role of 
BPSL2418 in reversing the oxidation of the free methionine residue, in 
understanding the binding method of Met-SO substrate to the active site, and the 
conformational changes that occur during the reduction. The crystal structures of 
the BPSL2418 forms indicate significant conformational changes in the active site 
in each catalytic step. The changes in the active site occur particularly in loop4 
including the catalytic CYS109. The reduced form (BPSL2418Reduced) creates an 
opened conformation (Figure 6.28) mostly to permit admission to the substrate. In 
the Met-SO substrate binding form, BPSL2418Met-SO has a closed conformation 
after access of the substrate (Figure 6.28). The comparison between the BPSL2418 
forms revealed that the cysteine located in loop4 CYS109 was the most mobile 
while the CYS75 position in loop1 and CYS85 in α3 remain unchanged (Figure 
6.17), but CYS85 may plays a role in substrate binding. This is in agreement with 
the Staphyloccus aureus fRMsr (Bong et al, 2010) and the Neisseria meningitidis 
fRMsr (Gruez et al, 2010) where the structural and biochemical analyses of these 
proteins suggest that their catalytic cysteines are CYS102 and CYS118, 
respectively which correspond to CYS109 in BPSL2418. CYS102 and CYS118 are 
the mobile cysteines, which forms a disulfide bond with CYS68 and CYS84, 
respectively leading to conformational changes in the active site (see section 1.2.3 
(2) and (3)). The corresponding residues to CYS75 in Staphyloccus aureus fRMsr 
and the Neisseria meningitidis fRMsr are CYS68 and CYS84 respectively and they 
are immobile cysteines as CYS75 in BPSL2418. The third conserved cysteine 
CYS78 and CYS94 located in α3 of Staphyloccus aureus fRMsr and the Neisseria 
meningitidis fRMsr respectively are also immobile cysteines as BPSL2418. The 
crystal structure of BPSL2418 in complex with Met-R-SO illuminates not only the 
catalysis of the reductase step but also how BPSL2418 binds Met-R-SO with a 
strong preference for the Met-R-SO isomer. The structure of the reduced form has 
an open conformation to allow access to the substrate. Another complex structure 
BPSL2418MES was determined in this project with a MES molecule in the binding 
site. BPSL2418MES is an oxidized form with a disulfide bond between CYS75 and 
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CYS109. This suggests that MES molecule can act as competitive inhibitor of 
BPSL2418 enzyme. Our structural analysis suggests that CYS109 is the catalytic 
residue of BPSL2418. The hydrophobic region in the active site could 
accommodate the ε-methyl group of the substrate via van der Waals interactions, 
where the hydrophilic region with the nitrogen of the substrate. Also, this 
hydrophilic region may play a role in stabilizing the protonated oxygen atom of the 
sulfoxide moiety during catalysis. Thus, the hydrophobic affinity to substrate, 
whereas the hydrophilic region seems important for binding specificity.  
Taken together, it can be suggested that the catalytic mechanism of BPSL2418 
includes three steps (Figure 6.29):  
(1) The BPSL2418 is reduced by a reductant (usually Trx in vivo or DTT in 
vitro) generating an opened pocket to permit access to the free Met-SO 
substrate. CYS109 in BPSL2418 loop4 attacks the sulfoxide group of Met-
SO and is then oxidized forming CYS sulfenic acid (CYS-SOH). This 
reverses the Met-SO into a free methionine residue.  
(2) CYS75 in BPSL2418 loop1 interacts with the CYS109 sulfenic acid 
intermediate forming a disulfide bond (generating a close conformation) 
and releasing a water molecule.  
(3) The BPSL2418 enzyme activity is regenerated by reducing the CYS75-
CYS109 disulfide.  
The crystals of the different forms of BPSL2418 comprise dimer in the asymmetric 
unit and the two active sites within the dimer are separated from each other by 
approximately 23.8 Å, which suggests no communication between the two active 
sites. Also the interfaces have no significant change seen between the structures. In 
thermophilic enzymes, a decrease in flexibility cause low enzyme activity while in 
less stable proteins an increase in flexibility is associated with enhanced enzyme 
activity. In this study the role of active site rigidity in enzyme activity is misleading 
because the disulfide bond forms after Met-SO reduction. Thioredoxin reductase is 
is the only enzyme known to catalyze the reduction of thioredoxin and hence is a 
central component in the thioredoxin system. Together with thioredoxin (Trx) and 
NADPH this system's most general description is as a method of forming reduced 























Figure 6.28:  Structural representation of proposed catalytic mechanism of 
BPSL2418. Reduced BPSL2418 exhibits an opened conformation permitting the access of 
Met-SO into the active site. After substrate binding, the BPSL2418 enzyme forms a 














Reduced form has an opened 
conformation 





















Figure 6.29: Schematic representation of proposed catalytic mechanism of 
BPSL2418. (A) The substrate binds to the active site with its sulfoxide function largely 
polarized, leading to a transition state compatible with a sulfurane of bipyramidal geometry. 
The rearrangement of the transition state leads to the formation of a sulfenic acid 
intermediate on the catalytic Cys109 residue. In this scenario, Asp133 and Cys85 , stabilize the 
sulfurane transition state via interaction with the OH group. (B) The reductase step (the 
first one) leads to the formation of a sulfenic acid intermediate on the catalytic Cys109  and 
of Met. In the second step, attack of Cys75 on the sulfur atom of the sulfenic acid 
intermediate leads to the formation of a disulfide bond between Cys109 and Cys75 and the 
release of a water molecule. Return of the active site to a fully reduced state can proceed 




























transferred to the active site of Trx, which goes on to reduce protein disulfides or 
other substrates. The Trx system exists in all living cells and has an evolutionary 
history tied to DNA as a genetic material, defense against oxidative damage due to 
oxygen metabolism, and redox signaling using molecules like hydrogen peroxide 
and nitric oxide (Meyer et al, 2009). However, other GAF domain proteins 
basically play role in ligand binding specifically cyclic nucleotide for signal 
potentiation. This may suggest that Met-SO plays role as a signaling ligand in 
response to oxidative stress in some organism. This might be in a signaling cascade 
which is a series of chemical reactions that are initiated by a first messenger acting 
on a receptor that is transduced to the cell interior through second messengers 
(which amplify the initial signal) and ultimately to effector molecules, resulting in 
a cell response to the initial stimulus.  
 
6.4 Conclusion and future work 
The methionine sulfoxide reductase (Msr) is the responsible protein family of the 
reduction of methionine sulfoxide (Met-SO). The Msr family includes three types: 
MsrA, MsrB and fRMsr. MsrA and MsrB capable of reducing free Met-SO and 
Met-SO in peptides. This mechanism is stereospecific with the S- and R forms of 
Met-SO reduced by MsrA and MsrB, respectively. The third type of Msr is the free 
methionine-R-sulfoxide reductase (fRMsr), which catalyzes the reduction of the R-
form of free methionine sulfoxide back to free methionine. The fRMsr subfamily 
discovered in 2007 and interestingly only four structures of this type are known so 
far. The fRMsr type belongs to the GAF domain family and it is the only member 
that shows enzymatic activity. Other GAF domain proteins basically play role in 
ligand binding specifically cyclic nucleotide for signal potentiation. This may 
suggest that Met-SO plays role as a signaling ligand in response to oxidative stress 
in some organism. This thesis presents the BPSL2418 protein from Burkholderia 
pseudomallei as a novel member of fRMsr family. The crystal structures of the 
reduced (BPSL2418Reduced), Met-SO-bound (BPSL2418Met-SO) and MES-bound 
(BPSL2418MES) forms of free methionine-R-sulfoxide reductase from Burkholderia 
pseudomallei were determined in this work. This is the first project provides the 
structural analysis of MES-bound form with the reduced and substrate-bound forms 
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of a free methionine-R-sulfoxide reductase protein. The structural analysis and 
comparison of the BPSL2418 forms indicate conformational changes in the active 
site particularly in loop4 (residues 98-113). The project suggests the catalytic 
mechanism of BPSL2418 in which CYS109 (located in loop4) is a mobile residue 
functions as the catalytic cysteine and CYS75 functions as the resolving cysteine, 
which forms a disulfide bond with CYS109. The position of CYS85 is like CYS75 
remains unchanged during the catalytic activity; CYS85 involves in the interaction 
of BPSL2418 with Met-SO substrate and MES molecule.  
In this project future work should focus on produce the crystal structure of the 
unbound oxidized form to complete the comparison image of the reduction 
mechanism. Also obtain a crystal structure of CYS109, CYS102 and CYS85 
mutant forms either as a single or double mutations can confirm the catalytic 
residues and the function of each cysteine. In this project no experiment have done 
to test the substrate specificity of BPSL2418 enzyme which suggest performing an 
enzyme assay to monitor the reduction activity against different substrates such as 
free and peptide bound forms of S- isomer Met-SO and the peptide bound form of 
R- isomer Met-SO. Also enzyme assays can be used to examine the activity of 
BPSL2418 mutants comparing with the wild type. This can be achieved by using 
steady-state kinetics of wild type and mutants with Trx-regeneration system and 








Chapter 7: CT1 and CT2 Expression, 
Purification and crystallization attempts 
 
This chapter presents all the efforts to express, purify and crystalize the C-terminal 
domains of Polycystin1 (CT1) (26 kDa) and of Polycystin2 (CT2) (35 kDa) in 
order to use the crystals of these proteins for experimental X-ray diffraction.  
 
7.1  Preparation of CT1 protein 
 
7.1.1 Recombinant plasmid of CT1  
The insert gene including a GB1 domain at the N-terminus was ligated into the     
E. coli expression vector pET-21a(+) which contains an ampicillin resistance gene. 
The GB1 domain is an immunoglobulin-binding fusion protein (8 kDa) often used 
to increase the solubility of other proteins (Cheng & Patel, 2004). The GB1-CT1 
pET-21a(+) plasmid was provided by Prof. Albert Ong. 
 
7.1.2  CT1 overexpression in E. coli   
An E. coli expression method was used to express GB1-CT1. To achieve large-
scale 4 l expression the following protocol was applied: competent cells (BL21-
DE3-RIPL) were transformed with the GB1-CT1pET-21a(+) construct. Cells were 
plated on LB-agar plates provided with 75 µg/ml Chloramphenicol to select BL21-
DE3-RIPL, 50 µg/ml ampicillin to select the plasmid and 1% glucose to inhibit 
expression. LB-agar plates were incubated at 37 °C overnight. A starter culture of 
LB (5 ml) supplemented with 50 µg/ml ampicillin and 1% glucose was inoculated 
with a single colony and incubated at 37 °C, 200 rpm overnight. The secondary 
culture of LB (500 ml) supplemented with 50 µg/ml ampicillin, 75 µg/ml 
Chloramphenicol and 1% glucose was inoculated at 1:100 dilution of the starter 
culture and incubated at 37 °C, 200 rpm until the OD600 nm reached 0.6-0.9 
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(approximately 4-5 hours). CT1 expression was induced by adding 1 mM IPTG to 
the culture. The main cultures were incubated at 37 °C, 200 rpm for 3 hours. Cells 
were harvested by centrifugation at 6000 g for 10 minutes. Pellets were stored at       
-80 °C. GB1-CT1 was expressed as insoluble inclusion bodies (Figure 7.1). 
Expression conditions were optimized to try to achieve soluble yield, but no 
soluble protein was expressed. The optimization included changing induction time, 
induction temperature and IPTG concentration. None of the optimization attempts 
produced soluble protein.    
 
7.1.3  CT1 protein refolding    
The mentioned protocol in section 2.12 was used to refold the inclusion bodies of 
CT1, this attempt did not improve the protein folding.  
 
7.2 Preparation of CT2 protein 
 
7.2.1 Recombinant plasmid of CT2 
The human polycystin-2 C-terminal domain (CT2) was amplified by the PCR 
technique in a His-CT2 construct. The insert gene included a His tag at the N-
terminus. The PCR product was ligated into the E. coli expression vector          
pET-28a(+) which contains a kanamycin resistance gene (Figure 7.2). This 
recombinant plasmid was provided by Prof. Albert Ong. 
 
7.2.2 CT2 overexpression in E. coli   
An E. coli expression method was used to express His-CT2 protein. To achieve 
large-scale 4 l expression the following protocol was applied: competent cells 
(BL21-DE3-RIPL) were transformed with the His-CT2 pET-28a(+) construct. 
Cells were plated on LB-agar plates provided with 75 µg/ml chloramphenicol to 
select BL21-DE3-RIPL, 50 µg/ml kanamycin to select the plasmid and 1% 














Figure 7.1:  12% SDS- PAGE gel showing GB1-CT1 (34 kDa) expression. Lane M: 
Molecular weight marker, lane 1: Pre-induction, lane 2: Band in the insoluble fraction and 



































Figure 7.2: His-CT2 construct (35 kDa). Green color indicates the histidine tag, red color 
indicates linker amino acids including thrombin site in blue (rgs). CT2 residues colored in 
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supplemented with 50 µg/ml kanamycin and 1% glucose was inoculated with a 
single colony and incubated at 37 °C, 200 rpm for overnight. The secondary culture 
of LB (500 ml) supplemented with 50 µg/ml kanamycin, 75 µg/ml 
chloramphenicol and 1% glucose was inoculated at 1:100 dilution of the starter 
culture and incubated at 37 °C, 200 rpm until the OD600 nm reached 0.6-0.9. 
(approximately 2-5 hours). CT2 expression was induced by adding 1 mM IPTG to 
the culture. The main cultures were incubated at 37 °C, 200 rpm for 3 hours. Cells 
were harvested by centrifugation at 6000 g for 10 minutes. Pellets were stored at -
80 °C. CT2 was expressed by the methods described above and the SDS-PAGE gel 
reveals a strong expression band in the soluble fraction in the expected size  
(Figure 7.3). 
 
7.2.3 CT2 purification 
The cell pellet from the large-scale E. coli expression was defrosted on ice, and 
was resuspended in lysis buffer (50 mM Tris pH8, 500 mM NaCl) using a 1:5 w/v 
ratio. The suspension was incubated on ice for 30 minutes then it was aliquoted 
into 2 centrifuge tubes (10 ml in each tube). The suspension in each tube was 
sonicated for 3x20 seconds (on ice) and centrifuged at 40,000 g at 4 °C for 30 
minutes. The supernatant was taken for the purification step. Soluble fractions of 
His-CT2 were purified by Nickel column affinity chromatography. The purity of 
eluted His-CT2 protein was checked by 12% SDS-PAGE. The His-CT2 
purification using the Nickel column was run successfully and bands were seen on 
the gel at the expected size (Figure 7.4). The SDS-PAGE showed many impurities, 
which suggested another purification step was needed. Gel filtration 
chromatography was used as a second purification step. Gel filtration was 
performed on a Hi load Superdex200, 16x60 cm (GE healthcare life science) 
column. The column flow rate was 1.5 ml/min. Gel filtration was performed in gel 
filtration buffer (25 mM Tris, 150 mM NaCl, pH 8.0 at 4 °C) and the purity of 
eluted protein was checked by12% SDS-PAGE (Figure 7.5 a). The gel filtration 
elution profile shows that CT2 tends to form oligomers (Figure 7.5 b). The 
calibration plot for the Hi-load Superdex 200 column was used to calculate the 


















Figure 7.3: 12% SDS- PAGE gel showing His-CT2 (35 KDa) overexpression. Lane M: 































Figure 7.4: 12% SDS-PAGE of His-CT2 (35 KDa) nickel affinity chromatography. Lane 








































 Figure 7.5:  Gel filtration of His-CT2 (35 KDa). A: 12% SDS-PAGE of samples 2-8 gel 















would correspond roughly to an octamers (Figure 7.6). The protein concentration 
was determined by spectrophotometer at 280 nm. Concentration of the protein was 
performed using the Centricon centrifugal ultrafiltration device (Vivascience). The 
final concentration of His-CT2 was 50 mg/ml in 100 µl. 
 
7.2.4 Initial crystallization trials  
The protein concentrations used for the initial crystal screens were 7, 15, 21, 34 
and 50 mg/ml. Initial screens were set up using the sitting drop vapour diffusion 
method. The PACT, JCSG, PEG and Classics screen suites were used. Initial 
crystal screens were incubated in a temperature-controlled environment at 17 ºC. 
Plates were checked after a few days and then every week after that. In all the 
crystallization attempts using different concentrations, the same unsatisfactory 
stage of crystal formation was achieved. Quasi crystals were produced in all of 
these trials (Figure 7.7). They were seen in the JCSG suite wells A11, B6, E9 and 
also in the Classic suite wells E11, F7, H9. Attempts were made to optimize the 
initial hits by reproducing the condition in 24-well plate format using the hanging 
drop vapour diffusion method, but better crystals were not grown. 
 
7.2.5 Investigation of the CT2 oligomeric state by Electron 
Microscopy  
To examine the CT2 oligomeric state by Electron Microscopy, diluted sample of 
His-CT2 (0.1 mg/ml) was negatively stained using 2% ammonium molybdate 
Stain, pH 7. Negatively stained electron images were record on a Philips CM100 
transmission electron microscope, by a Gatan MultiScan 794 charge-coupled 
device camera (Ohi et al, 2004). The His-CT2 electron microscope image shows a 
variety of protein particle sizes. Particles of 65-75, 100 and 150-165 Å diameters 
were found suggesting dimers, trimers and tetramers, respectively (Figure 7.8).  
The heterogeneous state of His-CT2 may inhibit crystal growth. Pure, 
homogeneous protein is the most critical prerequisite for successful protein 




















Figure 7.6: The calibration plot for Hi-Load superdex 200 column chart to calculate 
CT2 molecular weight: Ve (elution volume)/Vo (column void volume)= 1.2, from the chart 





















Figure 7.7: Quasi crystals of CT2 grew in 0.2 M ammonium phosphate, 0.1 M Tris pH 




























Figure 7.8: EM image for the oligomeric state of His-CT2. The red circle surround 
particles 100 Å diameter size which may be tetramers. The blue circles show particles of 
65-80 Å diameter size suggesting trimers. The smallest particles are 50-60 Å diameter size 










7.2.6 Obtaining separated homogeneous fractions by using 
gel filtration  
The previous gel filtration purification of His-CT2 and the Electron microscopy 
investigation show that CT2 tends to form oligomeric molecules, which might be 
the reason crystals do not grow. To change the heterogeneous state of CT2, two 
approaches have been taken: the first one was using gel filtration chromatography 
to obtain separated homogeneous fractions and the second was the introduction of a 
mutation in the predicted site of oligomerization. The gel filtration protocol was 
done as described before and the elution profile used to separate fractions (Figure 
7.9). Two separated fractions were collected and reloaded on the gel filtration 
column. Initial crystallization trials have been prepared for each protein fraction. 
The two separated fractions behaved the same in gel filtration: two similar elution 
peaks were produced in the elution profiles. Also they produced quasi crystals, like 
those seen before.  
 
7.2.7 Mutation in CT2 coiled-coil  
CT2 has four hydrophobic residues in the CT2 predicted coiled coil (VAL846, 
ILE853, ILE860 and LEU867) which can be replaced with alanine to disrupt the 
coiled coil and prevent oligomerization. The mutant CT2 (CT2,4M) (the four 
hydrophobic residues in the coiled coil domain were replaced with alanine)  was 
provided by the Sheffield University Medical School. The His-CT24M plasmid 
was transformed into competent cells (BL21-DE3-RIPL), and expressed using the 
same protocol as for the wild-type CT2 expression. The SDS gel shows that His-
CT24M expressed as well as the wild-type. The soluble fraction was purified by 
Nickel affinity chromatography and gel filtration and then the pure protein was 
used to set down the initial crystallization trials, but once again no crystals were 
found (Figure 7.10). The oligomeric state of His-CT24M was also examined by 
Electron Microscopy. The EM image shows particles of 25-35 Å diameters 


























Figure 7.9:  using gel filtration to achieve homogenous fractions of His-CT2. A: 
Elution profile divided into two peaks. B: Elution profiles of the reloaded separated peaks 


















































Figure 7.10: Mutation in CT2 coiled-coil. A: His-CT24M overexpression. B: His-CT24M 



























7.2.8 Removing the His-tag 
 The His-CT2 plasmid has a thrombin cleavage site between the His-tag and the 
CT2 protein (Figure 7.2). In attempts to improve the crystal formation, the 6 
histidine tag was removed in the following way: wild type His-CT2 was expressed 
and purified on a Nickel column. The pure protein was dialyzed in thrombin 
digestion buffer (50% Hepes pH 7.4, 2.5 mg/ml CaCl2, 250 mg NaCl) for 3 hours. 
The protein was then incubated with 50 units of thrombin overnight. The incubated 
mixture was loaded on a gel filtration column to elute the cleaved protein. The His-
CT2 construct has by chance, in addition to the thrombin-cutting site (RGS) at the 
N-terminus, another cutting site in the following residues (ARG827, GLY828, 
SER829). Therefore thrombin cut at both cleavage sites and consequently CT2 was 
divided into two portions in addition to the His-tag removal. The N-terminal part is 
146 residues (ILE680-ARG826) with a mass of 16.6 kDa and the C-terminal 
portion is 144 residues (ARG826-VAL970) with a molecular weight of 16.3 kDa. 
Although the two parts have approximately equal molecular weights, the gel 
filtration elution profile shows two different peaks (peak1 59.95 ml, peak2 44 ml) 
(Figure 7.11). The molecular weights of both portions were measured by using the 
gel filtration chart: the molecular weight of peak1 portion is ~ 35 kDa which 
suggests a dimer and the molecular weight of the peak2 portion is ~ 17 kDa 
suggesting a monomer. By applying both fragments to a SDS-PAGE gel, peak1 
appeared at size ~ 35 kDa and peak2 at ~ 17 kDa (Figure 7.11). According to what 
is known about the CT2 domains, the monomer portion might be the N-terminal 
domain, which includes the EF-hand domain and the portion that ran as an 
oligomer might be the C-terminus, which contains the coiled-coil oligomerization 
domain. Although it might be expected that the dimer would run as a monomer in 
the denaturing SDS/PAGE condition, it has been observed that coiled coil proteins 
can remain as dimer on SDS/PAGE.  However, these two separated proteins are 


























Figure 7.11: Removing the His-tag experiment. A: The N-terminal portion sequence 
represented as black letters and the C-terminal portion sequence as blue letters. The 
elution profile of the N-terminal portion (peak 44 ml) was indicated by a black arrow and 
the C-terminal portion (peak 59.95 ml) was indicated by a blue arrow. B: 12% SDS gel 
after gel filtration, where B1 represents the C-terminal portion (peak 59.95 ml) and B2 
represents the N-terminal portion (peak 44 ml).  
 




















7.3 Conclusion and future work 
During the course of this thesis we have successfully CT2 protein.. The C-terminal 
domain of Polycystin2 (CT2), which is predicted to consist of two domains, the 
EF-hand domain and the coil-coiled domain, is highly overexpressed in the E. coli 
and it can be purified successfully, producing a highly concentrated protein. 
Unfortunately this project has not reach the desired goal yet, although progress has 
been made, the protein was not able to generate crystals due to the heterogeneous 
status of the sample. The oligomeric state of CT2 was investigated using the gel 
filtration and electron microscopy. The chemical and physical characteristics of a 
protein are very important in its ability to crystallise. It might be useful to try the 
Fab mediated crystallization, which is a powerful technique to crystallise difficult 
proteins, particulary when one has access to a panel of monoclonal antibodies.  
The CT1 the C-terminal domain of Polycystin 1 is a small protein, which might be 
explain the production of this protein as inclusion bodies even it has a binding 
fusion to increase the solubility. Several efforts have been done to refold CT1 using 
the protein refolding procedure that mentioned in thesis. Unfortunately we did not 
produce a significant amount of soluble protein. Future progress with this project 
may be achieved through the use of alterative vectors or another expression system, 














Abbink FC, Orendi JM, de Beaufort AJ (2001) Mother-to-child 
transmission of Burkholderia pseudomallei. N Engl J Med 344: 1171-
1172 
 
Adelsberg J, Chamberlain S, Agati V (1997) Polycystic expression is 
temporally and spatially regulated during renal development. Am J 
Physiol 272: 602-609 
 
Aldhous P (2005) Tropical medicine: melioidosis? Never heard of it. 
Nature 434: 692-693 
 
Aravind L, Ponting CP (1997) The GAF domain: an evolutionary link 
between diverse phototransducing proteins. Trends Biochem Sci 22: 
458-459 
 
Ashdown LR, Koehler JM (1990) Production of hemolysin and other 
extracellular enzymes by clinical isolates of Pseudomonas 
pseudomallei. J Clin Microbiol 28: 2331-2334 
 
AuCoin DP, Reed DE, Marlenee NL, Bowen RA, Thorkildson P, Judy 
BM, Torres AG, Kozel TR (2012) Polysaccharide specific monoclonal 
antibodies provide passive protection against intranasal challenge with 
Burkholderia pseudomallei. PLoS ONE 7: e35386 
 
Badger J, Sauder J, Adams J, Antonysamy S, Bain K, Bergseid M, 
Buchanan S, Buchanan M, Batiyenko Y, Christopher J, Emtage S, 
Eroshkina A, Feil I, Furlong E, Gajiwala K, Gao X, He D, Hendle J, 
Huber A, Hoda K, Kearins P, Kissinger C, Laubert B, Lewis H, Lin J, 
Loomis K, Lorimer D, Louie G, Maletic M, Marsh C, Miller I, 
Molinari J, Muller-Dieckmann H, Newman J, Noland B, Pagarigan B, 
Park F, Peat T, Post K, Radojicic S, Ramos A, Romero R, Rutter M, 
Sanderson W, Schwinn K, Tresser J, Winhoven J, Wright T, Wu L, Xu 
J, Harris T (2005) Structural analysis of a set of proteins resulting from 
a bacterial genomics project. Proteins: Structure, Function, and 
Bioinformatics 60: 787-796 
 265 
 
Barman P, Kaur R, Kumar K (2013) Clinically lesser known entity in 
India: A Report of two cases of Melioidosis. Indian J Crit Care Med 
17: 46-48 
 
Bartlett JM, Stirling D (2003) A short history of the polymerase chain 
reaction. Methods Mol Biol 226: 3-6 
 
Behera B, Prasad Babu TL, Kamalesh A, Reddy G (2012) Ceftazidime 
resistance in Burkholderia pseudomallei: first report from India. Asian 
Pac J Trop Med 5: 329-330 
 
Blundell TL, Johnson LN (1976) Protein Crystallography,  New York: 
Academic Press. 
 
Bondi SK, Goldberg JB (2008) Strategies toward vaccines against 
Burkholderia mallei and Burkholderia pseudomallei. Expert Rev 
Vaccines 7: 1357-1365 
 
Bong SM, Chi YM. (2011) structure of fRMsr from streptococcus 
pneumoniae. 
 
Bong SM, Kwak GH, Moon JH, Lee KS, Kim HS, Kim HY, Chi YM 
(2010) Structural and kinetic analysis of free methionine-R-sulfoxide 
reductase from Staphylococcus aureus: conformational changes during 
catalysis and implications for the catalytic and inhibitory mechanisms. 
J Biol Chem 285: 25044-25052 
 
Boschi-Muller S, Gand A, Branlant G (2008) The methionine sulfoxide 
reductases: Catalysis and substrate specificities. Arch Biochem Biophys 
474: 266-273 
 
Bradford MM (1976) A rapid and sensitive method for the quantitation 
of microgram quantities of protein utilizing the principle of protein-dye 
binding. Analytical Biochemistry 72: 248-254 
 
 266 
Brändén C-I, Tooze J (2009) Introduction to protein structure, 2nd 
edn. New York, NY: Garland Pub. 
 
Burtnick MN, Brett PJ, Harding SV, Ngugi SA, Ribot WJ, Chantratita 
N, Scorpio A, Milne TS, Dean RE, Fritz DL, Peacock SJ, Prior JL, 
Atkins TP, DeShazer D (2011) The Cluster 1 Type VI Secretion 
System Is a Major Virulence Determinant in Burkholderia 
pseudomallei. Infect Immun 79: 1512-1525 
 
Caldwell P, Luk DC, Weissbach H, Brot N (1978) Oxidation of the 
methionine residues of Escherichia coli ribosomal protein L12 
decreases the protein's biological activity. Proc Natl Acad Sci U S A 
75: 5349-5352 
 
Chan PH (1996) Role of oxidants in ischemic brain damage. Stroke 27: 
1124-1129 
 
Chan YY, Chua KL (2005a) The Burkholderia pseudomallei BpeAB-
OprB efflux pump: Expression and impact on quorum sensing and 
virulence. J Bacteriol 187: 4707-4719 
 
Chan YY, Chua KL (2005b) The Burkholderia pseudomallei BpeAB-
OprB efflux pump: expression and impact on quorum sensing and 
virulence. J Bacteriol 187: 4707-4719 
 
Chantratita N, Wuthiekanun V, Boonbumrung K, Tiyawisutsri R, 
Vesaratchavest M, Limmathurotsakul D, Chierakul W, 
Wongratanacheewin S, Pukritiyakamee S, White NJ, Day NP, Peacock 
SJ (2007) Biological relevance of colony morphology and phenotypic 
switching by Burkholderia pseudomallei. J Bacteriol 189: 807-817 
 
Chaowagul W, White NJ, Dance DA, Wattanagoon Y, Naigowit P, 
Davis TM, Looareesuwan S, Pitakwatchara N (1989) Melioidosis: a 
major cause of community-acquired septicemia in northeastern 
Thailand. J Infect Dis 159: 890-899 
 
 267 
Chapin H, Caplan M (2010) The cell biology of polycystic kidney 
disease. JCB 191: 701-710 
 
Chen VB, Arendall WB, 3rd, Headd JJ, Keedy DA, Immormino RM, 
Kapral GJ, Murray LW, Richardson JS, Richardson DC (2010) 
MolProbity: all-atom structure validation for macromolecular 
crystallography. Acta Crystallogr D Biol Crystallogr 66: 12-21 
 
Chen YS, Chen SC, Kao CM, Chen YL (2003) Effects of soil pH, 
temperature and water content on the growth of Burkholderia 
pseudomallei. Folia Microbiol (Praha) 48: 253-256 
 
Cheng AC, Currie BJ (2005a) Melioidosis: epidemiology, 
pathophysiology, and management. Clin Microbiol Rev 18: 383-416 
 
Cheng AC, Currie BJ (2005b) Melioidosis: epidemiology, 
pathophysiology, and management. Clin Microbiol Rev 18: 383-416 
 
Chong CE, Lim BS, Nathan S, Mohamed R (2006) In silico analysis of 
Burkholderia pseudomallei genome sequence for potential drug targets. 
In Silico Biol 6: 341-346 
 
Chua KL, Chan YY, Gan YH (2003) Flagella are virulence 
determinants of Burkholderia pseudomallei. Infect Immun 71: 1622-
1629 
 
Costerton JW, Stewart PS, Greenberg EP (1999) Bacterial biofilms: a 
common cause of persistent infections. Science 284: 1318-1322 
 
Currie BJ, Mayo M, ANSTEY NM, DONOHOE P, Haase G, KEMP 
DJ (2001) A CLUSTER OF MELIOIDOSIS CASES FROM AN 
ENDEMIC REGION IS CLONAL AND IS LINKED TO THE 
WATER SUPPLY USING MOLECULAR TYPING OF 
BURKHOLDERIA PSEUDOMALLEI ISOLATES. Am J Trop Med 
Hyg 65: 177-179 
 
 268 
Dance DA (1991a) Melioidosis: the tip of the iceberg? Clin Microbiol 
Rev 4: 52-60 
 
Dance DA (1991b) Melioidosis: the tip of the iceberg? Clin Microbiol 
Rev 4: 52-60 
 
Dance DA (2000a) Ecology of Burkholderia pseudomallei and the 
interactions between environmental Burkholderia spp. and human-
animal hosts. Acta Tropica 74: 159-168 
 
Dance DA (2000b) Melioidosis as an emerging global problem. Acta 
Tropica 74: 115-119 
 
DeLano W, Lam J (2005) PyMOL: A communications tool for 
computational models. Abstr Pap Am Chem Soc 230: 254-COMP 
 
DeShazer D, Brett PJ, Burtnick MN, Woods DE (1999) Molecular 
characterization of genetic loci required for secretion of exoproducts in 
Burkholderia pseudomallei. J Bacteriol 181: 4661-4664 
 
Deshazer D, Brett PJ, Woods DE (1998) The type II O-antigenic 
polysaccharide moiety of Burkholderia pseudomallei 
lipopolysaccharide is required for serum resistance and virulence. 
Molecular Microbiology 30: 1081-1100 
 
Drenth J (1999) Principles of Protein X-ray Crystallography, 2nd edn. 
Berlin: Spring-Verlag. 
 
El Hassouni M, Chambost JP, Expert D, Van Gijsegem F, Barras F 
(1999) The minimal gene set member msrA, encoding peptide 
methionine sulfoxide reductase, is a virulence determinant of the plant 
pathogen Erwinia chrysanthemi. Proc Natl Acad Sci U S A 96: 887– 
892 
 
Emsley P, Cowtan K (2004) Coot: model-building tools for molecular 
graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132 
 269 
 
Essex-Lopresti AE, Boddey JA, Thomas R, Smith MP, Hartley MG, 
Atkins T, Brown NF, Tsang CH, Peak IR, Hill J, Beacham IR, Titball 
RW (2005) A type IV pilin, PilA, Contributes To Adherence of 
Burkholderia pseudomallei and virulence in vivo. Infect Immun 73: 
1260-1264 
 
Ezraty B, Aussel L, Barras F (2005) Methionine sulfoxide reductases in 
prokaryotes. Biochim Biophys Acta 1703: 221-229 
 
Finkel T (2000) Redox-dependent signal transduction. FEBS Lett 476: 
52-54 
 
Fogazzi G (1998) The description of polycystic kidney by Domenico 
Gusmano Galeazzi 
. Nephrol Dial Transplant 13: 1039-1040 
 
Foggensteiner L, Bevan A, Thomas R, Coleman N, Boulter C, Bradley 
J, Ibraghimove-Beskrovnaya O, Klinger K, Sandford R (2000) Cellular 
and subcellular distribution of polycystin-2, the protein product of the 
PKD2 gene. J Am Soc Nephrol 11: 814-827 
 
Francis SH, Lincoln TM, Corbin JD (1980) Characterization of a novel 
cGMP binding protein from rat lung. J Biol Chem 255: 620-626 
 
Gal D, Mayo M, Smith-Vaughan H, Dasari P, McKinnon M, Jacups 
SP, Urquhart AI, Hassell M, Currie BJ (2004) Contamination of hand 
wash detergent linked to occupationally acquired melioidosis. Am J 
Trop Med Hyg 71: 360-362 
 
Gamage AM, Shui G, Wenk MR, Chua KL (2011) N-
Octanoylhomoserine lactone signalling mediated by the BpsI-BpsR 
quorum sensing system plays a major role in biofilm formation of 
Burkholderia pseudomallei. Microbiology 157: 1176-1186 
 
 270 
Gauthier YP, Thibault FM, Paucod JC, Vidal DR (2000) Protease 
production by Burkholderia pseudomallei and virulence in mice. Acta 
Tropica 74: 215-220 
 
Geng L, Segal Y, Peissel B, Deng N, Pei Y, Carone F, Rennke HG, 
Glucksmann-Kuis AM, Schneider MC, Ericsson M, Reeders ST, Zhou 
J (1996) Identification and localization of polycystin, the PKD1 gene 
product. The Journal of clinical investigation 98: 2674-2682 
 
Grimaud R, Ezraty B, Mitchell JK, Lafitte D, Briand C, Derrick PJ, 
Barras F (2001) Repair of oxidized proteins. Identification of a new 
methionine sulfoxide reductase. J Biol Chem 276: 48915-48920 
 
Gruez A, Libiad M, Boschi-Muller S, Branlant G (2010) Structural and 
biochemical characterization of free methionine-R-sulfoxide reductase 
from Neisseria meningitidis. J Biol Chem 285: 25033-25043 
 
Hames D, Hooper N (2005) Biochemistry,  Abingdon UK: Taylor & 
Francis Group. 
 
Heikaus CC, Pandit J, Klevit RE (2009) Cyclic nucleotide binding 
GAF domains from phosphodiesterases: structural and mechanistic 
insights. Structure 17: 1551-1557 
 
Ho YJ, Burden LM, Hurley JH (2000) Structure of the GAF domain, a 
ubiquitous signaling motif and a new class of cyclic GMP receptor. The 
EMBO Journal 19: 5288-5299 
 
Holden MT, Titball RW, Peacock SJ, Cerdeno-Tarraga AM, Atkins T, 
Crossman LC, Pitt T, Churcher C, Mungall K, Bentley SD, Sebaihia 
M, Thomson NR, Bason N, Beacham IR, Brooks K, Brown KA, 
Brown NF, Challis GL, Cherevach I, Chillingworth T, Cronin A, 
Crossett B, Davis P, DeShazer D, Feltwell T, Fraser A, Hance Z, 
Hauser H, Holroyd S, Jagels K, Keith KE, Maddison M, Moule S, 
Price C, Quail MA, Rabbinowitsch E, Rutherford K, Sanders M, 
Simmonds M, Songsivilai S, Stevens K, Tumapa S, Vesaratchavest M, 
Whitehead S, Yeats C, Barrell BG, Oyston PC, Parkhill J (2004) 
 271 
Genomic plasticity of the causative agent of melioidosis, Burkholderia 
pseudomallei. Proc Natl Acad Sci U S A 101: 14240-14245 
 
Holm L, Rosenstrom P (2010) Dali server: conservation mapping in 
3D. Nucleic Acids Res 38: W545-549 
 
Hoshi T, Heinemann S (2001) Regulation of cell function by 
methionine oxidation and reduction. J Physiol 531: 1-11 
 
Howard K, Inglis TJ (2003) The effect of free chlorine on Burkholderia 
pseudomallei in potable water. Water Res 37: 4425-4432 
 
Hughes J, Ward C, Peral B, Aspinwall R, Clark K, San Millan J, 
Gamble V, Harris P (1995) The polycystic kidney disease 1 (PKD1) 
gene encodes a novel protein with multiple cell recognition domains. 
Nat Genet 10: 151-160 
 
Jones AL, Beveridge TJ, Woods DE (1996) Intracellular survival of 
Burkholderia pseudomallei. Infect Immun 64: 782-790 
 
Jones S, Thornton JM (1995) Protein-protein interactions: a review of 
protein dimer structures. Progress in biophysics and molecular biology 
63: 31-65 
 
Kabsch W (1988) Evaluation of single-crystal X-ray diffraction data 
from a position-sensitive detector. J Appl Crystallogr 21: 916-924 
 
Kabsch W (2010a) Integration, scaling, space-group assignment and 
post-refinement. Acta Crystallogr D Biol Crystallogr 66: 133-144 
 
Kabsch W (2010b) Xds. Acta Crystallogr D Biol Crystallogr 66: 125-
132 
 
Kaminski N (2000) Bioinformatics. A user's perspective. Am J Respir 
Cell Mol Biol 23: 705-711 
 272 
 
Kantardjieff K, Rupp B (2003) Matthews coefficient probabilities: 
Improved estimates for unit cell contents of proteins, DNA, and 
proteinnucleic acid complex crystals. Protein Sci 12: 1865-1871 
 
Kelley L, Sternberg M (2009) Protein structure prediction on the Web: 
a case study using the Phyre server. Nature 4: 363-371 
 
Kespichayawattana W, Rattanachetkul S, Wanun T, Utaisincharoen P, 
Sirisinha S (2000) Burkholderia pseudomallei induces cell fusion and 
actin-associated membrane protrusion: a possible mechanism for cell-
to-cell spreading. Infect Immun 68: 5377-5384 
 
Kim HY, Gladyshev VN (2005a) Different catalytic mechanisms in 
mammalian selenocysteine- and cysteine-containing methionine-R-
sulfoxide reductases. PLoS Biol 3: e375 
 
Kim HY, Gladyshev VN (2005b) Role of structural and functional 
elements of mouse methionine-S-sulfoxide reductase in its subcellular 
distribution. Biochemistry 44: 8059-8067 
 
Korbsrisate S, Tomaras AP, Damnin S, Ckumdee J, Srinon V, 
Lengwehasatit I, Vasil ML, Suparak S (2007) Characterization of two 
distinct phospholipase C enzymes from Burkholderia pseudomallei. 
Microbiology 153: 1907-1915 
 
Krissinel E, Henrick K (2007) Inference of macromolecular assemblies 
from crystalline state. Journal of molecular biology 372: 774-797 
 
Kryukov GV, Kumar AR, Koc A, Sun Z, Gladyshev VN (2002) 
Selenoprotein R is a zinc-containing stereo-specific methionine 
sulfoxide reductase. Proc Natl Acad Sci U S A 99: 4245–4250 
 
Kumar A, Mayo M, Trunck LA, Cheng AC, Currie BJ, Schweizer HP 
(2008) Expression of resistance-nodulation-cell-division efflux pumps 
in commonly used Burkholderia pseudomallei strains and clinical 
 273 
isolates from northern Australia. Trans R Soc Trop Med Hyg 102: 45-
51 
 
Kuschel L, Hansel A, Schonherr R, Weissbach H, Brot N, Hoshi T, 
Heinemann SH (1999) Molecular cloning and functional expression of 
a human peptide methionine sulfoxide reductase (hMsrA). FEBS Lett 
456: 17-21 
 
Laemmli UK (1970) Cleavage of structural proteins during the 
assembly of the head of bacteriophage T4. Nature 227: 680-685 
 
Laskowski RA (1993) PROCHECK: a program to check the 
stereochemical quality of protein structures. J Appl Crystallogr 26: 
283-291 
 
Lee BC, Dikiy A, Kim HY, Gladyshev VN (2009) Functions and 
evolution of selenoprotein methionine sulfoxide reductases. Biochim 
Biophys Acta 1790: 1471-1477 
 
Leslie AGW (1994) MOSFLM. Joint CCP4 + ESF-EAMCB. 
Newsletter on Protein Crystallography 26 
 
Lim WK, Gurdeep GS, Norain K (2001) Melioidosis of the head and 
neck. Med J Malaysia 56: 471-477 
 
Lin Z, Johnson LC, Weissbach H, Brot N, Lively MO, Lowther WT 
(2007) Free methionine-(R)-sulfoxide reductase from Escherichia coli 
reveals a new GAF domain function. Proc Natl Acad Sci U S A 104: 
9597-9602 
 
Ling JLL, Nathan S, Hin LK, Mohamed R (2001) Purification and 
Characterisation of a Burkholderia pseudomallei Protease Expressed in 




Lowther WT, Brot N, Weissbach H, Honek JF, Matthews BW (2000) 
Thiol–disulfide exchange is involved in the catalytic mechanism of 
peptide methionine sulfoxide reductase. Proc Natl Acad Sci U S A 97: 
6463–6468 
 
Lu W, Peissel B, Babakhanlou H, Pavlova A, Geng L, Fan X, Larson 
C, Brent G, Zhou J (1997) Perinatal lethality with kidney and 
pancrease defects in mice with a targeted pkd1 mutation. Nat Genet 17: 
179-181 
 
Luo Y, Vassilev P, Xiaogang L, Yoshifumi K, Zhou J (2003) Native 
Polycystin 2 Functions as a Plasma Membrane Ca2-Permeable Cation 
Channel in Renal Epitheli. MOLECULAR AND CELLULAR BIOLOGY 
23 2600-2607 
 
Martinez S, Wu A, Glavas N, Tang X, Turley S, Hol W (2002a) The 
two GAF domains in phosphodiesterase 2A have distinct roles in 
dimerization and in cGMP binding. PNAS 99: 13260-13265 
 
Martinez SE, Beavo JA, Hol WGJ (2002b) GAF Domains: Two-
Billion-Year-Old Molecular Switches that Bind Cyclic Nucleotides. 
Molecular interventions 2: 317-323 
 
Martinez SE, Bruder S, Schultz A, Zheng N, Schultz JE, Beavo JA, 
Linder JU (2005) Crystal structure of the tandem GAF domains from a 
cyanobacterial adenylyl cyclase: modes of ligand binding and 
dimerization. Proc Natl Acad Sci U S A 102: 3082-3087 
 
Matthews BW (1968) Solvent content of protein crystals. Journal of 
molecular biology 33: 491-497 
 
McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, 




Meyer Y, Buchanan BB, Vignols F, Reichheld JP (2009) Thioredoxins 
and glutaredoxins: unifying elements in redox biology. Annual review 
of genetics 43: 335-367 
 
Mima T, Schweizer HP (2010) The BpeAB-OprB efflux pump of 
Burkholderia pseudomallei 1026b does not play a role in quorum 
sensing, virulence factor production, or extrusion of aminoglycosides 
but is a broad-spectrum drug efflux system. Antimicrob Agents 
Chemother 54: 3113-3120 
 
Mochizuki T, Wu G, Hayashi T, Xenophontos S, Veldhuisen B, Saris 
J, Reynolds D, Cai Y, Gabow P, Pierides A, Kimberling W, Breuning 
M, Deltas C, Peters D, Somlo S (1996) PKD2, a gene for polycystic 
kidney disease that encodes an integral membrane protein. Sience 272: 
1339-1342 
 
Moore RA, DeShazer D, Reckseidler S, Weissman A, Woods DE 
(1999) Efflux-mediated aminoglycoside and macrolide resistance in 
Burkholderia pseudomallei. Antimicrob Agents Chemother 43: 465-470 
 
Moskovitz J, Poston JM, Berlett BS, Nosworthy NJ, Szczepanowski R, 
Stadtman ER (2000) Identification and characterization of a putative 
active site for peptide methionine sulfoxide reductase (MsrA) and its 
substrate stereospecificity. J Biol Chem 275: 14167-14172 
 
Moskovitz J, Weissbach H, Brot N (1996) Cloning the expression of a 
mammalian gene involved in the reduction of methionine sulfoxide 
residues in proteins. Proc Natl Acad Sci U S A 93: 2095-2099 
 
Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of 
macromolecular structures by the maximum-likelihood method. Acta 
Crystallogr D Biol Crystallogr 53: 240-255 
 
Nair U, Bartsch H, Nair J (2007) Lipid peroxidation-induced DNA 
damage in cancer-prone inflammatory diseases: a review of published 




Nieves W, Asakrah S, Qazi O, Brown KA, Kurtz J, Aucoin DP, 
McLachlan JB, Roy CJ, Morici LA (2011) A naturally derived outer-
membrane vesicle vaccine protects against lethal pulmonary 
Burkholderia pseudomallei infection. Vaccine 29: 8381-8389 
 
Nikaido H, Vaara M (1985) Molecular basis of bacterial outer 
membrane permeability. Microbiol Rev 49: 1-32 
 
O'Riordan K, Lee JC (2004) Staphylococcus aureus capsular 
polysaccharides. Clin Microbiol Rev 17: 218-234 
 
Ohi M, Li Y, Cheng Y, Walz T (2004) Negative Staining and Image 
Classification - Powerful Tools in Modern Electron Microscopy. Biol 
Proced Online 6: 23-34 
 
Ong A, Ward C, Butler R, Biddolph S, Bowker C, Torra R, Pei Y, 
Harris P (1999) Coordinate expression of the autosomal domainant 
polycystic kidney disease protein, polycystin-2 and polycystin-1, in 
normal and cystic tissue. Am J Phathol 154: 1721-1729 
 
Peacock SJ, Limmathurotsakul D, Lubell Y, Koh GC, White LJ, Day 
NP, Titball RW (2012) Melioidosis vaccines: a systematic review and 
appraisal of the potential to exploit biodefense vaccines for public 
health purposes. PLoS Negl Trop Dis 6: e1488 
 
Pei J, Kim BH, Grishin NV (2008) PROMALS3D: a tool for multiple 
sequence and structure alignment. Nucleic Acids Research 36: 2295-
2300 
 
Perry MB, MacLean LL, Schollaardt T, Bryan LE, Ho M (1995) 
Structural characterization of the lipopolysaccharide O antigens of 
Burkholderia pseudomallei. Infect Immun 63: 3348-3352 
 
Petri E, Ćelića A, Kennedyb S, Ehrlicha B, Boggona T, Hodsdonc M 
(2010) Structure of the EF-hand domain of polycystin-2 suggests a 
 277 
mechanism for Ca2þ-dependent regulation of polycystin-2 channel 
activit. PNAS Proceeding of the National Academy of Sciences of the 
united states of America 107: 9176-9181 
 
Pumpuang A, Chantratita N, Wikraiphat C, Saiprom N, Day NP, 
Peacock SJ, Wuthiekanun V (2011) Survival of Burkholderia 
pseudomallei in distilled water for 16 years. Trans R Soc Trop Med 
Hyg 105: 598-600 
 
Puthucheary SD, Vadivelu J, Ce-Cile C, Kum-Thong W, Ismail G 
(1996) Short report: Electron microscopic demonstration of 
extracellular structure of Burkholderia pseudomallei. Am J Trop Med 
Hyg 54: 313-314 
 
Qian F, Germino F, Cai Y (1997) PKD1 interacts with PKD2 through a 
probable coild-coil domain. Nat Genet 16: 179-183 
 
Reckseidler SL, Deshazer D, Sokol PA, Woods DE (2001) Detection 
of Bacterial Virulence Genes by Subtractive Hybridization: 
Identification of Capsular Polysaccharide of Burkholderia 
pseudomallei as a Major Virulence Determinant. Infect Immun 69: 34 
 
Reckseidler-Zenteno SL, DeVinney R, Woods DE (2005) The capsular 
polysaccharide of Burkholderia pseudomallei contributes to survival in 
serum by reducing complement factor C3b deposition. Infect Immun 
73: 1106-1115 
 
Reeders S, Keith T, Green P, Germino G, Barton N, Lehmann O, 
Brown V, Phipps P, Morgan J, Bear J (1988) regional localization of 
the autosomal dominant polycystic kidney disease locus. Genomics 3: 
150-155 
 
Rhodes G (2006) Crystallography made crystal clear : a guide for 




Rotz LD, Khan AS, Lillibridge SR, Ostroff SM, Hughes JM (2002) 
Public health assessment of potential biological terrorism agents. 
Emerg Infect Dis 8: 225-230 
 
Rupp B (2010) Biomolecular Crystallography: Principles, Practice, 
and Application to Structural Biology,  New York: Garland Science. 
 
Sambrook JW, Russell DW (2006) The condensed protocols from 
molecular cloning: a Laboratory Manual,  New York, USA: Cold 
Spring Harbor Press. 
 
Sandowski Y, Raver N, Gussakovsky EE, Shochat S, Dym O, Livnah 
O, Rubinstein M, Krishna R, Gertler A (2002) Subcloning, expression, 
purification, and characterization of recombinant human leptin-binding 
domain. J Biol Chem 277: 46304-46309 
 
Sawasdidoln C, Taweechaisupapong S, Sermswan RW, Tattawasart U, 
Tungpradabkul S, Wongratanacheewin S (2010) Growing Burkholderia 
pseudomallei in biofilm stimulating conditions significantly induces 
antimicrobial resistance. PLoS ONE 5 
 
Shafer WM, Rest RF (1989) Interactions of gonococci with phagocytic 
cells. Annu Rev Microbiol 43: 121-145 
 
Shalom G, Shaw JG, Thomas MS (2007) In vivo expression 
technology identifies a type VI secretion system locus in Burkholderia 
pseudomallei that is induced upon invasion of macrophages. 
Microbiology 153: 2689-2699 
 
Singh VK, Moskovitz J (2003) Multiple methionine sulfoxide 
reductase genes in Staphylococcus aureus: expression of activity and 
roles in tolerance of oxidative stress. Microbiology 149: 2739-2747 
 




Stadtman ER, Berlett BS (1998) Reactive oxygen-mediated protein 
oxidation in aging and disease. Drug Metab Rev 30: 225-243 
 
Stawicki S, Lombardo G (2008) ABSITE CORNER Polycystic kidney 
disease. OPUS 12 Scientist 2: 17-20 
 
Stevens MP, Wood MW, Taylor LA, Monaghan P, Hawes P, Jones 
PW, Wallis TS, Galyov EE (2002) An Inv/Mxi-Spa-like type III 
protein secretion system in Burkholderia pseudomallei modulates 
intracellular behaviour of the pathogen. Molecular Microbiology 46: 
649-659 
 
Stone R (2007) Infectious disease. Racing to defuse a bacterial time 
bomb. Science 317: 1022-1024 
 
Suparak S, Kespichayawattana W, Haque A, Easton A, Damnin S, 
Lertmemongkolchai G, Bancroft GJ, Korbsrisate S (2005) 
Multinucleated Giant Cell Formation and Apoptosis in Infected Host 
Cells Is Mediated by Burkholderia pseudomallei Type III Secretion 
Protein BipB. J Bacteriol 187: 6556-6560 
 
Suputtamongkol Y, Chaowagul W, Chetchotisakd P, Lertpatanasuwun 
N, Intaranongpai S, Ruchutrakool T, Budhsarawong D, Mootsikapun P, 
Wuthiekanun V, Teerawatasook N, Lulitanond A (1999) Risk factors 
for melioidosis and bacteremic melioidosis. Clin Infect Dis 29: 408-
413 
 
Taweechaisupapong S, Kaewpa C, Arunyanart C, Kanla P, 
Homchampa P, Sirisinha S, Proungvitaya T, Wongratanacheewin S 
(2005) Virulence of Burkholderia pseudomallei does not correlate with 
biofilm formation. Microbial Pathogenesis 39: 77-85 
 
Thibault FM, Hernandez E, Vidal DR, Girardet M, Cavallo JD (2004) 
Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei 
and Burkholderia mallei to 35 antimicrobial agents. J Antimicrob 
Chemother 54: 1134-1138 
 
 280 
TSIOKAS L, KIM E, ARNOULD T, SUKHATME VP, WALZ G 
(1997) Homo- and heterodimeric interactions between the gene 
productsof PKD1 and PKD2. Proc Natl Acad Sci U S A 94: 6965-6970 
 
Tu Z, He G, Li K, Chen M, Chang J, Chen L, Yao Q, Liu D, Ye H, Shi 
J, Wu X (2005) An improved system for competent cell preparation 
and high efficiency plasmid transformation using different Escherichia 
coli strains. Electronic Journal of Biotechnology 8 
 
Ulrich RL, Deshazer D, Brueggemann EE, Hines HB, Oyston PC, 
Jeddeloh JA (2004) Role of quorum sensing in the pathogenicity of 
Burkholderia pseudomallei. J Med Microbiol 53: 1053-1064 
 
Vorachit M, Lam K, Jayanetra P, Costerton JW (1995) Electron 
microscopy study of the mode of growth of Pseudomonas pseudomallei 
in vitro and in vivo. J Trop Med Hyg 98: 379-391 
 
Wallace AC, Laskowski RA, Thornton JM (1995) LIGPLOT: a 
program to generate schematic diagrams of protein-ligand interactions. 
Protein engineering 8: 127-134 
 
Warawa J, Woods DE (2005) Type III secretion system cluster 3 is 
required for maximal virulence of Burkholderia pseudomallei in a 
hamster infection model. FEMS Microbiology Letters 242: 101-108 
 
Ward C, Turley H, Ong A, Comley M, Biddolph S, Chetty R, Ratcliffe 
P, Gatter K, P H (1996) Polycystin, the polycystin kidney disease 1 
protein, is expressed by epithelial cell in fetal, and adult and polycystic 
kidney. Proc Natl Acad Sci U S A 93: 1524-1528 
 
Weissbach H, Resnick L, Brot N (2005) Methionine sulfoxide 
reductases: history and cellular role in protecting against oxidative 
damage. Biochim Biophys Acta 1703: 203-212 
 
White NJ (2003a) Meliodosis. Lacent 361: 1715-1722 
 
 281 
White NJ (2003b) Melioidosis. Lancet 361: 1715-1722 
 
White NJ, Dance DA, Chaowagul W, Wattanagoon Y, Wuthiekanun V, 
Pitakwatchara N (1989) Halving of mortality of severe melioidosis by 
ceftazidime. Lancet 2: 697-701 
 
Wiersinga WJ, Poll T, White NJ, Day NP, Peacock SJ (2006) 
Melioidosis: insights into the pathogenicity of Burkholderia 
pseudomallei. NATURE REVIEWS | MICROBIOLOGY 4: 272-282 
 
Wiersinga WJ, Poll T, White NJ, Day NP, Peacock SJ (2007) 
Melioidosis: Insights into the pathogenicity of Burkholderia 
pseudomallei. NATURE REVIEWS | MICROBIOLOGY 4: 272-282 
 
Wilson P (2001) Polycystin: New Aspect Of Structure, Function, and 
Regulation. Am Soc Nephrol 12: 834-845 
 
Wilson P (2004) Mechanism of Disease Polycystic Kidney Disease. . N 
Engl J Med 350: 151-164 
 
Winrow VR, Winyard PG, Morris CJ, Blake DR (1993) Free radicals 
in inflammation: second messengers and mediators of tissue 
destruction. Br Med Bull 49: 506-522 
 
Winter G (2010) xia2: an expert system for macromolecular 
crystallography data reduction. J Appl Crystallogr 43 
 
Wongtrakoongate P, Mongkoldhumrongkul N, Chaijan S, 
Kamchonwongpaisanc S, Tungpradabkul S (2007) Comparative 
proteomic profiles and the potential markers between Burkholderia 
pseudomallei and Burkholderia thailandensis. Molecular and Cellular 
Probes 21: 81–91 
 
Yang HM, Chaowagul W, Sokol PA (1991) Siderophore production by 
Pseudomonas pseudomallei. Infect Immun 59: 776-780 
 282 
 
Yee KC, Lee MK, Chua CT, Puthucheary SD (1988) Melioidosis, the 
great mimicker: a report of 10 cases from Malaysia. J Trop Med Hyg 
91: 249-254 
 
Yu BP, Kang CM, Han JS, Kim DS (1998) Can antioxidant 
supplementation slow the aging process? Biofactors 7: 93—101 
 
Yu Y, Ulbrich MH, Li MH, Buraei Z, Chen XZ, Ong AC, Tong L, 
Isacoff EY, Yang J (2009) Structural and molecular basis of the 
assembly of the TRPP2/PKD1 complex. Proc Natl Acad Sci U S A 
106: 11558-11563 
 
Zoraghi R, Corbin JD, Francis SH (2004) Properties and functions of 
GAF domains in cyclic nucleotide phosphodiesterases and other 
proteins. Mol Pharmacol 65: 267-278 
 ee)) 
